日本臨牀　70/増刊号2　造血器腫瘍学

出版社： 日本臨牀社
発行日： 2012-04-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 造血器腫瘍学―基礎と臨床の最新研究動向―
電子書籍版： 2012-04-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

目次

  • 日本臨牀　70/増刊号2　造血器腫瘍学

    ―目次―

    特集　造血器腫瘍学―基礎と臨床の最新研究動向―

    ?． 造血器腫瘍の疫学 　 　
    　１． 日本の造血器腫瘍疫学 　
    　２． 世界の造血器腫瘍の疫学 　
    　３． 白血病の自然史 　
    　４． 成人Ｔ細胞白血病・リンパ腫/HTLV-1感染の疫学
    　　　　　─HTLV-1感染症の根絶に向けて─

    II． 造血器腫瘍の基礎 　 　
    　１． 造血器発がんリスク 　 　
    　２． 発がんとがん抑制の分子機構 　 　
    　３． 白血病発症の分子機構 　 　
    　４． 悪性リンパ腫の発症機構：
    　　　　悪性リンパ腫関連遺伝子と染色体異常 　
    　５． 多発性骨髄腫発症の分子機構：
    　　　　多発性骨髄腫関連遺伝子と染色体異常
    　６． 特　論 　 　

    III． 造血器腫瘍の診断と治療 　 　
    　１． 診断・検査法 　 　
    　２． 治療法 　 　

    ?． 骨髄系腫瘍の臨床 　 　
    　１． FAB分類からWHO分類 渡部　玲子
    　２． 慢性骨髄性白血病 　 　
    　３． 慢性骨髄性白血病以外の骨髄増殖性腫瘍 　 　
    　４． 骨髄異形成/骨髄増殖性腫瘍の分類と治療 波多　智子
    　５． 骨髄異形成症候群 　 　
    　６． 急性骨髄性白血病 　 　
    　７． 急性前骨髄球性白血病 　 　

    V． リンパ系腫瘍の臨床 　 　
    　１． REAL分類からWHO分類
    　２． 急性リンパ性白血病 　 　
    　３． Ph染色体陽性急性リンパ性白血病の特徴と治療
    　４． 慢性リンパ性白血病の病因・病態と治療
    　５． B細胞リンパ腫
    　６． T細胞リンパ腫 　 　
    　７． NK細胞リンパ腫 　 　
    　８． ホジキンリンパ腫 　 　
    　９． 多発性骨髄腫と関連疾患 　 　

    VI． 小児造血器腫瘍の臨床 　 　
    　１． 小児白血病の診断と治療 　 　
    　２． その他 　 　

    VII． 特　論 　 　
    　１． 治療関連白血病の病因・病態と治療 　
    　２． 血管内大細胞型B細胞リンパ腫の治療 　
    　３． 免疫不全関連悪性リンパ腫の診断と治療　
    　４． 悪性リンパ腫に対する新規薬剤の開発動向　
    　５． 微小残存腫瘍量測定とその意義 　
    　６． 高齢者白血病の治療 　
    　７． 血球貪食症候群 　
    　８． 院内感染制御対策 　
    　９． 造血器腫瘍cancer survivorsの長期的メンタルケア 　
    　10． 造血器腫瘍治療に伴う不妊とその対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 造血器腫瘍の疫学

P.18 掲載の参考文献
1) 国立がん研究センターがん対策情報センター [http://ganjoho.jp/professional/statistics/statistics.html].
 
2) 国際がん研究機関 Globocan 2008 [http://globocan.iarc.fr/].
 
3) Cancer Incidence in Five Continents (ed by Curado M, et al), IARC Scientific Publications, No.160, Lyon, 2007.
 
4) Kim HJ, et al : Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335-351, 2000.
 
P.25 掲載の参考文献
1) GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (ed by Ferlay F, et al), Lyon, 2002.
 
2) Cancer Incidence in Five Continents, Vol IX (ed by Curado MP, et al), IARC Press, Lyon, 2007.
 
3) Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), IARC Press, Lyon, 2004.
 
4) 国際疾病分類-腫瘍学, 第3版 (厚生労働省大臣官房統計情報部編), 厚生統計協会, 2003.
 
5) Roman E, Smith AG : Epidemiology of lymphomas. Histopathology 58:4-14, 2011.
PubMed
6) Rodriguez-Abreu D, et al : Epidemiology of hematological malignancies. Ann Oncol 18 (Suppl 1):i3-i8, 2007.
 
7) Dockerty JD : Epidemiology of childhood leukemia in New Zealand : studies of infectious hypotheses. Blood Cells Mol Dis 42:113-116, 2009.
PubMed
8) Au WY, et al : Chronic myeloid leukemia in Asia. Int J Hematol 89:14-23, 2009.
PubMed
9) Grulich AE, Vajdic CM : The epidemiology of non-Hodgkin lymphoma. Pathology 37:409-419, 2005.
PubMed
10) Alexander DD, et al : Multiple myeloma : a review of the epidemiologic literature. Int J Cancer 120 (Suppl 12):40-61, 2007.
 
11) Lee JH, et al : Multiple myeloma in Korea : past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. Int J Hematol 92:52-57, 2010.
PubMed
P.30 掲載の参考文献
1) Visvader JE : Cells of origin in cancer. Nature 469:314-322, 2011.
PubMed
2) Martin RJ, et al : Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 287:49-50, 1980.
 
3) Bartram CR, et al : T lymphocytes lack rearrangement of the bcr gene in Philadelphia chromosome-positive chronic melocytic leukemia. Blood 69:1682-1685, 1987.
PubMed
4) Allouche M, et al : T cell lineage involvement in lymphoid crisis of chronic myeloid leukemia. Blood 66:155-1161, 1985.
 
5) Ross DM, et al : Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 10:1719-1724, 2010.
PubMed
6) Boultwood J, Wainscoat JS : Clonality in the myelodysplastic syndromes. Int J Hematol 73:411-415, 2001.
PubMed
7) Janssen JVV, et al : Clonal analysis of myelodysplastic syndromes : evidence of multipotent stem cell origin. Blood 73:248-254, 1989.
 
8) White NJ, et al : Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood 83:2809-2816, 1994.
 
9) Kohno T, et al : Progression from myelodysplastic syndrome to acute lymphoblastic leukemia with Philadelphia chromosome and p190 BCR-ABL transcript. Br J Haematol 93:389-391, 1996.
PubMed
10) Guibal FC, et al : Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 114 (27):5415-5425, 2009.
PubMed
11) Preston DL, et al : Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 137:S68-97, 1994.
PubMed
12) Iwanaga M, et al : Risk of myelodysplastic syndromes in people exposed to ionizing radiation : retrospective cohort study of Nagasaki Atomic Bomb survivors. J Clin Oncol 29:428-434, 2011.
PubMed
13) Kayser S, et al : The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137-2145, 2011.
PubMed
14) Gale KB, et al : Backtracking leukemia to birth : Identification of clonotype gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94:13950-13954, 1997.
PubMed
15) Marcucci G, et al : Molecular genetics of adult acute leukemia : prognostic and therapeutic implications. J Clin Oncol 29:475-486, 2011.
PubMed
P.36 掲載の参考文献
1) Yamaguchi K : Human T-lymphotropic virus type I in Japan. Lancet 343:213-216, 1994.
PubMed
2) 渡辺俊樹ほか (編) : HTLV-1と疾患, p263, 文光堂, 2007.
 
3) 平成21年度厚労科学研究費補助金 新型インフルエンザ等新興・再興感染症研究事業報告書. 本邦におけるHTLV-1感染及び関連疾患の実態調査と総合対策 (研究代表者 山口一成).
 
4) Tajima K, T-and B-cell Malignancy Study Group and co-authors : The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan : estimates of risk of ATL and its geographical and clinical features. Int J Cancer 45:237-243, 1990.
 
5) 平成21年度厚労科学研究費補助金 特別研究事業報告書. HTLV-1の母子感染予防に関する研究班 (研究代表者 斉藤滋).
 
6) Shimoyama M, members of The Lymphoma Study Group (1984-87) : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol 79:428-437, 1991.
 
7) Yamaguchi K, et al : The detection of human T-cell leukemia virus proviral DNA and its application for classification and diagnosis of T-cell malignancy. Blood 63:1235-1240, 1984.
PubMed
8) Kamihira S, et al : Intra-and inter-laboratory variability in HTLV-1 proviral load quantification using real-time polymerase chain reaction assays : a multi-center study. Cancer Sci 101 (11):2361-2367, 2010.
PubMed
9) JSPFADホームページ [http://www.htlv1.org/].
 
10) Iwanaga M, et al : Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a nationwide prospective study in Japan. Blood 116 (8):1211-1219, 2010.
PubMed
11) Yamaguchi K, et al : Polyclonal integration of HTLV-I proviral DNA in lymphocytes from HTLV-I seropositive individuals : an intermediate state between the healthy carrier state and smoldering ATL. Br J Haematol 68:169-174, 1988.
PubMed

II 造血器腫瘍の基礎

P.42 掲載の参考文献
1) Zhang L, et al : Systems biology of human benzene exposure. Chem Bil Interact 184:86-93, 2010.
 
2) Rinsky RA, et al : Leukemia in benzene workers. Am J Ind Med 52:217-224, 1981.
 
3) Rinsky RA, et al : Benzene and leukemia : an epidemiological risk assessment. N Engl J Med 316:1044-1050, 1987.
PubMed
4) Yin SN, et al : Leukemia in benzene workers : A retrospective cohort study. Br J Ind Med 44:124-128, 1987.
PubMed
5) IARC : Benzene. In : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall evaluations of carcinogenicity : An updating of IARC monographs volumes 1 to 42, Suppl 7, p120-122, International Agency for Research on Cancer, Lyon, 1987.
 
6) Khalade A, et al : Exposure to benzene at work and the risk of leukemia : a systematic review and meta-analysis. Environ Health 9:31-38, 2010.
PubMed
7) Kerns WD, et al : Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res 43:4382-4391, 1983.
PubMed
8) Hayes RB, et al : Mortality of US embalmers and funeral directors. Am J Ind Med 18:641-652, 1990.
PubMed
9) Freeman LEB, et al : Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries : the National Cancer Institute Cohort. J Natl Cancer Inst 101:751-761, 2009.
 
10) Hauptmann M, et al : Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. J Natl Cancer Inst 101:1696-1708, 2009.
PubMed
11) Zhang L, et al : Formaldehyde exposure and leukemia : A new meta-analysis and potential mechanisms. Mutat Res 681:150-168, 2009.
PubMed
12) Travis LB, et al : Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiat Res 160:691-706, 2003.
PubMed
13) Leone G, et al : The incidence of secondary leukemias. Hematologica 84:937-945, 1999.
 
14) Smith MA, et al : The secondary leukemias : challenges and research directions. J Natl Cancer Inst 88:407-418, 1996.
PubMed
P.49 掲載の参考文献
1) HTLV-1と疾患 (渡邉俊樹ほか編), p136-143, p166-177, 文光堂, 2007.
 
2) Matsuoka M, Jeang KT : Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation : viral infectivity, Tax, HBZ and therapy. Oncogene 30:1379-1389, 2011.
PubMed
3) Nicot C, et al : Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene 24:6026-6034, 2005.
PubMed
4) Iwanaga M, et al : Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a prospective study in Japan. Blood 116:1211-1219, 2010.
PubMed
5) Martin D, Gutkind JS : Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27:S31-S42, 2008.
PubMed
6) McLaughlin-Drubin ME, Munger K : Viruses associated with human cancer. Biochim Biophys Acta 1782:127-150, 2008.
PubMed
7) Damania B : DNA tumor viruses and human cancer. Trends Microbiol 15:38-44, 2007.
PubMed
8) Cesarman E : Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 305:163-174, 2011.
PubMed
9) Jacobson CA, Lacasce AS : Lymphoma : Risk and response after solid organ transplant. Oncology 24:936-944, 2010.
PubMed
P.54 掲載の参考文献
1) Kawai T, Akira S : Toll-like receptors and their crosstalk with other innate receptor in infection and immunity. Immunity 34 (5):637-650, 2011.
PubMed
2) Pomerantz JL, Baltimore D : Two pathways to NF-kappaB. Mol Cell 10:693-695, 2002.
PubMed
3) Ben-Neriah Y, Karin M : Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12 (8):715-723, 2011.
 
4) Matsumoto Y, et al : Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13:470-476, 2007.
PubMed
5) Dick JE : Stem cell concepts renew cancer research. Blood 112 (13):4793-4807, 2008.
PubMed
6) Rimsky L, et al : Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature 335 (6192):738-740, 1988.
 
7) Wano Y, et al : Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. Proc Natl Acad Sci USA 85 (24):9733-9737, 1988.
 
8) Dourmishev LA, et al : Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human her-pesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67 (2):175-212, 2003.
 
9) Castleman B, Towne VW : Case records of the Massachusetts General Hospital ; weekly clinicopathological exercises ; founded by Richard C. Cabot. N Engl J Med 251 (10):396-400, 1954.
 
10) Schulte KM, Talat N : Castleman's disease - a two compartment model of HHV8 infection. Nat Rev Clin Oncol 7 (9):533-543, 2010.
PubMed
11) Thorley-Lawson DA, et al : Epstein-Barr virus : a paradigm for persistent infection-for real and in virtual reality. Trends Immunol 29 (4):195-201, 2008.
PubMed
12) Marshall BJ, Warren JR : Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (8390):1311-1315, 1984.
PubMed
13) Greten FR, et al : IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (3):285-296, 2004.
 
14) Maeda S, et al : IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (7):977-990, 2005.
PubMed
15) Shibata W, et al : Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology 138 (3):1022-1034, 2010.
PubMed
16) Thorme M : Carma1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol 4 (5):348-359, 2004.
 
P.61 掲載の参考文献
1) Preston DL, et al : Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma, multiple myeloma, 1950-1987. Radiat Res 137 (2 Suppl):S68-97, 1994.
 
2) Iwanaga M, et al : Risk of myelodysplastic syndromes in people exposed to ionizing radiation : a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 29:428-434, 2011.
PubMed
3) Iwanaga M, et al : Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 113:1639-1650, 2009.
PubMed
4) Pierce DA, et al : Studies of the mortality of atomic bomb survivors : Report 12, Part I. Cancer : 1950-1990. Radiat Res 146:1-27, 1996.
PubMed
5) ICRP Report, 2007.
 
6) Reiners C, et al : Thyroid cancer in infants and adolescents after Chernobyl. Minerva Endocrinol 33:381-395, 2008.
PubMed
7) 25 Years after Chornobyl Accident, Safety for the Future, National Report of Ukraine, 2011.
 
8) Yamashita S, Saenko V : Mechanism of disease : molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3:422-429, 2007.
PubMed
9) Shibata Y, et al : 15 years after Chernobyl : new evidence of thyroid cancer. Lancet 359:1965-1966, 2001.
 
10) Eleenor CJ, et al : Ionizing radiation and hematopoietic malignancies : altering the adaptive landscape. Cell Cycle 9:3005-3011, 2010.
 
11) Hei TK, et al : Mechanism of radiation-induced bystander effects : a unifying model. J Pharm Phamacol 60:943-950, 2008.
 
12) Kamiya K, et al : Repair of potentially lethal damage in rat mammary clonogens following irradiation in organoid culture. Int J Radiat Biol 59:1207-1216, 1991.
PubMed
P.67 掲載の参考文献
1) Jaffe ES, et al (ed) : World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
2) Ohta M, et al : The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597, 1996.
PubMed
3) Kameoka Y, et al : Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 23:9148-9154, 2004.
 
4) Bednarek AK, et al : WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60:2140-2145, 2000.
PubMed
5) Chesi M, et al : Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463, 1998.
 
6) Krummel KA, et al : The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69:37-46, 2000.
PubMed
7) Burrow AA, et al : Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics 10:59, 2009.
PubMed
8) Calin GA, Croce CM : MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25:6202-6210, 2006.
PubMed
9) Bignell GR, et al : Signatures of mutation and selection in the cancer genome. Nature 463 (7283):893-898, 2010.
PubMed
10) List A, et al : Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005.
PubMed
11) Medina J, et al : Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98:1905-1911, 2003.
PubMed
12) Johansson B, et al : Cytogenetic polyclonality in hematologic malignancies. Genes Chromosomes Cancer 24:222-229, 1999.
PubMed
13) Graux C, et al : Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36:1084-1089, 2004.
 
14) Kobayashi S, et al : Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosomes Cancer 50:207-216, 2011.
 
15) Marcucci G, et al : IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia : a Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010.
 
16) Ley TJ, et al : DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010.
PubMed
17) Li H, et al : A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321:1357-1361, 2008.
 
P.74 掲載の参考文献
1) Koch U, et al : Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 111:160-164, 2008.
PubMed
2) Zhao C, et al : Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12:528-541, 2007.
PubMed
3) Tothova Z, et al : FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-339, 2007.
PubMed
4) Naka K, et al : TGF-beta-FOXO signaling maintains leukemia-initiating cells in chronic myeloid leukemia. Nature 463:676-680, 2010.
PubMed
5) Sykes SM, et al : The AKT/FOXO signaling pathway is required for the maintenance of acute myeloid leukemia. Cell 146:697-708, 2011.
 
6) Zhao C, et al : Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458:776-779, 2009.
PubMed
7) Braun T, Fenaux P : Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeioid leukaemia. Br J Haematol 141:576-586, 2008.
 
8) Renneville A, et al : Cooperating gene mutations in acute myeloid leukemia : a review of the literature. Leukemia 22:915-931, 2008.
PubMed
9) Pascheka P, et al : Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t(8;21) : a cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006.
 
10) Dohner H, et al : Implication of the molecular characterization of acute myeloid leukemia. In : Hematology 2007, p412-419, American Society of Hematology, Washington, 2007.
 
11) Advani AS, et al : Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res 32:913-918, 2008.
PubMed
12) Varnum-Finney B, et al : Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci 113:4313-4318, 2000.
PubMed
13) Wu M, et al : Imaging hematopoietic precursor division in real time. Cell Stem Cell 1:541-554, 2007.
PubMed
14) Tiedt R, et al : Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111:3931-3940, 2008.
PubMed
15) Quintas-Cardama A, et al : Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619-1630, 2009.
PubMed
P.78 掲載の参考文献
1) 北林一生 : クロマチン修飾因子の機能異常と白血病. 実験医学 21:1558-1565, 2003.
Medical*Online
2) 田村隆明 : 新転写制御のメカニズム, 羊土社, 2000.
 
3) Kurokawa M : AML1/Runx1 as a versatile regulator of hematopoiesis : regulation of its function and a role in adult hematopoiesis. Int J Hematol 84:136-142, 2006.
 
4) Katsumoto T, et al : Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci 99:1523-1527, 2008.
PubMed
5) Katsumoto T, et al : MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev 20:1321-1330, 2006.
PubMed
6) Camos M, et al : Gene expression profiling of acute myeloid leukemia with translocation t(8;16) (p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 66:6947-6954, 2006.
PubMed
7) Krivtsov AV, Armstrong SA : MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823-833, 2007.
PubMed
8) Morin RD, et al : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011.
PubMed
9) Mullighan CG, et al : CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471:235-239, 2011.
PubMed
10) Martin-Perez D, et al : Polycomb proteins in hematologic malignancies. Blood 116:5465-5475, 2010.
PubMed
11) de The H, Chen Z : Acute promyelocytic leukaemia : novel insights into the mechanisms of cure. Nat Rev Cancer 10:775-783, 2010.
PubMed
12) 岩間厚志 : 癌におけるポリコーム群複合体の機能と新規標的分子としての可能性. 臨床血液 51:605-611, 2010.
 
13) Quintas-Cardama A, et al : Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25:226-235, 2011.
PubMed
P.84 掲載の参考文献
1) Morgan DO : Principles of CDK regulation. Nature 374:131-134, 1995.
PubMed
2) Sherr CJ, Roberts JM : CDK inhibitors : positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999.
PubMed
3) 渡辺信元 : Wee1ファミリーキナーゼの活性制御機構-ヒトWee1Aのユビキチン化依存分解を中心に. 実験医学 23:1376-1382, 2005.
Medical*Online
4) Barr FA, et al : Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5:429-440, 2004.
PubMed
5) Elia AE, et al : Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299:1228-1231, 2003.
PubMed
6) Vader G, Lens SM : The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 1786:60-72, 2008.
PubMed
7) Yu J, et al : Greatwall kinase : a nuclear protein required for proper chromosome condensation and mitotic progression in Drosophila. J Cell Biol 164:487-492, 2004.
PubMed
8) Gharbi-Ayachi A, et al : The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science 330:1673-1677, 2010.
PubMed
9) Mochida S, et al : Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 330:1670-1673, 2010.
PubMed
10) 渡辺信元, 長田裕之 : 細胞周期. 癌化学療法update (西條長宏, 鶴尾隆編), p20-28, 中外医学社, 2005.
 
11) Dickson MA, Schwartz GK : Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16:36-43, 2009.
PubMed
12) Gumireddy K, et al : ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7:275-286, 2005.
PubMed
13) Lenart P, et al : The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17:304-315, 2007.
PubMed
14) Peters U, et al : Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2:618-626, 2006.
PubMed
15) McInnes C, et al : Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2:608-617, 2006.
PubMed
16) Santamaria A, et al : Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 18:4024-4036, 2007.
PubMed
17) Lansing TJ, et al : In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 6:450-459, 2007.
PubMed
18) Steegmaier M, et al : BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322, 2007.
PubMed
19) Rudolph D, et al : BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094-3102, 2009.
PubMed
20) Gilmartin AG, et al : Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69:6969-6977, 2009.
PubMed
21) Garland LL, et al : A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12:5182-5189, 2006.
PubMed
22) Ditchfield C, et al : Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280, 2003.
PubMed
23) Hauf S, et al : The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294, 2003.
PubMed
24) Girdler F, et al : Validating Aurora B as an anti-cancer drug target. J Cell Sci 119:3664-3675, 2006.
PubMed
25) Harrington EA, et al : VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267, 2004.
PubMed
26) Manfredi MG, et al : Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106-4111, 2007.
PubMed
27) Watanabe N, et al : Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 284:2344-2353, 2009.
PubMed
28) Reindl W, et al : Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15:459-466, 2008.
PubMed
29) Reindl W, et al : A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem 10:1145-1148, 2009.
PubMed
P.90 掲載の参考文献
1) Esteller M : Cancer epigenomics : DNA methylomes and histone-modification maps. Nat Rev Genet 8:286-298, 2007.
PubMed
2) Bhutani N, et al : DNA demethylation dynamics. Cell 146:866-872, 2011.
PubMed
3) Issa JP : Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 24:317-330, 2010.
PubMed
4) Hopfer O, et al : Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 33:434-442, 2009.
PubMed
5) Scandura JM, et al : Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118:1472-1480, 2011.
PubMed
6) Dimartino JF, Cleary ML : Mll rearrangements in haematological malignancies : lessons from clinical and biological studies. Br J Haematol 106:614-626, 1999.
PubMed
7) Bernt KM, et al : MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20:66-78, 2011.
PubMed
8) Whitman SP, et al : DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 112:2013-2016, 2008.
PubMed
9) Stumpel DJ, et al : Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia : major matters at a micro scale. Leukemia 25:429-439, 2011.
 
10) Sugimoto T, et al : Escape mechanisms from antibody therapy to lymphoma cells : downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 390 (1):48-53, 2009.
 
11) Gore SD, et al : Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006.
PubMed
12) Xia X, et al : Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106:4260-4265, 2009.
PubMed
P.94 掲載の参考文献
1) Ramiro AR, et al : Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440:105-109, 2006.
PubMed
2) Kolomietz E, et al : The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 35 (2):97-112, 2002.
PubMed
3) Broeker PL, et al : Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia : correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87 (5):1912-1922, 1996.
PubMed
4) Nakada S, et al : Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 116 (1):80-89, 2006.
PubMed
5) Sun J, et al : ATM modulates the loading of recombination proteins onto a chromosomal transloca-tion breakpoint hotspot. PLoS One 5 (10):e13554, 2010.
 
6) Slupianek A, et al : BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8 (4):795-806, 2001.
PubMed
7) Buck D, et al : Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 36 (1):224-235, 2006.
PubMed
8) Rooney S, et al : The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev 200 (1):115-131, 2004.
PubMed
9) Xie A, et al : Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 16 (8):814-818, 2009.
PubMed
10) Nussenzweig A, Nussenzweig MC : A backup DNA repair pathway moves to the forefront. Cell 131 (2):223-225, 2007.
 
11) Fan J, et al : Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways : implications for genomic instability and therapy. Blood 116 (24):5298-5305, 2010.
PubMed
12) Cramer K, et al : BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 68 (17):6884-6888, 2008.
PubMed
13) Roix JJ, et al : Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 34 (3):287-291, 2003.
PubMed
14) Kuroda M, et al : Alteration of chromosome positioning during adipocyte differentiation. J Cell Sci 117 (Pt 24):5897-5903, 2004.
 
15) Rubtsov MA, et al : Repositioning of ETO gene in cells treated with VP-16, an inhibitor of DNA-topoisomerase II. J Cell Biochem 104:692-699, 2008.
PubMed
P.100 掲載の参考文献
1) 岩井一宏 : ユビキチン修飾系の多彩な機能. 細胞工学 29:1190-1194, 2010.
 
2) Bergink S, Jentsch S : Principles of ubiquitin and SUMO modifications in DNA repair. Nature 26:461-467, 2009.
 
3) Verhelst K, et al : Linear ubiquitination in NF-κB signaling and inflammation : What we do under-stand and what we do not. Biochem Pharmacol 82:1057-1065, 2011.
 
4) Mukhopadhyay D, Riezman H : Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 12:201-205, 2007.
 
5) 村田茂穂 : プロテアソームによるタンパク質分解制御. 細胞工学 29:1216-1221, 2010.
 
6) Frescas D, Pagano M : Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP : tipping the scales of cancer. Nat Rev Cancer 8:438-449, 2008.
 
7) Hainaut P, Wiman KG : 30 years and a long way into p53 research. Lancet Oncol 10:913-919, 2009.
 
8) Dick LR, Fleming PE : Building on bortezomib : second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15:243-249, 2010.
PubMed
9) Hideshima T, et al : NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647, 2002.
 
10) Chen S, et al : Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 70:4318-4326, 2010.
PubMed
11) Adams J : The proteasome : a suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004.
PubMed
12) ヤンセンファーマ株式会社 : ベルケイド (R)注射用3mgインタビューフォーム2011年9月改訂第6版.
 
13) Bao W, et al : PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 10:301-307, 2011.
PubMed
14) Cohen P, Tcherpakov M : Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143:686-693, 2010.
PubMed
15) Lin G, et al : Inhibitors selective for mycobacterial versus human proteasomes. Nature 461:621-626, 2009.
PubMed
16) Nencioni A, et al : Proteasome inhibitors : antitumor effects and beyond. Leukemia 21:30-36, 2007.
PubMed
P.107 掲載の参考文献
1) Huang ME, et al : Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988.
PubMed
2) Grignari F, et al : Fusion proteins of the retinoic acid receptor-alfa recruit histone deacetylase in pro-myelocytic leukemia. Nature 391:815-818, 1998.
 
3) Zhu J, et al : A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7:143-153, 2005.
 
4) Nowell PC, Hungerford DA : A minute chromosome in human chronic granulocytic leukemia. Sci-ence 132:1488-1501, 1960.
 
5) Rowley JD : Letter : A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293, 1973.
 
6) Lugo TG, et al : Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990.
PubMed
7) Li S, et al : The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399-1412, 1999.
PubMed
8) Miyoshi H, et al : t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88:10431-10434, 1991.
PubMed
9) Ichikawa M, et al : AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10:299-304, 2004.
PubMed
10) Kiyoi H, et al : Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333-1337, 1998.
PubMed
11) Falini B, et al : Both carboxy-terminus NES motif and mutated tryptophan (s) are crucial for aber-rant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 107:4514-4523, 2006.
 
12) Zhang DE, et al : Absence of granulocyte colony-stimulating factor signaling and neutrophil develop-ment in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94:569-574, 1997.
 
13) Dang L, et al : Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009.
PubMed
P.112 掲載の参考文献
1) 三谷絹子 : 遺伝子異常からみたMDSの病態. 臨床血液 50:1325-1331, 2009.
 
2) Bejar R, et al : Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29:504-515, 2011.
PubMed
3) Ebert B, et al : Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451:335-339, 2008.
PubMed
4) Starczynowski DT, et al : Identification of miR-145 and miR-146a as mediators of the 5q-syn-drome phenotype. Nat Med 16:49-58, 2010.
 
5) Wei S, et al : A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 106:12974-12979, 2009.
 
6) Nikoloski G, et al : Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667, 2010.
PubMed
7) Walter J, et al : Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153-1158, 2011.
 
8) Langemeijer SMC, et al : Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842, 2009.
PubMed
9) Boultwood J, et al : Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplas-tic syndromes and in acute myeloid leukemia. Leukemia 24:1062-1065, 2010.
 
10) La Starza R, et al : NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS One 5:e12855, 2010.
PubMed
11) Yoshida K, et al : Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69, 2011.
PubMed
12) Sanada M, et al : Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904-908, 2009.
PubMed
13) Harada Y, Harada H : Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 220:16-20, 2009.
PubMed
14) Thol F, et al : IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668-1674, 2010.
PubMed
15) Bejar R, et al : Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011.
PubMed
P.116 掲載の参考文献
1) Maciejewski JP, Mufti GJ : Whole genome scanning as a cytogenetic tool in hematologic malig-nancies. Blood 112 (4):965-974, 2008.
 
2) Metzker ML : Sequencing technologies-the next generation. Nat Rev Genet 11 (1):31-46, 2010.
PubMed
3) Ley TJ, et al : DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (7218):66-72, 2008.
PubMed
4) Mardis ER, et al : Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361 (11):1058-1066, 2009.
PubMed
5) Ley TJ, et al : DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363 (25):2424-2433, 2010.
PubMed
6) Yan XJ, et al : Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43 (4):309-315, 2011.
PubMed
7) Zhao S, et al : Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324 (5924):261-265, 2009.
PubMed
8) Paschka P, et al : IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leuke-mia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28 (22):3636-3643, 2010.
 
9) Figueroa ME, et al : Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18 (6):553-567, 2010.
 
10) Mullighan CG : TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet 41 (7):766-767, 2009.
PubMed
11) Delhommeau F, et al : Mutation in TET2 in myeloid cancers. N Engl J Med 360 (22):2289-2301, 2009.
PubMed
12) Tahiliani M, et al : Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (5929):930-935, 2009.
PubMed
13) Cortellino S, et al : Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146 (1):67-79, 2011.
PubMed
14) He YF, et al : Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333 (6047):1303-1307, 2011.
PubMed
15) Ito S, et al : Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcyto-sine. Science 333 (6047):1300-1303, 2011.
 
16) Moran-Crusio K, et al : Tet2 loss leads to increased hematopoietic stem cell self-renewal and mye-loid transformation. Cancer Cell 20 (1):11-24, 2011.
 
17) Quivoron C, et al : TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20 (1):25-38, 2011.
PubMed
18) Yan XJ, et al : Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43 (4):309-315, 2011.
PubMed
19) Yamashita Y, et al : Array-based genomic resequencing of human leukemia. Oncogene 29 (25):3723-3731, 2010.
PubMed
20) Jankowska AM, et al : Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation : UTX, EZH2 and DNMT3A. Blood 118 (14):3932-3941, 2011.
PubMed
21) Walter MJ, et al : Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25 (7):1153-1158, 2011.
PubMed
22) Xie ZH, et al : Mutations in DNA methyltransferase DNMT3B in ICF syndrome affect its regulation by DNMT3. Hum Mol Genet 15 (9):1375-1385, 2006.
 
23) Fisher CL, et al : Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337 (1):9-15, 2010.
 
24) Scheuermann JC, et al : Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465 (7295):243-247, 2010.
PubMed
25) Gelsi-Boyer V, et al : Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145 (6):788-800, 2009.
PubMed
26) Fisher CL, et al : Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115 (1):38-46, 2010.
 
27) Morin RD, et al : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476 (7360):298-303, 2011.
PubMed
28) Pasqualucci L, et al : Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471 (7337):189-195, 2011.
 
29) Varela I, et al : Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469 (7331):539-542, 2011.
PubMed
P.125 掲載の参考文献
1) Pasqualucci L, et al : Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471 (7337):189-195, 2011.
 
2) Morin RD, et al : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476 (7360):298-303, 2011.
PubMed
3) Pasqualucci L, et al : Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43 (9):830-837, 2011.
PubMed
4) Ngo VN, et al : Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119, 2011.
PubMed
5) Davis RE, et al : Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010.
PubMed
6) Kato M, et al : Frequent inactivation of A20 in B-cell lymphomas. Nature 459:712-716, 2009.
 
7) Compagno M, et al : Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721, 2009.
PubMed
8) Pasqualucci L, et al : Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203:311-317, 2006.
PubMed
9) Savage KJ, et al : The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003.
 
10) Iqbal J, et al : Distinctive pattems of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21:2332-2343, 2007.
 
11) Iqbal J, et al : BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24:961-968, 2006.
PubMed
12) Lenz G, et al : Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105:13520-13525, 2008.
PubMed
13) Kobayashi S, et al : Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chro-mosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosomes Cancer 50 (4):207-216, 2011.
 
14) Fujimoto Y, et al : Immunoglobulin light chain gene translocations in non-Hodgkin's lymphoma as assessed by fluorescence in situ hybridisation. Eur J Haematol 80 (2):143-150, 2008.
PubMed
15) Hidaka T, et al : Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood 112 (2):383-393, 2008.
PubMed
16) Steidl C, et al : MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377-381, 2011.
PubMed
P.131 掲載の参考文献
1) Iida S, Ueda R : Multistep tumorigenesis of multiple myeloma : Its molecular delineation. Int J Hema-tol 77:207-212, 2003.
 
2) Kuehl WM, Bergsagel PL : Multiple myeloma : Evolving genetic events and host interactions. Nat Rev Cancer 2:177-192, 2002.
 
3) Kyle RA, et al : Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354 (13):1362-1369, 2006.
PubMed
4) Nishida K, et al : The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534, 1997.
PubMed
5) Bergsagel P, et al : Cyclin D dysregulation : an early and unifying pathogenic event in multiple myeloma. Blood 106:296-303, 2005.
PubMed
6) Chesi M, et al : Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674-681, 1996.
PubMed
7) Hanamura I, et al : Identification of three novel chromosomal translocation partners involving the immunoglobulin loci in newly diagnosed myeloma and human myeloma cell lines. Blood (ASH Annual Meeting Abstracts) 106:1552, 2005.
 
8) Shaughnessy J Jr, et al : Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98:217-223, 2001.
PubMed
9) Chesi M, et al : Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264, 1997.
PubMed
10) Chesi M, et al : Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463, 1998.
 
11) Hanamura I, et al : Ectopic expression of MAFB gene in human myeloma cells carrying (14;20) (q32;q11) chromosomal translocations. Jpn J Cancer Res 92:638-644, 2001.
PubMed
12) Hurt EM, et al : Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199, 2004.
PubMed
13) Suzuki A, et al : ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma : ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 24 (46):6936-6944, 2005.
PubMed
14) Iida S, et al : Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226-230, 1997.
PubMed
15) Shaffer AL, et al : IRF4 addiction in multiple myeloma. Nature 454 (7201):226-231, 2008.
PubMed
16) Hatzivassiliou G, et al : IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14:277-289, 2001.
 
17) Avet-Loiseau H, et al : Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98:3082-3086, 2001.
 
18) Gabrea A, et al : Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 3:119-123, 1999.
 
19) Hayami Y, et al : Inactivation of the E3/LAPTm5 gene by chromosomal rearrangements and DNA methylation in human multiple myeloma. Leukemia 17:1650-1657, 2003.
PubMed
20) Annunziata CM, et al : Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2):115-130, 2007
PubMed
21) Mattioli M, et al : Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24 (15):2461-2473, 2005.
PubMed
22) Hanamura I, et al : Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leu-kemia 20 (7):1288-1290, 2006.
 
23) Kato M, et al : Lack of ku80 alteration in multiple myeloma. Jpn J Cancer Res 93:359-362, 2002.
PubMed
24) Hanamura I, et al : Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization : Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood 108 (5):1724-1732, 2006.
PubMed
25) Fonseca R, et al : Genetics and cytogenetics of multiple myeloma : A workshop report. Cancer Res 64:1546-1558, 2004.
PubMed
26) Shaughnessy JD Jr, et al : Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118 (13):3512-3524, 2011.
PubMed
27) Keats JJ, et al : Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12 (2):131-144, 2007.
PubMed
28) Neri A, et al : RAS oncogene mutation in multiple myeloma. J Exp Med 170:1715-1725, 1989.
PubMed
29) Neri A, et al : p53 mutations in multiple myeloma are associated with advanced forms of malig-nancy. Blood 81:128-135, 1993.
 
30) Uchida T, et al : Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 15:157-165, 2001.
PubMed
31) Chapman MA, et al : Initial genome sequencing and analysis of multiple myeloma. Nature 471 (7339):467-472, 2011.
PubMed
P.138 掲載の参考文献
1) Schofield R : The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4:7-25, 1978.
PubMed
2) Zhang J, Li L : Stem cell niche : microenvironment and beyond. J Biol Chem 283:9499-9503, 2008.
 
3) Mendez-Ferrer S, et al : Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829-834, 2010.
 
4) Morrison SJ, Spradling AC : Stem cells and niches : mechanisms that promote stem cell maintenance throughout life. Cell 132:598-611, 2008.
PubMed
5) Sugiyama T, et al : Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25:977-988, 2006.
PubMed
6) Li L, Clevers H : Coexistence of quiescent and active adult stem cells in mammals. Science 327:542-545, 2010.
PubMed
7) Arai F, et al : Niche regulation of hematopoietic stem cells in the endosteum. Ann N Y Acad Sci 1176:36-46, 2009.
PubMed
8) Hosokawa K, et al : Knockdown of N-cadherin suppresses the long-term engraftment of hemato-poietic stem cells. Blood 116:554-563, 2010.
 
9) Hosokawa K, et al : Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. Cell Stem Cell 6:194-198, 2010.
PubMed
10) Frisch BJ, et al : Hematopoietic niche and bone meet. Curr Opin Support Palliat Care 2:211-217, 2008.
PubMed
11) Eliasson P, Jonsson JI : The hematopoietic stem cell niche : low in oxygen but a nice place to be. J Cell Physiol 222:17-22, 2010.
 
12) Takubo K, et al : Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 7:391-402, 2010.
PubMed
13) Fuller MT, Spradling AC : Male and female Drosophila germline stem cells : two versions of immortality. Science 316:402-404, 2007.
PubMed
14) Bonnet D, Dick JE : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997.
PubMed
15) Iwasaki H, Suda T : Cancer stem cells and their niche. Cancer Sci 100:1166-1172, 2009.
PubMed
16) Ishikawa F, et al : Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25:1315-1321, 2007.
PubMed
17) Ito K, et al : PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453:1072-1078, 2008.
PubMed
18) Raaijmakers MH, et al : Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852-857, 2010.
PubMed
P.145 掲載の参考文献
1) Bonnet D, Dick JE : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997.
PubMed
2) Takenaka K, et al : Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8:1313-1323, 2007.
PubMed
3) Hope KJ, et al : Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5:738-743, 2004.
PubMed
4) Taussig DC, et al : Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112:568-575, 2008.
PubMed
5) Sarry JE, et al : Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 121:384-395, 2011.
 
6) Majeti R, et al : Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1:635-645, 2007.
PubMed
7) Krivtsov AV, et al : Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822, 2006.
PubMed
8) Miyamoto T, et al : AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 97:7521-7526, 2000.
PubMed
9) Goardon N, et al : Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19:138-152, 2011.
 
10) Ishikawa F, et al : Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25:1315-1321, 2007.
PubMed
11) Eppert K, et al : Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086-1093, 2011.
PubMed
12) Castor A, et al : Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11:630-637, 2005.
PubMed
13) Notta F, et al : Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469:362-367, 2011.
PubMed
14) Majeti R, et al : CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299, 2009.
PubMed
15) Kikushige Y, et al : TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7:708-717, 2010.
PubMed
P.150 掲載の参考文献
1) Takahashi K, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872, 2007.
PubMed
2) Okabe M, et al : Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood 114:1764-1767, 2009.
PubMed
3) 鈴木奈緒 : テラトーマ形成を介した人工多能性幹細胞からの機能的な造血幹細胞の分化誘導. 再生医療 10:63-67, 2011.
 
4) 大澤光次郎 : リプログラミングによる多能性造血前駆細胞創出の現状と展望. 血液内科 63:344-347, 2011.
 
5) Kaufman DS : Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114:3513-3523, 2009.
PubMed
6) Kyba M, et al : HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 109:29-37, 2002.
PubMed
7) Kimbrel EA, Lu SJ : Potential clinical applications for human pluripotent stem cell-derived blood components. Stem Cells Int 2011:1-11, 2011.
 
8) Ma F, et al : Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 105:13087-13092, 2008.
PubMed
9) Takayama N, et al : Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 111:5298-5306, 2008.
PubMed
10) Takayama N, et al : Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 207:2817-2830, 2010.
PubMed
11) Otsu M, Ariga T : Stem cell gene therapy for ADA-deficiency without myelopreparative conditioning. In : Progress in Gene Therapy (ed by Bertolotti R, Ozawa K), p1-18, World Scientific, Singapore, 2007.
 
12) 大津真 : 先天性免疫不全症の遺伝子細胞治療. 臨床免疫 33:312-316, 2010.
Medical*Online
13) Hanna J, et al : Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-1923, 2007.
PubMed
P.156 掲載の参考文献
1) Pluznik DH, Sachs L : The cloning of normal "mast" cells in tissue culture. J Cell Physiol 66:319-324, 1965.
PubMed
2) Bradley TR, Metcalf D : The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287-299, 1966.
PubMed
3) Dexter TM, et al : Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 91 (3):335-344, 1977.
PubMed
4) Lux CT, et al : All primitive and definitive hematopoietic progenitor cells emerging before E10 in the mouse embryo are products of the yolk sac. Blood 111 (7):3435-3438, 2008.
PubMed
5) Medvinsky AL, et al : Development of hematopoietic stem cell activity in the mouse embryo. Immu-nity 1:291, 1994.
 
6) Boisset JC, et al : In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 464:116, 2010.
PubMed
7) Petit-Cocault L, et al : Dual role of Mpl receptor during the establishment of definitive hematopoiesis. Development 134:3031-3040, 2007.
PubMed
8) Ara T, et al : Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 19:257-267, 2003.
 
9) Kimura Y, et al : c-Kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One 6 (10):e26918, 2011.
PubMed
10) Buza-Vidas N, et al : Cytokines regulate postnatal hematopoietic stem cell expansion : opposing roles of thrombopoietin and LNK. Genes Dev 20 (5):18-2023, 2006.
 
11) Sugiyama T, et al : Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 signaling in bone marrow stromal cell niches. Immunity 25:977-988, 2006.
PubMed
12) Wu H, et al : Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83 (1):59-67, 1995.
 
13) Carver-Moore K, et al : Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 88 (3):803-808, 1996.
 
14) Lieschke GJ, et al : Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84 (6):1737-1746, 1994.
PubMed
15) Nagasawa T, et al : Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:635-638, 1996.
PubMed
16) Egawa T, et al : The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 15 (2):323-334, 2001.
PubMed
17) Waskow C, et al : Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 17 (3):277-288, 2002.
 
18) Buza-Vidas N : Crucial role of FLT3 ligand in immune reconstitUtion after bone marrow transplantation and high-dose chemotherapy. Blood 110 (1):424-432, 2007.
PubMed
19) von Freeden-Jeffry U, et al : Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 181 (4):1519-1526, 1995.
PubMed
20) Nagasawa T, et al : Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 91 (6):2305-2309, 1994.
PubMed
21) Hargreaves DC, et al : A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 194:45-56, 2001.
PubMed
22) Tokoyoda K, et al : Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20:707-718, 2004.
PubMed
23) Pui JC, et al : Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11 (3):299-308, 1999.
PubMed
24) Radtke F, et al : Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10 (5):547-558, 1999.
PubMed
25) Hozumi K, et al : Delta-like 4 is indispensable in thymic environment specific for T cell development. J Exp Med 205 (11):2507-2513, 2008.
 
26) Koch U, et al : Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J Exp Med 205 (11):2515-2523, 2008.
PubMed
27) Lodolce JP, et al : IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9 (5):669-676, 1998.
PubMed
28) McKenna HJ, et al : Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95 (11):3489-3497, 2000.
PubMed
29) Noda M, et al : CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood 117 (2):451-458, 2011.
PubMed
30) Brawand P, et al : Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 169 (12):6711-6719, 2002.
PubMed
31) Kohara H, et al : Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood 110 (13):4153-4160, 2007.
PubMed
32) Borkowski TA, et al : A role for endogenous transforming growth factor beta 1 in Langerhans cell biology : the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184 (6):2417-2422, 1996.
PubMed
33) Rodig SJ, et al : Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (3):373-383, 1998.
PubMed
34) Neubauer H, et al : Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (3):397-409, 1998.
PubMed
35) Park SY, et al : Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 (6):771-782, 1995.
PubMed
36) Yao Z, et al : Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 103 (4):1000-1005, 2006.
PubMed
37) Cui Y, et al : Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferaion, survival, and differentiation. Mol Cell Biol 24 (18):8037-8047, 2004.
 
38) Yoshihara H, et al : Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1 (6):685-697, 2007.
PubMed
39) Omatsu Y, et al : The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33 (3):387-399, 2010.
PubMed
40) Xiong J, et al : Matrix-embedded cells control osteoclast formation. Nat Med 17 (10):1235-1241, 2011.
PubMed
41) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expres-sion. Nat Med 17 (10):1231-1234, 2011.
 
42) Zhang J, et al : Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841, 2003.
PubMed
43) Kiel MJ, et al : SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121:1109-1121, 2005.
PubMed
44) Rossi SW, et al : RANK signals from CD4 (+)3 (-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 204 (6):1267-1272, 2007.
PubMed
45) Irla M, et al : Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cell cellularity. Immunity 29 (3):451-463, 2008.
PubMed
P.164 掲載の参考文献
1) Nakamura T : Retroviral insertional mutagenesis identifies oncogene cooperation. Cancer Sci 96:7-12, 2005.
PubMed
2) Collins EC, et al : Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep 1:127-132, 2000.
PubMed
3) Drynan LF, et al : Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J 24:3136-3146, 2005.
PubMed
4) Kitamura T, et al : Retrovirus-mediated gene transfer and expression cloning : Powerful tools in functional genomics. Exp Hematol 31:1007-1014, 2003.
PubMed
5) Gilliland DG : Molecular genetics of human leukemias : new insights into therapy. Semin Hematol 39 (4 Suppl 3):6-11, 2002.
 
6) Ono R, et al : Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 115:919-929, 2005.
PubMed
7) Ono R, et al : Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 23:2197-2209, 2009.
PubMed
8) So CW, et al : MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3:161-171, 2003.
PubMed
9) Chen W, et al : Malignant transformation initiated by Mll-AF9 : Gene dosage and critical target cells. Cancer Cell 13:432-440, 2008.
PubMed
10) Arai S, et al : Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117:6304-6314, 2011.
PubMed
11) Lapidot T, et al : A cell initiating human acute myeloid leuekaemia after transplantation into SCID mice. Nature 367:645-648, 1994.
PubMed
12) Larochelle A, et al : Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow : implications for gene therapy. Nat Med 2:1329-1337, 1996.
PubMed
13) Ito M, et al : NOD/SCID/γc null mouse : an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182, 2002.
 
14) Barabe F, et al : Modeling the initiation and progression of human acute leukemia in mice. Science 316:600-604, 2007.
PubMed
15) Bonnet D, Dick JE : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997.
PubMed

III 造血器腫瘍の診断と治療

P.170 掲載の参考文献
1) Bennett JM, et al : Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol 78:325-329, 1991.
 
2) Bennett JM, et al : Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 103:460-462, 1985.
PubMed
3) Mufti GJ, et al : Diagnosis and classification of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1713-1718, 2008.
 
4) Brunning RD, et al : Myelodysplastic syndromes/neoplasms, overview. Pathology and genetics tumours of haematopoietic and lymphoid tissues. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p88-93, International Agency for Research on Cancer, Lyon, 2008.
 
5) 朝長万左男, 松田晃 (編) : 不応性貧血 (骨髄異形成症候群)の形態学的異形成に基づく診断確度区分と形態診断アトラス, 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班, 2008.
 
P.175 掲載の参考文献
1) The 9th International Conference on Human Leukocyte Differentiation Antigens (HLDA9) in Barcelona from 11-13 March 2010.
 
2) Leukocyte and Stromal Cell Molecules : The CD Markers (ed by Zora H, et al), John Wiley & Sons, New York, 2007.
 
3) WHO Classification of Tumours : Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissue, 4th ed (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
 
4) Craig FE, Foon KA : Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111 (8):3941-3967, 2008.
PubMed
5) 日本臨床検査標準化検討委員会, フローサイトメトリーワーキンググループ : フローサイトメトリーによるCD34陽性細胞検出に関するガイドライン (JCCJS H3-P V1.0). 日臨検標準会誌 22:18-30, 2007.
 
6) 日本臨床検査標準化検討委員会, フローサイトメトリーワーキンググループ : フローサイトメトリーによる造血器腫瘍表面抗原検査に関するガイドライン (JCCLS H2-P V1.0). 日臨検標準会誌 18:69-107, 2003.
 
P.179 掲載の参考文献
1) Zerler B : The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells 3:471-479, 1991.
PubMed
2) Kamihira S, et al : Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753-2758, 1994.
PubMed
3) Niitsu N, et al : A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 66:24-30, 2001.
PubMed
4) Kohara T, et al : Clinical prognostic analysis of 280 FL cases from OLSG registry : OLSG cohort analysis. 臨床血液 52:1036, 2011.
 
5) Saglio G, et al : WT1 overexpression : A clinically useful marker in acute and chronic myeloid leukemias. Hematology 10 (Suppl 1):76-78, 2005.
 
6) Inoue K, et al : Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412, 1997.
PubMed
7) Nannya Y, et al : Clinical significance of WT1 mRNA expression level in patients with myelodysplastic syndrome (MDS). 臨床血液 51:1037, 2010.
 
8) O'Brien SG, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
PubMed
9) Baccarani M, et al : Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051, 2009.
PubMed
10) Saglio G, et al : Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010.
PubMed
11) Kantarjian H, et al : Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010.
PubMed
12) Mahon FX, et al : Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010.
PubMed
13) Yagasaki F, et al : Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. 臨床血液 50:481-487, 2009.
 
P.187 掲載の参考文献
1) Yoshioka T, et al : Cytogenetic features of de novo CD5-positive diffuse large B-Cell lymphoma : chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 42:149-157, 2005.
PubMed
2) Niitsu N, et al : Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23:777-783, 2009.
 
3) Tomita N, et al : Clinicopathological features of lymphoma/Leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94:935-943, 2009.
PubMed
P.191 掲載の参考文献
1) Saiki RK, et al : Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354, 1985.
PubMed
2) Mullis KB, Faloona F : Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155:335-350, 1987.
 
3) Heid CA, et al : Real time quantitative PCR. Genome Res 6:986-994, 1996.
PubMed
4) Gibson UEM, et al : A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001, 1996.
 
5) Kamogawa C, et al : Performance of the "DNA probe 'Chugai' Amp-CML" in vitro diagnostics kit. Hematol Oncol 45:175-182, 2002.
 
6) 安藤麻子, 成瀬妙子 : 血液検査実践マニュアル HLAタイピング 2) DNAタイピング. 検査と技術 28:964-968, 2000.
 
7) Southern EM : Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503-517, 1975.
PubMed
8) Sanger F, et al : DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977.
PubMed
P.196 掲載の参考文献
1) 菊池昌弘ほか : 骨髄病理アトラス, p114-127, 文光堂, 2003.
 
2) International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br JHaematol 121:749-757, 2003.
 
3) Kyle RA, Rajkumar SV : Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma : emphasis on risk factors for progression. Br J Haematol 139:730-743, 2007.
PubMed
4) Tanaka T, et al : Frequent downregulation or loss of CD79a expression in plasma cell myelomas : potential clue for diagnosis. Pathol Int 59:804-808, 2009.
 
5) Huang X, et al : Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma : a possible post transcriptional regulation. Pathol Int 61:122-129, 2011.
 
6) O'Connel FP, et al : CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 121:254-263, 2004.
 
7) Swerdlow SH, et al : WHO classification of tumours of haematopoietic and lymphoid tissues, IARC, Lyon, 2008.
 
8) 中村栄男ほか : WHO血液腫瘍分類 -WHO分類2008をうまく活用するために-, p511-528, 医薬ジャーナル社, 2010.
 
9) 高田尚良, 吉野正 : 濾胞性リンパ腫. 病理と臨床 28 (7):720-726, 2010.
Medical*Online
10) Meyer PN, et al : Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29:200-207, 2011.
PubMed
P.201 掲載の参考文献
1) Raanani P, et al : Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17:117-122, 2006.
PubMed
2) Schoder H, et al : Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651. 2005.
PubMed
3) Jerusalem G, et al : Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999.
PubMed
4) Cheson BD, et al : Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
PubMed
5) Juweid ME, et al : Response assessment of aggressive non-Hodgkin's lymphoma by integrated Inter-national Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005.
 
6) Durie BG : The role of anatomic and functional staging in myeloma : description of Durie/Salmon plus staging system. Eur J Cancer 42:1539-1543, 2006.
PubMed
7) Haznedar R, et al : Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/com-puted tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 38:1046-1053, 2011.
 
8) Dimopoulos M, et al : International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Mye-loma. Leukemia 23:1545-1556, 2009.
 
P.206 掲載の参考文献
1) Busque L, et al : Clonal evolution in acute myeloid leukemia. Blood 82:337-342, 1993.
PubMed
2) Skipper HE, et al : Experimental evaluation of potential anticancer agents. VIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-111, 1964.
 
3) Schabel FM Jr, Simpson-Herren L : Some variables in experimental tumor systems which compli-cate interpretation of data from in vivo kinetic and pharmacologic studies with anticancer drugs. Antibiot Chemother 23:113-127, 1978.
 
4) Levin L, Hryniuk WM : Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756, 1987.
PubMed
5) Frei E III, Antman KH : Principles of dose, schedule, and combination chemotherapy. In : Cancer Medicine, 5th ed (ed by Bast RC, et al), p556-568, BC Decker, New York, 2000.
 
6) Goldie JH, Coldman AJ : A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979.
PubMed
7) Yamauchi T, et al : Close correlation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N4-behenoyl-1-β-D-arabinofuranosyl-cytosine therapy for acute myelogenous leukemia. Cancer Sci 92:975-982, 2001.
 
8) Endicott JA, Ling V : The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 58:137-171, 1989.
PubMed
9) Urasaki Y, et al : Establishment of a daunorubicin-resistant cell line which shows multidrug resis-tance by multifactorial mechanisms. Anticancer Res 16:709-714, 1996.
 
10) Takemura H, et al : Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 61:172-177, 2001.
PubMed
11) Bonnet D, et al : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997.
PubMed
12) 上田孝典 : 化学療法. 三輪血液病学, 第3版 (浅野茂隆ほか編), p609-638, 文光堂, 2005.
 
13) Bishop JF, et al : A randomized study of high-dose cytarabine in induction in acute myeloid leu-kemia. Blood 87:1710-1717, 1996.
 
14) Lowenberg B, et al : High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-1248, 2009.
PubMed
P.210 掲載の参考文献
1) Skipper HE : Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA 230:1033-1035, 1974.
PubMed
2) Sanz MA, Lo-Coco F : Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 29:495-503, 2011.
PubMed
3) Mrozek K, et al : Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics : are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007.
PubMed
4) Koeffler HP : Is there a role for differentiation therapy in non-APL AML? Best Pract Res Clin Haematol 23:503-508, 2010.
 
5) Baer MR, Greer JP : Acute myeloid leukemia in adults. In : Wintrobe's Clinical Hematology, 12th ed (ed by Greer JP, et al), p1843-1888, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
6) Wang ZY, Chen Z : Acute promyelocytic leukemia : from highly fatal to highly curable. Blood 111:2505-2515, 2008.
PubMed
7) Sanz MA, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009.
 
8) Ferrara F : Acute promyelocytic leukemia : what are the treatment opinions? Expert Opin Pharmacother 11:587-596, 2010.
 
9) Asou N, et al : A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy : the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59-66, 2007.
 
10) Montesions P, et al : Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy : characteristics, outcome, and prognostic factors. Blood 113:775-783, 2009.
PubMed
11) Kizaki M, et al : Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 88:1824-1833, 1996.
PubMed
12) Takayama N, et al : Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 29:864-872, 2001.
 
P.215 掲載の参考文献
1) Zarrinkar PP, et al : AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114:2984-2992, 2009.
PubMed
2) Ravandi F, et al : Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28:1856-1862, 2010.
PubMed
3) Santos FP, Verstovsek S : JAK2 inhibitors : what's the true therapeutic potential? Blood Rev 25:53-63, 2011.
PubMed
4) Pardanani A, et al : JAK inhibitor therapy for myelofibrosis : critical assessment of value and limitations. Leukemia 25:218-225, 2011.
PubMed
5) Zhang YJ, et al : Targeting the mTOR kinase domain : the second generation of mTOR inhibitors. Drug Discov Today 16:325-331, 2011.
PubMed
6) Johnston SR : Farnesyl transferase inhibitors : a novel targeted therapy for cancer, Lancet Oncol 2:18-26, 2001.
PubMed
7) Blum R, Kloog Y : Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat 8:369-380, 2005.
PubMed
8) Lancet JE, Karp JE : Farnesyltransferase inhibitors in hematologic malignancies : new horizons in therapy. Blood 102:3880-3889, 2003.
PubMed
9) Yan A, et al : Aurora-A kinase inhibitor scaffolds and binding modes. Drug Discov Today 16:260-269, 2011.
PubMed
10) Richardson PG, et al : Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 152:367-379, 2011.
PubMed
11) Federico M, Bagella L : Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011:475641, 2011.
PubMed
12) Garcia-Manero G, Fenaux P : Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29:516-523, 2011.
PubMed
P.220 掲載の参考文献
1) Balaian L, Ball ED : Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia 20 (12):2093-2101, 2006.
PubMed
2) Vaickus L, et al : Immune markers in hematologic malignancies. Crit Rev Oncol Hematol 11 (4):267-297, 1991.
PubMed
3) Paietta E : Immunobiology of acute leukemia. In : Neoplastic Diseases of the Blood (ed by Wiernik P, et al), p194-231, Cambridge University Press, Cambridge, 2003.
 
4) Freeman SD, et al : Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 (8):2005-2012, 1995.
PubMed
5) Nguyen DH, et al : Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol 34 (6):728-735, 2006.
PubMed
6) Ulyanova T, et al : The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 29 (11):3440-3449, 1999.
PubMed
7) Taylor VC, et al : The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 274 (17):11505-11512, 1999.
PubMed
8) Paul SP, et al : Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96 (2):483-490, 2000.
PubMed
9) Sievers EL : Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother Pharmacol 46 (Suppl):S18-22, 2000.
 
10) Cohen AD, et al : Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant : efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30 (1):23-28, 2002.
PubMed
11) de Lima M, et al : Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22 (2):258-264, 2008.
PubMed
12) Sutherland MK, et al : Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 1 (5):481-490, 2009.
PubMed
13) Jurcic JG, et al : Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 6 (2):372-380, 2000.
PubMed
14) Feldman EJ, et al : Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23 (18):4110-4116, 2005.
PubMed
15) WHO分類第4版による白血病・リンパ系腫瘍の病態学 (押味和夫監, 木崎昌弘, 田丸淳一編), 中外医学社, 2009.
 
16) Hagemeister F : Rituximab for thetreatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70 (3):261-272, 2010.
 
17) Palanca-Wessels MC, Press OW : Improving the efficacy of radio-immunotherapy for non-Hodg-kin lymphomas. Cancer 116 (4 Suppl):1126-1133, 2010.
 
18) Osterborg A : Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opin Biol Ther 10 (3):439-449, 2010.
PubMed
19) Czuczman MS, Gregory SA : The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 51 (6):983-994, 2010.
 
20) Advani A, et al : Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I study. J Clin Oncol 28 (12):2085-2093, 2010.
PubMed
21) Bhat SA, Czuczman MS : Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth J Med 67 (8):311-321, 2009.
PubMed
22) Tomillero A, Moral MA : Gateways to clinical trials. Methods Find Exp Clin Pharmacol 30 (4):313-331, 2008.
PubMed
23) Bhat S, Czuczman MS : Galiximab : a review. Expert Opin Biol Ther 10 (3):451-458, 2010.
PubMed
24) Yamamoto K, et al : Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28 (9):1591-1598, 2010.
PubMed
P.225 掲載の参考文献
1) Hoppe RH : Hodgkin lymphoma. In : Perezand Brady's Principles and Practice of Radiation Oncology (ed by Halperin EC, et al), p1721, Lippincott Williams & Wilkins, New York, 2008.
 
2) Hancock SL, et al : Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993.
PubMed
3) Franklin J, et al : Second malignancy risk associated with treatment of Hodgkin's lymphoma : meta-analysis of the randomised trials. Ann Oncol 17:1749, 2006.
PubMed
4) PDQ [http://www.cancer.gov/cancertopics/pdq/treatment/adulthodgkins/HealthProfessional].
 
5) Yahalom J, Mauch P : The involved field is back : issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13 (Suppl 1):79-83, 2002.
 
6) Eich H, et al : Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma : Interim Analysis of the German Hodgkin Study Group Trial HD10. Int J Radia Oncol Biol Phys 63 (Suppl):s1, 2005.
 
7) Eich HT, et al : Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406, 2008.
 
8) Miller TP, et al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998.
PubMed
9) Miller TP : The limits of limited stage lymphoma. J Clin Oncol 22:2982-2984, 2004.
PubMed
10) Horning SJ, et al : Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma : Eastern Cooperative Oncology Group study 1,484. J Clin Oncol 22:3032-3038, 2004.
 
11) Reyes F, et al : ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005.
PubMed
12) Bonnet C, et al : CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007.
 
13) NCCN [http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf].
 
14) Campbell BA, et al : Long-term outcomes for patients with limited stage follicular lymphoma : involved regional radiotherapy versus involved node radiotherapy. Cancer 116:3797-3806, 2010.
PubMed
15) Tobinai K, et al : Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158-164, 2009.
Medical*Online
P.229 掲載の参考文献
1) Dohner H, et al : Diagnosis and management of acute myeloid leukemia in adult : recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010.
 
2) Fielding AK, et al : Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia ; final results of the UKALLXII/ECOG2993 trial. Blood 116 (21):169, 2010.
 
3) Rambaldi A, et al : Improved clinical outcome of adult patients with Ph+ ALL after a combined imatinib-chemotherapy induction/consolidation program followed by allogeneic hematopoietic stem cell transplantation : results from a prospective study of the Northern Italy Leukemia Group. Blood 116 (21):682, 2010.
 
4) Rives S, et al : Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) : results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 154:600-611, 2011.
PubMed
5) Baccarani M, et al : Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 22:331-341, 2009.
PubMed
6) Bjorkstrand B, et al : Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma : long-term follow-up. J Clin Oncol 29:3016-3022, 2011.
PubMed
7) Giaccone L, et al : Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 117:6721-6727, 2011.
PubMed
P.234 掲載の参考文献
1) Jain N, et al : Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease : a phase 2 trial. Cancer 115 (17):3924-3934, 2009.
PubMed
2) Rojas JM, et al : Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia : results of the EPIC study. Leukemia 21 (11):2287-2295, 2007.
 
3) Oka Y, et al : Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 (38):13885-13890, 2004.
PubMed
4) Keilholz U, et al : A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113 (26):6541-6548, 2009.
PubMed
5) Maslak PG, et al : Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 116 (2):171-179, 2010.
PubMed
6) Qazilbash MH, et al : PR1 peptide vaccination for patients with myeloid leukemias. J Clin Oncol 25 (18) (Suppl):7017, 2007.
 
7) Rezvani K, et al : Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111 (1):236-242, 2008.
PubMed
8) Rezvani K, et al : Repeated PR1 and WT1 peptide vaccination in Montanide-adluvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96 (3):432-440, 2011.
PubMed
9) Schmitt M, et al : RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111 (3):1357-1365, 2008.
PubMed
10) Greiner J, et al : High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95 (7):1191-1197, 2010.
PubMed
11) Kohrt HE, et al : Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation. Blood 118 (19):5319-5329, 2011.
 
P.239 掲載の参考文献
1) Sadelain M, et al : The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21:215-223, 2009.
PubMed
2) Park JH, Brentjens RJ : Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 9:277-288, 2010.
PubMed
3) Huang X, et al : Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 16:580-589, 2008.
PubMed
4) Brentjens RJ, et al : Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13:5426-5435, 2007.
PubMed
5) Cheadle EJ, et al : Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 184:1885-1896, 2010.
 
6) Kochenderfer JN, et al : Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116:3875-3886, 2010.
PubMed
7) Kochenderfer JN, et al : Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 16:4099-4102, 2010.
 
8) Brentjens RJ, et al : Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817-4828, 2011.
PubMed
9) Brentjens R, et al : Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells : case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18:666-668, 2010.
 
10) Milone MC, et al : Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453-1464, 2009.
PubMed
11) Kalos M, et al : T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73, 2011.
PubMed
12) Porter DL, et al : Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011.
PubMed
13) Hoyos V, et al : Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Lukemia 24:1160-1170, 2010.
 
P.244 掲載の参考文献
1) 輸血後鉄過剰症の診療ガイド : 厚生労働省科学研究費補助金難治疾患克服研究事業. 特発性造血障害に関する調査研究 (研究代表者 小澤敬也), 平成20年度.
 
2) Rose C, et al : Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 34:864-870, 2010.
PubMed
3) Fox FA, et al : Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 114:694a, 2009.
 
4) Terasaki PI, Cai J : Human leukocyte antigen antibodies and chronic rejection : from association to causation. Transplantation 86:377-383, 2008.
PubMed
5) Ashihara E, et al : Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants : effect on survival. Transplantation 83:506-509, 2007.
PubMed
6) Kopko PM, et al : HLA class II antibodies in transfusion-related acute lung injury. Transfusion 41:1244-1248, 2001.
PubMed
7) Sachs UJ, et al : Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood 117:669-677, 2011.
PubMed
8) Yamamichi J, et al : Single-step, label-free quantification of antibody in human serum for clinical applications based on localized surface plasmon resonance. Nanomedicine 7:889-895, 2011.
PubMed
9) 佐治博夫 : 移植における液性免疫制御の重要性とHLA血清学-直接クロスマッチからHLAタイプ & スクリーンへ-. MHC 18:31-46, 2011.
Medical*Online
10) Takanashi M, et al : The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 116:2839-2846, 2010.
PubMed
11) Spellman S, et al : The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 115:2704-2708, 2010.
PubMed
12) Yoshihara S, et al : Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant, 2011. (in press)
 
13) 万木紀美子ほか : BMT後ドナー由来HLA抗体により血小板輸血不応となった一例. 第92回近畿血液学地方会, 2009.
 
14) 林晃司ほか : HLA不適合ハプロ半合致移植を目的としたHLA抗体検査. MHC 18:147, 2011.
Medical*Online
15) Perry DK, et al : Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9:201-209, 2009.
PubMed
16) Everly MJ, et al : Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 90:1493-1498, 2010.
PubMed
P.251 掲載の参考文献
1) Masaoka T : Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan : executive summary. Clin Infect Dis 39 (Suppl 1):S49-52, 2004.
 
2) Freifeld AG, et al ; Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-93, 2011.
 
3) Rolston KVI, Bodey GP : Infection in the cancer patients. In : Holland-Frei Cancer Medicine, 7th ed (ed by Kufe DW, et al), p2222-2245, BC Decker, Hamilton, London, Ontario, 2006.
 
4) Tamura K, et al ; Japan Febrile Neutropenia Study Group : Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 39 (Suppl 1):S15-24, 2004.
 
5) Kanamaru A, Tatsumi Y : Microbiological data for patients with febrile neutropenia. Clin Infect Dis 39 (Suppl 1):S7-10, 2004.
 
6) Wingard JR : Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39 (Suppl 1):S38-43, 2004.
 
7) Kastersky J, et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000.
PubMed
8) Clark OA, et al : Colony-stimulating factors for chemotherapy-induced febrile neutropenia : a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005.
PubMed
9) Marr KA, et al : Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis : variables that affect performance. J Infect Dis 190:641-649, 2004.
PubMed
10) Herbrecht R, et al : Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and Global Aspergillus Study Group : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002.
 
11) Vinuesa CG, et al : Clinical implications of the specialised B cell response to polysaccharide encapsu-lated pathogens. Postgrad Med J 77:562-569, 2001.
 
P.257 掲載の参考文献
1) Ascioglu S, et al : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants : an international consensus. Clin Infect Dis 34:7-14, 2002.
PubMed
2) De Pauw B, et al : Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821, 2008.
 
3) Pappas PG, et al : Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535, 2009.
 
4) Walsh TJ, et al : Treatment of aspergillosis : clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360, 2008.
 
5) Freifeld AG, et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93, 2011.
 
6) 深在性真菌症のガイドライン作成委員会 (編) : 深在性真菌症の診断・治療ガイドライン2007, p1-127, 協和企画, 2007.
 
7) Kume H, et al : Epidemiology of visceral mycoses in autopsy cases in Japan : comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J 52:117-127, 2011.
PubMed
8) Fujita H, et al : Management of infection in patients with acute leukemia during chemotherapy in Japan : questionnaire analysis by the Japan Adult Leukemia Study Group. Int J Hematol 90:191-198, 2009.
 
9) Wingard JR : Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39:S33-S38, 2004.
 
10) Yoshida M, et al : Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Ann Haematol 91:449-457, 2012.
 
11) Herbrecht R, et al : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002.
PubMed
12) Marr KA, et al : Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 29:797-802, 2004.
 
13) Spellberg B, et al : Recent advances in the management of mucormycosis : from bench to bedside. Clin Infect Dis 48:1743-1751, 2009.
PubMed
14) Matsue K, et al : Breakthrough Trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42:753-757, 2006.
PubMed
15) Cordonnier C, et al : Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients : a randomized, controlled trial. Clin Infect Dis 48:1042-1051, 2009.
PubMed
P.262 掲載の参考文献
1) Schmidt GM, et al : Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplanta-tion 46:905-907, 1988.
 
2) Goodrich JM, et al : Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic mar-row transplant. Ann Intern Med 118:173-178, 1993.
 
3) Winston DJ, et al : Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179-184, 1993.
PubMed
4) Boeckh M, et al : Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation : a randomized double-blind study. Blood 88:4063-4071, 1996.
PubMed
5) Arvin AM : Varicella-Zoster virus : pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 6:219-230, 2000.
PubMed
6) Asano-Mori Y, et al : Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 83:472-476, 2008.
PubMed
7) Kanda Y, et al : Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28:689-692, 2001.
PubMed
8) Hata A, et al : Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347:26-34, 2002.
PubMed
9) Aoki T, et al : Efficacy of continuous, daily, oral, ultra-low-dose 200mg acyclovir to prevent herpes zoster events among bortezomib-treated patients : a report from retrospective study. Jpn J Clin Oncol 41:876-881, 2011.
 
10) Freifeld AG, et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56-93, 2011.
 
11) Asano-Mori Y, et al : Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 87:310-318, 2008.
PubMed
12) Peck AJ, et al : Respiratory virus infection among hematopoietic cell transplant recipients : evidence for asymptomatic parainfluenza virus infection. Blood 110:1681-1688, 2007.
PubMed
13) Yeo W, et al : Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009.
PubMed
14) Goyama S, et al : Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 43:2159-2163, 2002.
PubMed
15) Onozawa M, et al : HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 14:1226-1230, 2008.
PubMed
16) Ennishi D, et al : Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse Iarge B-cell lymphoma treated with rituximab-containing chemotherapy regimens : a Japanese multicenter analysis. Blood 116:5119-5125, 2010.
PubMed
17) Peffault de Latour R, et al : Long-tenn outcome of hepatitis C infection after bone marrow transplantation. Blood 103:1618-1624, 2004.
 
18) Asano Y, et al : Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 32:1175-1179, 2003.
PubMed
19) Llungman P, et al : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation : a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 31:481-486, 2003.
 
20) Akiyama H, et al : Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis 32:1325-1330, 2001.
PubMed
21) van Esser JW, et al : Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364-4369, 2002.
PubMed
22) Wang FZ, et al : Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients : does it have clinical significance? Clin Infect Dis 28:562-568, 1999.
PubMed
P.267 掲載の参考文献
1) Teshima T, et al : Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy 3:833-852, 2011.
PubMed
2) Yu Y, et al : Prevention of GVHD while sparing GVL by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 118:5011-5020, 2011.
 
3) Hill GR, et al : Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scle-roderma. Blood 116:819-828, 2010.
 
4) He S, et al : Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PloS One 6:e20107, 2011.
PubMed
5) Kato K, et al : Identication of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant 16:751-771, 2010.
 
6) Sakoda Y, et al : Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109:1756-1764, 2007.
PubMed
7) Matsuoka K, et al : Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120:1479-1493, 2010.
PubMed
8) Asakura S, et al : Alloantigen expression on non-hematopoietic cells reduces graft-versus-leuke-mia effects in mice. J Clin Invest 120:2370-2378, 2010.
 
9) Takashima S, et al : The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. J Exp Med 208:285-294, 2011.
PubMed
10) Luznik L, et al : High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115:3224-3230, 2010.
PubMed
11) Alousi AM, et al : Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease : a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114:511-517, 2009.
 
12) Brunstein CG, et al : Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood : safety profile and detection kinetics. Blood 117:1061-1070, 2011.
PubMed
13) Di Ianni M, et al : Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117:3921-3928, 2011.
PubMed
14) Hoffmann P, et al : Polyclonal expansion of human CD4(+) CD25(+) regulatory T cells. Methods Mol Biol 677:15-30, 2011.
PubMed
15) Prasad VK, et al : Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a com-passionate use study. Biol Blood Marrow Transplant 17:534-541, 2011.
 
P.273 掲載の参考文献
1) 重篤副作用疾患別対応マニュアル 腫瘍崩壊症候群, 平成23年厚生労働省 [http://www.mhlw.go.jp/stf/shingi/2r98520000013qef-att/2r98520000013r8d.pdf#search='腫瘍崩壊症候群厚生省'].
 
2) Cairo MS, Bishop M : Tumour lysis syndrome : new therapeutic strategies and classification. Br J Haematol 127:3-11, 2004.
PubMed
3) Coiffier B, et al : Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. J Clin Oncol 26:2767-2778, 2008.
PubMed
4) Howard SC, et al : The tumor lysis syndrome. N Engl J Med 364:1844-1854, 2011.
PubMed
5) Will A, Tholouli E : The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 154:3-13, 2011.
PubMed
6) 総合製品情報概要 がん化学療法用尿酸分解酵素製剤ラスリテック点滴静注用, サノフィ・アベンティス.
 
7) Ishizawa K, et al : Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci 100:357-362, 2009.
 
8) Kikuchi A, et al : A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 90:492-500, 2009.
PubMed
9) 大野桂司, 田原一二 : がん化学療法用尿酸分解酵素製剤ラスブリカーゼ (ラスリテック点滴静注用). 日薬理誌 135:255-260, 2010.
 
10) Goldman SC, et al : A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998-3003, 2001.
PubMed
11) Pui CH, et al : Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697-704, 2001.
 
12) Browning LA, Kruse JA : Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 39:1932-1935, 2005.
PubMed
P.278 掲載の参考文献
1) Selvaggi TA, et al : Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89:776-779, 1997.
PubMed
2) Kantoff PW, et al : Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010.
PubMed
P.283 掲載の参考文献
1) Foon KA : Chapter 15 Biologic therapy with interferon-α and β : Clinical applications. In : Biologic Therapy of Cancer, 2nd ed, p365-373, Lippincott Co., Philadelphia, 1995.
 
2) Gutterman JU : Cytokine therapeutics : lessons from interferon alpha. Proc Natl Acad Sci USA 91:1198-1205, 1994.
PubMed
3) Interferon alfa versus chemotherapy for chronic myeloid leukemia : a meta-analysis of seven random-ized trials : Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 89:1616-1620, 1997.
 
4) Mahon FX, et al : Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92:4059-4065, 1998.
PubMed
5) Guilhot F, et al : Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337:223-229, 1997.
 
6) Kantarjian H, et al : Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 103:2099-2108, 2005.
PubMed
7) Druker BJ, et al : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001.
PubMed
8) Sawyers CL, et al : Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis : results of a phase II study. Blood 99:3530-3539, 2002.
PubMed
9) Hensley ML, et al : Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia : analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 18:1301-1308, 2000.
 
10) Musselman DL, et al : Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961-966, 2001.
PubMed
11) Keating GM : Lenograstim : a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. Drugs 71:679-707, 2011.
PubMed
12) Bradstock K, et al : Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 15:1331-1338, 2001.
PubMed
13) Dombret H, et al : A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332:1678-1683, 1995.
 
14) Wheatley K, et al : Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia : a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 146:54-63, 2009.
PubMed
15) Holowiecki J, et al : G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome : a randomized multicenter study. Leuk Lymphoma 43:315-325, 2002.
PubMed
16) Ria R, et al : Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 45:277-281, 2010.
PubMed

IV 骨髄系腫瘍の臨床

P.292 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, WHO, Geneva, 2008.
 
2) Benette JM, et al : Proposals for the classification of acute leukaemias. French-American-British (FAB) cooperative Group. Br J Haematol 33:451-458, 1976.
 
3) Jaffe ES, et al : World Health Organization Classification of tumours. In : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue, IARC, Lyon, 2001.
 
4) 押味和夫 : WHO血液腫瘍分類における「表現型」と「遺伝子異常/発生機序」. WHO分類第4版による白血病・リンパ系腫瘍の病態学, p1-8, 中外医学社, 2009.
 
P.297 掲載の参考文献
1) Bruns I, et al : The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23:892-899, 2009.
PubMed
2) Huntly BJ, et al : MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6:587-596, 2004.
 
3) Cross NC, et al : BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders : some common and contrasting features. Leukemia 22:1975-1989, 2008.
PubMed
4) Sonoyama J, et al : Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277:8076-8082, 2002.
PubMed
P.302 掲載の参考文献
1) Druker BJ, et al : Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006.
PubMed
2) Baccarani M, et al : Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051, 2009.
PubMed
3) Saglio G, et al : Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010.
PubMed
4) Kantarjian H, et al : Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010.
PubMed
5) Mahon FX, et al : Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010.
PubMed
P.307 掲載の参考文献
1) Goldman JM, Melo JV : Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464, 2003.
PubMed
2) Deininger M, et al : International randomized study of interferon vs STI571 (IRIS) 8-year follow up : Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:1126a, 2009.
 
3) Tanaka R, Kimura S : From the second generation Abl tyrosine kinase inhibitors to the next generation for overriding Bcr-Abl/T315I. Exp Rev Anticancer Ther 8:1387-1398, 2008.
 
4) Breccia M, et al : Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol 28:89-92, 2010.
PubMed
5) Baccarani M, et al : Chronic myeloid leukemia : an update of concepts and management recommen-dations of European LeukemiaNet. J Clin Oncol 27:6041-6051, 2009.
 
6) Kantarjian H, et al : Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily : two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136-4147, 2009.
 
7) Jabbour E, et al : Choosing the best treatment strategy for chronic myeloid leukemia patients resis-tant to imatinib : weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24:6-12, 2010.
 
8) Shah NP, et al : Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004.
PubMed
9) Hantschel O, et al : Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49:615-619, 2008.
PubMed
10) Deguchi Y, et al : Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32:980-983, 2008.
PubMed
11) Mustjoki S, et al : Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398-1405, 2009.
PubMed
12) Weisberg D, et al : Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141, 2005.
 
13) Kantarjian HM, et al : Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007.
PubMed
14) Porkka K, et al : Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112:1005-1012, 2008.
PubMed
15) Kantarjian HM, et al : Second-generation tyrosine kinase inhibitors : the future of frontline CML therapy. Clin Cancer Res 17:1674-1683, 2011.
PubMed
P.312 掲載の参考文献
1) Melo JV, Barnes DJ : Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7 (6):441-453, 2007.
 
2) Perrotti D, et al : BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat Genet 30:48-58, 2002.
 
3) Dierov J, et al : BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S-phase checkpoint. Cancer Cell 5:275-285, 2004.
 
4) Neviani P, et al : The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8:355-368, 2005.
PubMed
5) Quintas-Cardama A, Cortes J : Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113 (8):1619-1630, 2009.
PubMed
6) Radich JP, et al : Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794-2799, 2006.
PubMed
7) Jamieson CH, et al : Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657-667, 2004.
PubMed
8) Tian E, et al : The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494, 2003.
PubMed
9) Baccarani M, et al : Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (6):1809-1820, 2006.
 
10) Talpaz M, et al : Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia : results of a phase 2 study. Blood 99:1928-1937, 2002.
PubMed
11) le Coutre P, et al : Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834-1839, 2008.
 
12) Guilhot F, et al : Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (10):4143-4150, 2007.
 
13) Sawyers CL, et al : Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis : results of a phase II study. Blood 99:3530-3539, 2002.
PubMed
14) Giles F, et al : Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. ASCO Meeting Abstracts, 7017, 2008.
 
15) Cortes J, et al : Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213, 2007.
 
16) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(TM))-Version 2, Chronic Myelo-genous Leukemia, 2011.
 
17) Thomas DA, et al : Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396-4407, 2004.
PubMed
18) Towatari M, et al : Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104:3507-3512, 2004.
PubMed
19) Horowitz MM, et al : Allogeneic bone marrow transplantation for CML : a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17 (Suppl 3):S5-6, 1996.
 
20) Saussele S, et al : Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880-1885, 2010.
PubMed
21) 日本造血細胞移植学会 : 平成22年度全国調査報告書, p125, 2011.
 
22) Or R, et al : Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445, 2003.
PubMed
P.319 掲載の参考文献
1) Swerdlow SH, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
2) Kaushansky K : The chronic myeloproliferative disorders and mutation of JAK2 : Dameshek's 54 year old speculation comes of age. Best Pract Res Clin Haematol 20:5-12, 2007.
PubMed
3) Jaffe ES, et al (ed) : World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
4) Tefferi A : JAK2 mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med 356:444-445, 2007.
PubMed
5) Sirhan S, et al : The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 83:363-365, 2008.
 
6) Girodon F, et al : Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2-V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 93:1723-1727, 2008.
PubMed
7) Ricksten A, et al : Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 93:1260-1261, 2008.
PubMed
8) Landolfi R, et al : Leukocytosis as a major thrombotic risk factor in patients with polycythemia. Blood 109:2446-2452, 2007.
 
9) Elliott MA, Tefferi A : Thrombosis and haemorrhage in polycythaemia vera and essential thrombo-cythaemia. Br J Haematol 128:275-290, 2005.
 
10) Marchioli R, et al : Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224-2232, 2005.
 
11) Chait Y, et al : Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129:553-560, 2005.
PubMed
12) Patel RK, et al : Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chi-ari syndrome. Gastroenterology 130:2031-2038, 2006.
 
13) Primignani M, et al : Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44:1528-1534, 2006.
PubMed
14) Colaizzo D, et al : The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5:55-61, 2007.
PubMed
15) Chung RT, et al : Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med 354:2166-2175, 2006.
PubMed
16) Yavasoglu I, et al : Recovery of splenic infarction with anti-platelet treatments and platelet-aphere-sis in polycythemia vera. Transfus Apher Sci 34:199-202, 2006.
 
17) Passamonti F, et al : A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111:3383-3387, 2008.
PubMed
18) Thepot S, et al : Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine : a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116:3735-3742, 2010.
PubMed
19) Verstovsek S, et al : Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010.
PubMed
20) Tefferi A, et al : Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365:1455-1457, 2011.
PubMed
21) Mesa RA, et al : A phase II trial of tipifarnib in myelobrosis : primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 21:1964-970, 2007.
PubMed
22) Rambaldi A, et al : A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150:446-455, 2010.
PubMed
23) Quintas-Cardama A, et al : A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22:965-970, 2008.
PubMed
24) Quintas-Cardama A, et al : Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418-5424, 2009.
PubMed
P.324 掲載の参考文献
1) Kralovics R, et al : Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108 (4):1377-1380, 2006.
 
2) Theocharides A, et al : Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative dis-orders are frequently negative for the JAK2-V617F mutation. Blood 110 (1):375-379, 2007.
 
3) Delhommeau F, et al : Mutation in TET2 in myeloid cancers. N Engl J Med 360 (22):2289-2301, 2009.
PubMed
4) Quivoron C, et al : TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20 (1):25-38, 2011.
PubMed
5) Chagraoui H, et al : Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100 (10):3495-3503, 2002.
PubMed
6) Chagraoui H, et al : Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 101 (8):2983-2989, 2003.
PubMed
7) Kroger N, et al : Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis : a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114 (26):5264-5270, 2009.
 
8) Patriarca F, et al : Allogeneic hematopoietic stem cell transplantation in myelofibrosis : the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93 (10):1514-1522, 2008.
PubMed
9) Robin M, et al : Allogeneic haematopoietic stem cell transplantation for myelofibrosis : a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Br J Haematol 152 (3):331-339, 2011.
 
10) Ballen KK, et al : Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16 (3):358-367, 2010.
PubMed
11) Baxter EJ, et al : Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464):1054-1061, 2005.
PubMed
12) Verstovsek S, et al : Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363 (12):1117-1127, 2010.
PubMed
12) David M, et al : Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109:61-64, 2007.
PubMed
13) Verstovsek S, et al : Results of COMFORT-I, a randomized, double-blind phase iii trial of the JAK1 and JAK2 inhibitor Ruxolitinib (INCB018424) versus placebo for patients with myelofibrosis. European Hematology Association Meeting, #0505 (Abstract), 2011.
 
13) Dahabreh IJ, et al : Management of hypereosinophilic syndrome : a prospective study in the era of molecular genetics. Medicine (Baltimore) 86:344-354, 2007.
PubMed
14) Harrison C, et al : A randomized study of JAK inhibitor Ruxolitinib (INC424) vs best available therapy in primary myelobrosis (MF), post-polycythemia vera-MF or post-essential thrombocythemia MF. European Hematology Association Meeting, #1020 (Abstract), 2011.
 
14) Helbig G, et al : Imatinib mesylate may induce long-term clinical response in FIPIL1-PDGFRα-negative hypereosinophilic syndrome. Med Oncol, 2011. [Epub ahead of print]
 
15) Rothenberg ME, et al ; Mepolizumab HES Study Group : Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:1215-1228, 2008.
 
15) Pardanani A, et al : Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29 (7):789-796, 2011.
PubMed
16) Verstovsek S, et al : Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15:368-373, 2009.
PubMed
17) Halaburda K, et al : Allogeneic bone marrow transplantation for hypereosinophilic syndrome : long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 38:319-320, 2006.
PubMed
18) Ueno NT, et al : Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119:131-134, 2002.
PubMed
19) Gotlib J : World Health Organization-defined eosinophilic disorders : 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86:677-688, 2011.
PubMed
20) Klion AD, et al : Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103:2939-2941, 2004.
PubMed
P.329 掲載の参考文献
1) Myeloproliferative neoplasms. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p31-65, IARC Press, Lyon, 2008.
 
2) Kralovics R, et al : A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005.
PubMed
3) Tefferi A : Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms : impact on prognosis and therapeutic choices. Leuk Lymphoma 51:576-582, 2010.
PubMed
4) Mullally A, et al : Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem cell and progenitor cells. Cancer Cell 17:584-596, 2010.
PubMed
5) Scott LM, et al : JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468, 2007.
PubMed
6) Pardanani AD, et al : MPL515 mutations in myeloproliferative and other myeloid disorders : a study of 1182 patients. Blood 108:3472-3476, 2006.
PubMed
7) Tefferi A, et al : TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-911, 2009.
PubMed
8) Carbuccia N, et al : Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183-2186, 2009.
PubMed
9) Grand FH, et al : Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113:6182-6192, 2009.
PubMed
10) Pardanani A, et al : IDH1 and IDH2 mutation analysis in chronic-and blast-phase myeloproliferative neoplasms. Leukemia 24:1146-1151, 2010.
PubMed
11) Landgren O, et al : Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,557 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199-2204, 2008.
 
12) Jones AV, et al : JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446-449, 2009.
 
13) Chen E, et al : Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18:524-535, 2010.
PubMed
14) Carobbio A, et al : Leukocytosis is a risk factor for thrombosis in essential thrombocytosis : interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310-2313, 2007.
PubMed
15) Quintas-Cardama A, et al : Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418-5424, 2009.
PubMed
P.334 掲載の参考文献
1) Chusid MJ, et al : The hypereosinophilic syndrome : analysis of fourteen cases with review of the literature. Medicine 54:1-27, 1975.
PubMed
2) Simon HU, et al : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112-1120, 1999.
PubMed
3) Swerdlow S, et al (ed) : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, p51-53, IARC Press, Lyon, 2008.
 
4) Vardiman JW, et al : The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia : rationale and important changes. Blood 114:937-951, 2009.
PubMed
5) Schaller JL, Burkland GA : Case report : rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3:9, 2001.
PubMed
6) Gleich GJ, et al : Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-1578, 2002.
PubMed
7) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003.
PubMed
8) Elling C, et al : Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117:2935-2943, 2011.
PubMed
9) Macdonald D, et al : The 8p11 myeloproliferative syndrome : a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101-107, 2002.
PubMed
10) Tefferi A, et al : Hypereosinophilic syndrome and clonal eosinophilia : point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85:158-164, 2010.
PubMed
11) Klion AD, et al : Relapse following discontinuation of imatinib mesylate therapy for FIPIL1-PDGFRA-positive chronic eosinophilic leukemia : implications for optimal dosing. Blood 110:3552-3556, 2007.
 
P.341 掲載の参考文献
1) Heide R, et al : Mastocytosis in childhood. Pediatr Dermatol 19:375-381, 2002.
 
2) Bodemer C, et al : Pediatric mastocytosis is a clonal disease associated with D816V and other activat-ing c-KIT mutations. J Invest Dermatol 130:804-815, 2010.
 
3) Valent P, et al : Standards and standardization in mastocytosis : consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435-453, 2007.
PubMed
4) Arock M, Valent P : Pathogenesis, classification and treatment of mastocytosis : state of the art in 2010 and future perspectives. Expert Rev Hematol 3:497-516, 2010.
PubMed
5) Pardanani A : Systemic mastocytosis in adults : 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86:362-371, 2011.
PubMed
6) Lim KH, et al : Systemic mastocytosis in 342 consecutive adults : survival studies and prognostic factors. Blood 113:5727-5736, 2009.
PubMed
7) Orfao A, et al : Recent advances in the understanding of mastocytosis : the role of KIT mutations. Br J Haematol 138:12-30, 2007.
PubMed
8) Zappulla JP, et al : Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 202:1635-1641, 2005.
PubMed
9) Gerbaulet A, et al : Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 117:2012-2021, 2011.
PubMed
10) Garcia-Montero AC, et al : KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders : a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372, 2006.
 
11) Tefferi A, et al : Frequent TET2 mutations in systemic mastocytosis : clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23:900-904, 2009.
PubMed
12) Wilson TM, et al : Clonal analysis of NRAS activating mutations in KIT-D816V systemic masto-cytosis. Haematologica 96:459-463, 2011.
 
13) Nedoszytko B, et al : Interleukin-13 promoter gene polymorphism-1112C/T is associated with the systemic form of mastocytosis. Allergy 64:287-294, 2009.
PubMed
14) Daley T, et al : Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 98:880-882, 2001.
 
15) Ustun C, ct al : Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35:1143-1145, 2011.
 
P.345 掲載の参考文献
1) Orazi A, et al : Chronic myelomonocytic leukemia. In : WHO Classification of Tumours of Haemato-poietic and Lymphoid Tissues (ed by Smerdlow SH, et al), p76-79, International Agency for Research on Cancer, Lyon, 2008.
 
2) Bennett JM, et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
PubMed
3) Such E, et al : Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 96:375-383, 2011.
PubMed
4) Beran M, et al : Topotecan and cytarabine is an active combination regimen in myelodysplastic syn-dromes and chronic myelomonocytic leukaemia. J Clin Oncol 17:2819-2830, 1999.
 
5) Costa R, et al : Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117:2690-2696, 2011.
PubMed
6) Aribi A, et al : Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109:713-717, 2007.
PubMed
7) Wijermans PW, et al : Efficacy of decitabine in the treatment of patients with chronic myelomono-cytic leukemia (CMML). Leuk Res 32:587-591, 2008.
 
8) Eissa H, et al : Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leuke-mia : relapse-free survival is deterrnined by karyotype and comorbidities. Biol Blood Marrow Trans-plant 17:908-915, 2011.
 
9) Symeonidis A, et al : Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukemia : the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Annual meeting of the EBMT 2010. Bone Marrow Transplant 45:Abstract p803, 2010.
 
10) 日本造血細胞移植学会 : 平成22年度全国調査報告書, p185-195, 2011.
 
11) Germing U, et al : Chronic myelomonocytic leukemia in the light of the WHO proposals. Haemato-logica 92:974-977, 2007.
 
12) Onida F, et al : Prognostic factors and scoring systems in chronic myelomonocytic leukemia : a retro-spective analysis of 213 patients. Blood 99:840-849, 2002.
 
13) Grand FH, et al : Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113:6182-6192, 2009.
PubMed
P.350 掲載の参考文献
1) Ebert BL, et al : Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451:335-339, 2008.
PubMed
2) Barlow JL, et al : A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 16:59-66, 2010.
 
3) Hasle H, Niemeyer CM : Advances in the prognostification and management of advanced MDS in children. Br J Haematol 154:185-195, 2011.
 
4) Hasse D, et al : New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes : evidenceom a core dataset of 2124 patients. Blood 110:4385-4395, 2007.
 
5) Zhang Y, et al : MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood 113:1455-1463, 2009.
PubMed
6) Madan V, et al : Impaired function of primitive hematopoietic stem cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood 113:1444-1454, 2009.
PubMed
7) Heuser M, et al : Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil function, and extreme sensitivity to DNA demethylation. Blood 113:1432-1443, 2009.
PubMed
8) Maserati E, et al : Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 33:93-97, 2002.
PubMed
9) Langemeijer SM, et al : Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842, 2009.
PubMed
10) Kosmider O, et al : TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-3291, 2009.
PubMed
11) Smith AE, et al : Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923-3932, 2010.
PubMed
12) Ito S, et al : Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466:1129-1133, 2010.
PubMed
13) Gelsi-Boyer V, et al : Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800, 2009.
PubMed
14) Boultwood J, et al : Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24:1062-1065, 2010.
PubMed
15) Fisher CL, et al : Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38-46, 2010.
 
16) Fisher CL, et al : Characterization of Asxl1, a murine homolog of Additional sex combs, and analy-sis of the Asx-like gene family. Gene 369:109-118, 2006.
 
17) Thol F, et al : Prognostic significance ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-2506, 2011.
PubMed
18) Ernst T, et al : Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726, 2010.
PubMed
19) Thol F, et al : DNMT3A mutations are rare in childhood acute myeloid leukaemia. Haematologica 96:1238-1240, 2011.
PubMed
20) Walter MJ, et al : Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153-1158, 2011.
PubMed
21) Yamashita Y, et al : Array-based genomic resequencing of human leukemia. Oncogene 29:3723-3731, 2010.
PubMed
22) Yan XJ, et al : Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3 in acute leukemia. Nat Genet 43:309-315, 2011.
 
23) Thol F, et al : IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668-1674, 2010.
PubMed
24) Dang L, et al : Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009.
PubMed
25) Ward PS, et al : The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomor-phic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-234, 2010.
 
26) Figueroa ME, et al : Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010.
 
27) Chen CY, et al : RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 139:405-414, 2007.
PubMed
28) Bejar R, et al : Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011.
PubMed
29) Watanabe-Okochi N, et al : AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111:4297-4308, 2008.
 
30) Bacher U, et al : A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92:744-752, 2007.
PubMed
31) Jadersten M, et al : TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol 29:1971-1979, 2011.
PubMed
32) Yoshida K, et al : Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69, 2011.
PubMed
P.356 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
PubMed
2) Jaffe ES, et al (ed) : World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
3) Brunning RD, et al : WHO histological classification of myelodysplastic syndromes. In : World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), p62-73, IARC Press, Lyon, 2001.
 
4) Swerdlow SH, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
5) Brunning R, et al : Myelodysplastic syndromes/neoplasms, overview. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p88-93, IARC Press, Lyon, 2008.
 
6) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
7) Matsuda A, et al : Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106:2633-2640, 2005.
PubMed
8) Tasaka T, et al ; Japanese Cooperative Study Group for Intractable Bone Marrow Diseases : Myelodysplastic syndrome with chromosome 5 abnormalities : a nationwide survey in Japan. Leukemia 22:1874-1881, 2008.
 
9) List A, et al : Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006.
PubMed
10) Ebert BL, et al : Identhication of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451:335-339, 2008.
PubMed
P.360 掲載の参考文献
1) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
2) Harris NL, et al : World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
PubMed
3) Malcovati L et al : Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007.
PubMed
4) Haase D, et al : New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes : evidence from a core dataset of 2124 patients. Blood 110:4385-4395, 2007.
PubMed
5) Schanz J, et al : Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the interna-tional prognostic scoring system. J Clin Oncol 29:1963-1970, 2011.
 
6) Garcia-Manero G : Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:330-337, 2010.
PubMed
7) Wang R, et al : Comorbidities and survival in a large cohort of patients with newly diagnosed myelo-dysplastic syndromes. Leuk Res 33:1594-1598, 2009.
 
8) Kantarjian H, et al : Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008.
 
9) Naqvi K, et al : Association of comorbidities with overall survival in myelodysplastic syndrome : development of a prognostic model. J Clin Oncol 29:2240-2246, 2011.
 
10) Itzykson R, et al : Prognostic factors for response and overall survival in 282 patients with higherrisk myelodysplastic syndromes treated with azacitidine. Blood 117:403-411, 2011.
PubMed
P.365 掲載の参考文献
1) Brunning RD, et al : Myelodysplastic syndromes. In : WHO Classification of Tumours of Haemato-poietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p87-107, IARC Press, Lyon, 2008.
 
2) Tasaka T, et al : Myelodysplastic syndrome with chromosome 5 abnormalities : a nationwide survey in Japan. Leukemia 22:1874-1881, 2008.
PubMed
3) Tasaka T, et al : 5q-syndrome in Japan. Int J Hematol 93:827-829, 2011.
PubMed
4) Boultwood J, et al : Advances in the 5q-syndrome. Blood 116:5803-5811, 2010.
PubMed
5) Pellagatti A, et al : Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 104:11406-11411, 2007.
 
6) Ebert BL, et al : Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451:335-339, 2008.
PubMed
7) Wei S, et al : A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 106:12974-12979, 2009.
 
8) Starczynowski DT, et al : Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 16:49-58, 2010.
PubMed
9) Barlow JL, et al : A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 16:59-66, 2010.
 
10) 通山薫 : MDSに対するレナリドミドの作用機構と臨床効果. 血液内科 62:9-15, 2011.
 
11) List A, et al : Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005.
PubMed
12) List A, et al : Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl JMed 355:1456-1465, 2006.
 
13) Harada H, et al : Lenalidomide is active in Japanese patients with symptomatic anemia in low-or intermediate-1 risk myelodysplastic syndromes (MDS) with a deletion 5q abnormality. Int J Hematol 90:353-360, 2009.
PubMed
14) Matsuoka A, et al : Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 24:748-755, 2010.
 
15) Jadersten M, et al : Clonal heterogeneity in the 5q-syndrome : p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94:1762-1766, 2009.
PubMed
P.372 掲載の参考文献
1) 厚生労働省医薬食品局血液対策課 : 血液製剤の使用指針 (改訂版), 平成17年9月 (平成19年7月一部改正).
 
2) Brunning RD, et al : Myelodysplastic syndromes. In : WHO CIassification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p87-107, IARC Press, Lyon, 2008.
 
3) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
4) Malcovati L, et al : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005.
PubMed
5) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology. Myelo-dysplastic syndromes, Version 2, 2011 [http://www.nccn.org/professionals/physician-gls/f-guidelines.asp].
 
6) 黒川峰夫ほか : 不応性貧血 (骨髄異形成症候群)診療の参照ガイド. 特発性造血障害疾患の診療の参照ガイド 平成22年度改訂版 (小澤敬也編), p57-98, 2011.
 
7) 日本造血細胞移植学会 : 造血細胞移植ガイドライン 骨髄異形成症候群 (成人), 2009.
 
8) 小澤敬也 (研究代表者) : 輸血後鉄過剰症の診療ガイド, 厚生労働科学研究・特発性造血障害に関する調査研究班 平成20年度研究, 2009.
 
P.378 掲載の参考文献
1) Greenberg P, et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
2) Cutler CS, et al : A decision analysis of allogeneic bone marrow transplantation for the myelodysplas-tic syndromes : delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004.
 
3) 日本造血細胞移植学会ホームページ [http://www.jshct.com/guideline/pdf/2009MDS.pdf].
 
4) Sorror ML, et al : Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell trans-plantation. J Clin Oncol 25:4246-4254, 2007.
PubMed
5) 日本骨髄移植推進財団ホームページ [http://www.jmdp.or.jp/documents/file/04-medical/houkoku2007.pdf]
 
6) Anderson JE, et al : Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology : a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14:220-226, 1996.
PubMed
7) Martino R, et al : Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846, 2006.
PubMed
8) Castro-Malaspina H, et al : Unrelated donor marrow transplantation for myelodysplastic syndromes : outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002.
PubMed
9) 日本膀帯血バンクネットワークホームページ［https://www.j-cord.gr.jp/ja/wnew/isyokuseiseki2007.pdf].
 
10) Field T, et al : 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45:255-260, 2009.
PubMed
11) Jabbour E, et al : Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115:1899-1905, 2009.
PubMed
12) Alessandrino EP, et al : Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation : a GITMO study. Haematologica 95:476-484, 2010.
PubMed
13) Lee JW, et al : Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44:793-797, 2009.
 
P.382 掲載の参考文献
1) Ichikawa M, et al : AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol 180:4402-4408, 2008.
PubMed
2) Hess JL : MLL : a histone methyltransferase disrupted in leukemia. Trends Mol Med 10 (10):500-507, 2004.
PubMed
3) Okada Y, et al : hDOT1L links histone methylation to leukemogenesis. Cell 121 (2):167-178, 2005.
PubMed
4) Falini B, et al : Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1 : molecular basis and clinical implications. Leukemia 23 (10):1731-1743, 2009.
PubMed
5) Pabst T, Mueller BU : Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 15 (17):5303-5307, 2009.
PubMed
6) Lin TC, et al : CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 25 (1):32-40, 2011.
PubMed
7) Ley TJ, et al : DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010.
PubMed
8) Figueroa ME, et al : DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17 (1):13-27, 2010.
PubMed
9) Jongen-Lavrencic M, et al : MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111 (10):5078-5085, 2008.
 
10) Seca H, et al : miR signatures and the role of miRs in acute myeloid leukaemia. Eur J Cancer 46 (9):1520-1527, 2010.
PubMed
11) Schwind S, et al : Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia : a Cancer and Leukemia Group B study. J Clin Oncol 28 (36):5257-5264, 2010.
 
12) Garzon R, et al : MicroRNA 29b functions in acute myeloid leukemia. Blood 114 (26):5331-5341, 2009.
PubMed
13) Garzon R, et al : MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113 (25):6411-6418, 2009.
PubMed
14) Rombouts EJ, et al : Relation between CXCR-4 expression, Flt3 mutations, and unfavorable progno-sis of adult acute myeloid leukemia. Blood 104:550-557, 2004.
 
15) Zeng Z, et al : Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113 (24):6215-6224, 2009.
PubMed
P.387 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976.
PubMed
2) Bennett JM, et al : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625, 1985.
PubMed
3) Swerdlow SH, et al : World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
4) Grimwade D, et al : The importance of diagnostic cytogenetics on outcome in AML : analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998.
PubMed
5) Bloomfield CD, et al : Frequency of prolonged remission duration after high-dose cytarabine intensi-fication in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998.
 
6) Baer MR, et al : Expression of the neural cell adhesion molecule CD56 is associated With short remis-sion duration and survival in acute myeloid leukemia with t(8;21) (2:q22). Blood 90:1643-1648, 1997.
 
7) Paschka P, et al : Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t(8;21) : a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006.
 
8) Oyarzo MP, et al : Acute myeloid leukemia with t(6;9) (p23;q34) is associated wlth dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 122:348-358, 2004.
 
9) Schnittger S, et al : Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005.
PubMed
10) Preudhomme C, et al : Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia : a study from the Acute Leukemia French Association (ALEA). Blood 100:2717-2723, 2002.
 
P.392 掲載の参考文献
1) Jabbour EJ, et al : Adult acute myeloid leukemia. Mayo Clin Proc 81:247-260, 2006.
PubMed
2) Slovak ML, et al : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia : a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000.
 
3) Grimwade D, et al : The importance of diagnostic cytogenetics on outcome in AML : analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Chil-dren's Leukaemia Working Parties. Blood 92:2322-2333, 1998.
 
4) Rollig C, et al : Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations : evaluation of the proposed reporting system. J Clin Oncol 29:2758-2765, 2011.
 
5) Paschka P, et al : Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t(8:21) : a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006.
 
6) Schlenk RF, et al ; German-Austrian Acute Myeloid Leukemia Study Group : Mutations and treat-ment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008.
 
7) Ley TJ, et al : DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010.
PubMed
8) Schnittger S, et al : Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66, 2002.
PubMed
9) Gale RE, et al : No evidence that FLT3 status should be considered as an indicator for transplanta-tion in acute myeloid leukemia (AML) : an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106:3658-3665, 2005.
 
10) Thiede C, et al : Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020, 2006.
PubMed
11) Boissel N, et al : Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970, 2006.
PubMed
12) Wakita S, et al : Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21) (q22;q22) acute myeloid leukemia. Leukemia 25:1423-1432, 2011.
PubMed
13) Slingerland JM, et al : Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77: 1500-1507, 1991.
PubMed
14) Inokuchi K, et al : Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res 8:1882-1888, 2002.
PubMed
15) Paschka P, et al : IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leuke-mia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643, 2010.
 
P.397 掲載の参考文献
1) Cheson BD, et al : Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003.
 
2) Rai KR, et al : Treatment of acute myelocytic leukemia : A study by Cancer and Leukemia Group B. Blood 58:1203-1212, 1981.
 
3) 大竹茂樹 : 急性骨髄性白血病治療の最適化研究. 日本臨牀 65 (増刊号1):469-473, 2007.
Medical*Online
4) The AML Collaborative Group : A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 103:100-109, 1998.
PubMed
5) Lowenberg B, et al : Acute myeloid leukemia. N Engl J Med 341:1051-1062, 1999.
PubMed
6) Fernandez HF, et al : Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009.
PubMed
7) Lowenberg B, et al : High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl JMed 361:1235-1248, 2009.
 
8) Pautas C, et al : Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years : Results of the ALFA-9801 study. J Clin Oncol 28:808-814, 2010.
 
9) Ohtake S, et al : Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia : JALSG AML201 Study. Blood 117:2358-2365, 2011.
PubMed
10) Mayer RJ, et al : Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994.
 
11) Bloomfield CD, et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998.
PubMed
12) Byrd JC, et al : Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999.
 
13) Miyawaki S, et al : A randomized comparison of four courses of standard-dose multiagent chemotherapy versus three courses of high-dose cytarabine alone in post-remission therapy for acute myeloid leukemia in adults : the JALSG AML201 study. Blood 117:2366-2372, 2011.
 
14) Burnett AK, et al : Attempts to optimize induction and consolidation treatment in acute myeloid leukemia : Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010.
 
P.408 掲載の参考文献
1) Leopold LH, Willemze R : The treatment of acute myeloid leukemia in first relapse : a comprehensive review of the literature. Leuk Lymphoma 43:1715-1727, 2002.
PubMed
2) Kurosawa S, et al : Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Hematologica 95:1857-1864, 2010.
 
3) Breens DA, et al : Prognostic index for adult acute myeloid leukemia in first relapse. J Clin Oncol 23:1969-1978, 2005.
 
4) Larson RA, et al : Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452, 2005.
PubMed
5) Chevallier P, et al : Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leu-kemia. Leuk Res 9:1003-1007, 2005.
PubMed
6) Petersdorf S, et al : Preliminary results of Southwest Oncology Group SO106 : An international inter-group phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induc-tion therapy versus standard induction therapy followed by a second randomization to post-consolida-tion gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:326, Abstract 790, 2009.
 
7) Sauter C, et al : Acute myelogenous leukemia : successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V). Eur J Cancer Clin Oncol 18:733-737, 1982.
PubMed
8) 宮脇修一ほか : 治療抵抗性または再発急性骨髄性白血病に対する"A-Triple-V"療法の治療成績. 臨床血液 28:34-39, 1987.
 
9) Ho AD, et al : Combination of mitoxantrone and etoposide in refractory acute myelogenous leu-kemia-an active and well-tolerated regimen. J Clin Oncol 6:213-217, 1988.
 
10) Amadori S, et al : Mitoxantrone, etoposide, and intermediate-dose cytarabine : an effective and tol-erable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210-1214, 1991.
 
11) Archimbaud E, et al : Intensive sequential chemotherapy with mitoxantrone and continuous infUsion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 77:1894-1900, 1991.
PubMed
12) Hiddemann W, et al : High-dose cytosine arabinoside and mitoxantrone : preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie 11:10-12, 1988.
PubMed
13) Yamada K, et al : Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study. Leuke-mia 9:10-14, 1995.
 
14) Gandhi V, et al : Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124, 1993.
PubMed
15) Miyawaki S, et al : Phase 2 Study of FLAGM (Fludarabine+High-dose ara-C+G-CSF+Mitoxan-trone) for refractory or relapse acute myeloid leukemia (AML) : a Report from the Japan Adult Leuke-mia Study Group (JALSG). Blood 114:437, Abstract 1058, 2009.
 
P.413 掲載の参考文献
1) Ablain J, de The H : Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117:5795-5802, 2011.
PubMed
2) Zhu J, et al : A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7:143-153, 2005.
 
3) Petrie K, et al : Differentiation therapy of acute myeloid leukemia : past, present and future. Curr Opin Hematol 16:84-91, 2009.
PubMed
4) Redner RL : Variations on a theme : the alternate translocations in APL. Leukemia 16:1927-1932, 2002.
PubMed
5) Plass C, et al : Epigenetics in acute myeloid leukemia. Semin Oncol 35:378-387, 2008.
PubMed
6) Altucci L, Gronemeyer H : The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193, 2001.
PubMed
7) Kamashev DE, et al : PML-RARA-RXR oligomers mediate retinoid and rexinoid/camp cross talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199:1163-1174, 2004.
 
8) van Wageningen S, et al : Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR. Blood 111:1634-1643, 2008.
 
9) Nowak D, et al : Differentiation therapy of leukemia : 3 decades of development. Blood 113:3655-3665, 2009.
PubMed
10) Chen GQ, et al : Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I : As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353, 1997.
PubMed
11) Wang ZY, Chen Z : Acute promyelocytic leukemia : from highly fatal to highly curable. Blood 111:2505-2515, 2008.
PubMed
12) Tatham MH, et al : RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10:538-546, 2008.
PubMed
13) Lallemand-Breitenbach V, et al : Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10:547-555, 2008.
 
14) Lallemand-Breitenbach V, de The H : A new oncoprotein catabolism pathway. Blood 116:2200-2201, 2010.
PubMed
15) Nasr R, et al : Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14:1333-1342, 2008.
PubMed
16) Sanz MA, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009.
 
17) Ferrara F : Acute promyelocytic leukemia : what are the treatment options? Expert Opin Pharmacother 11:587-596, 2010.
PubMed
P.418 掲載の参考文献
1) Ohno R, et al : Treatment of acute promyelocytic leukemia : strategy toward further increase of cure rate. Leukemia 17:1454-1463, 2003.
PubMed
2) Sanz MA, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009.
 
3) Fenaux P, et al : A randomized comparison of all transretinoic acid (ATRA) followed by chemother-apy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute pro-myelocytic leukemia. The European APL Group. Blood 94:1192-1200, 1999.
 
4) Ades L, et al : Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy : the European APL Group experience. Blood 115:1690-1696, 2010.
PubMed
5) Asou N, et al : Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16:78-85, 1998.
 
6) Sanz MA, et al : Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia : a joint study of the PETHEMA and GIMEMA coopera-tive groups. Blood 96:1247-1253, 2000.
 
7) Grimwade D, et al : Prospective minimal residual disease monitoring to predict relapse of acute pro-myelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009.
 
8) Asou N, et al : A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy : the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59-66, 2007.
 
9) Lo-Coco F, et al : Front-line treatment of acute promyelocytic leukemia with AIDA induction fol-lowed by risk-adapted consolidation for adults younger than 61 years : results of the AIDA-2000 trial of the GIMEMA Group. Blood 116:3171-3179, 2010.
 
10) Powell BL, et al : Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia : North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010.
PubMed
11) Avvisati G, et al : AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia : very long-term results and role of maintenance. Blood 117:4716-4725, 2011.
PubMed
12) Yanada M, et al : Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia : incidence, risk factors, and influence on outcome, Eur J Haematol 78:213-219, 2007.
PubMed
13) De Botton S, et al : Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 92:2712-2718, 1998.
PubMed
14) Sanz MA, et al : Hematopoietic stem cell transplantation for adults with acute promyelocytic leuke-mia in the ATRA era : a survey of the European Cooperative Group for Blood and Marrow Transplan-tation. Bone Marrow Transplant 39:461-469, 2007.
 
15) Mandelli F, et al : Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17:1085-1090, 2003.
 
P.424 掲載の参考文献
1) Wang ZY, Chen Z : Acute promyelocytic leukemia : from highly fatal to highly curable. Blood 111 (5):2505-2515, 2008.
PubMed
2) JALSG APL204 プロトコール (委員長 品川克至).
 
3) Sanz MA, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113 (9):1875-1891, 2009.
 
4) Akoz AG, et al : Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia. Hematology 12 (5):419-422, 2007.
PubMed
5) de Botton S ; European APL Group ; PETHEMA Group : Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20 (1):35-41, 2006.
PubMed
6) Soignet SL, et al : United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (18):3852-3860, 2001.
 
7) Dombret H, et al : Established practice in the treatment of patients with acute promyelocytic leuke-mia and the introduction of arsenic trioxide as a nove therapy. Semin Hematol 39 (2 Suppl 1):8-13, 2002.
 
8) Hashimoto Y, Shudo K : Retinoids and their nuclear receptors. Cell Biol Rev 25 (3):209-230, 1991.
 
9) Tobita T, et al : Treatment with a new synthetic retinoid, Am-80, 0f acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90 (3):967-973, 1997.
 
10) Lo-Coco F, et al : Gemtuzumab ozogamicin (Myelotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104 (7):1995-1999, 2004.
 
11) Guidez F, et al : Reduced retinoic acid-sensitivities of nuclear receptor co-repressor binding to PML-and PLZF-RAR alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91 (8):2634-2642, 1998.
PubMed
12) Yamamoto Y, et al : BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17) (p11;q12) variant of acute promyelocytic leukemia. Blood 116 (20):4274-4283, 2010.
 

V リンパ系腫瘍の臨床

P.432 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976.
PubMed
2) The Non-Hodgkin's Lymphoma Pathologic Classification Project : National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas : Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135, 1982.
PubMed
3) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
 
4) Stansfeld AG, et al : Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988.
PubMed
5) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, 2008.
 
6) Jaffe ES, et al : Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
7) Raimondi SC, et al : Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leu-kemia. Leukemia 10:213-224, 1996.
 
8) Nachman JB, et al : Outcome of treatment in children with hypodiploid acute lymphoblastic leu-kemia. Blood 110:1112-1115, 2007.
 
9) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.
PubMed
10) Ferran M, et al : Acute myeloid dendritic cell leukaemia with specific cutaneous involvement : a diagnostic challenge. Br J Dermatol 158:1129-1133, 2008.
PubMed
P.437 掲載の参考文献
1) Eguchi-Ishimae M, et al : Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood 97 (3):737-743, 2001.
PubMed
2) Pui CH, et al : Acute lymphoblastic leukemia. N Engl J Med 350 (15):1535-1548, 2004.
PubMed
3) Mullighan CG, et al : Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360 (5):470-480, 2009.
PubMed
4) Mullighan CG, et al : BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453 (7191):110-114, 2008.
PubMed
5) Roman-Gomez J, et al : Promoter hypermethylation of cancer-related genes : a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104 (8):2492-2498, 2004.
 
6) Bonnet D, et al : Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (7):730-737, 1997.
PubMed
7) Castor A, et al : Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11 (6):630-637, 2005.
PubMed
8) le Viseur C, et al : In childhood acute lymphoblastic leukemia, blasts at different stages of immuno-phenotypic maturation have stem cell properties. Cancer Cell 14 (1):47-58, 2008.
 
9) Notta F, et al : Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469 (7330):362-367, 2011.
PubMed
10) Mullighan CG, et al : Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322 (5906):1377-1380, 2008.
PubMed
11) Jabbour EJ, et al : Adult acute myeloid leukemia. Mayo Clin Proc 81 (2):247-260, 2006.
PubMed
P.441 掲載の参考文献
1) Bennett JM, et al : Proposals for the classification of acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol 33:451-458, 1976.
PubMed
2) Swerdlow SH, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
3) 薄井紀子 : 急性リンパ性白血病. 臨床血液, p231, 日本血液学会, 2009.
 
4) Pui CH, Evans WE : Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006.
PubMed
5) Maitra A, et al : Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol 115:868-875, 2001.
PubMed
6) Hatta Y, et al : Promising outcome of Imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia : results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 regimen [abstract]. Blood 114:1201, Abstract 3090, 2009.
 
7) Nachman JB, et al : Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007.
PubMed
8) Pilozzi E, et al : Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267-270, 1999.
 
P.445 掲載の参考文献
1) Kuhnl A, et al : High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737-3744, 2010.
PubMed
2) Goldstone AH, et al : In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients : final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008.
 
3) Rowe JM, et al : Inducdon therapy for adults with acute lymphoblastic leukemia : result of more than 1,500 patients from the international ALL trial : MRC UKALL XII/ECOG E2993. Blood 106:3760-3767, 2005.
 
4) Ludwig WD, et al : Immunophenotypic and genotypic features, clinical characteristics, and treat-ment outcome of adult pro-B acute lymphoblastic leukemia : results of German multicenter trials GMALL 03/87 and 04/89. Blood 92:1898-1909, 1998.
 
5) Thomas DA, et al : Chemoimmunotherapy with hyper CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
6) Larson RA, et al : A five induction remission regimen with intensive consolidation for adults with acute lymphoblastic leukemia group B study 8811. Blood 85:2025-2037, 1995.
 
7) Thiel E, et al : Prethymic phenotype and genotype of pre-T (CD7+/ER-) cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 73:1247-1258, 1989.
PubMed
8) Moorman AV, et al : Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL) : analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109:3189-3197, 2007.
PubMed
9) Secker-Walker LM, et al : Cytogenetics adds lymphoblastic leukemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 96:601-610, 1997.
PubMed
10) Mancini M, et al : A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL) : analysis of the GIMEMA 0496 protocol. Blood 105:3434-3441, 2005.
 
11) Asnafi V, et al : NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL) : a group for research on adult acute lymphoblas-tic leukemia (GRAALL) sutdy. Blood 113:3918-3924, 2009.
 
12) Mansour MR, et al : Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 27:4352-4356, 2009.
 
13) Baldus CD, et al : Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739-3745, 2007.
PubMed
14) Martinelli G, et al : IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse : a GIMEMA AL WP report. J Clin Oncol 27:5202-5207, 2009.
PubMed
15) Hoelzer D, et al : Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64:38-47, 1984.
PubMed
16) Schultz KR, et al : Risk and response-based classification of childhood B-precursor acute lympho-blastic leukemia : a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109:926-935, 2007.
 
17) Tafuri A, et al : MRD1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 100:974-981, 2002.
 
18) Damiani D, et al : P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukemia. Br J Haematol 116:519-527, 2002.
PubMed
19) Renato B, et al : Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113:4153-4162, 2009.
 
P.454 掲載の参考文献
1) Bassan R, Hoelzer D : Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29:532-543, 2011.
PubMed
2) Annino L, et al : Treatment of adult acute lymphoblastic leukemia (ALL) : long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99:863-871, 2002.
PubMed
3) Kantarjian H, et al : Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788-2801, 2004.
PubMed
4) Boissel N, et al : Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003.
 
5) Stock W : Adolescents and young adults with acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) : 21-29, 2010.
 
6) Ribera JM, et al : Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hema-tologia pediatric-based protocol ALL-96. J Clin Oncol 26:1843-1849, 2008.
 
7) Huguet F, et al : Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : the GRAALL-2003 study. J Clin Oncol 27:911-918, 2009.
 
8) Rowe JM, et al : Induction therapy for adults with acute lymphoblastic leukemia : results of more than 1500 patients from the international ALL trial : MRC UKALL XII/ECOG E2993. Blood 106:3760-3767, 2005.
PubMed
9) Sebban C, et al : Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission : a comparative study. French Group of Therapy of Adult Acute Lymphoblas-tic Leukemia. J Clin Oncol 12:2580-2587, 1994.
 
10) Thomas X, et al : Outcome of treatment in adults with acute lymphoblastic leukemia : analysis of the LALA-94 trial. J Clin Oncol 22:4075-4086, 2004.
 
11) Hunault M, et al : Better outcome of adult acute lymphoblastic leukemia after early genoidentical allo-geneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT : a GOELAMS trial. Blood 104:3028-3037, 2004.
 
12) Ribera JM, et al : Comparison of intensive chemotherapy, allogeneic or autologous stem cell trans-plantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90:1346-1356, 2005.
 
13) Yanada M, et al : Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytoge-netic risk for acute myeloid leukemia in first disease remission : a metaanalysis. Cancer 103:1652-1658, 2005.
 
14) Fielding AK, et al : Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplanta-tion over chemotherapy in the pre-imatinib era : results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 113:4489-4496, 2009.
 
15) Cornelissen JJ, et al : Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission : a prospective sibling donor versus no-donor comparison. Blood 113:1375-1382, 2009.
PubMed
16) Ram R, et al : Management of adult patients with acute lymphoblastic leukemia in first complete remission : systematic review and meta-analysis. Cancer 116:3447-3457, 2010.
PubMed
17) Takeuchi J, et al : Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 16:1259-1266, 2002.
PubMed
18) Attal M, et al : Consolidation treatment of adult acute lymphoblastic leukemia : a prospective, ran-domized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 86:1619-1628, 1995.
 
19) Labar B, et al : Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients < or=50 years old in first complete remission : results of the EORTC ALL-3 trial. Haematologica 89:809-817, 2004.
PubMed
20) Kako S, et al : A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia 25:259-265, 2011.
PubMed
P.461 掲載の参考文献
1) Kantarjian HM, et al : Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116:5568-5574, 2010.
PubMed
2) Fielding AK, et al : Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL) ; an MRC UKALL12/ECOG 2993 study. Blood 109:944-950, 2007.
PubMed
3) Thomas DA, et al : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
4) Woodruff RK, et al : Combination chemotherapy for haematological relapse in adult acute lympho-blastic leukaemia (ALL). Am J Hematol 4:173-177, 1978.
 
5) Thomas DA, et al : Primary refractory and relapsed adult acute lymphoblastic leukemia : characteristics, treatment results, and prognosis with salvage therapy. Cancer 86:1216-1230, 1999.
PubMed
6) O'Brien S, et al : Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113:3186-3191, 2008.
PubMed
7) Bassan R, Hoelzer D : Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29:532-543, 2011.
PubMed
8) Litzow MR : Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs 71:415-442, 2011.
PubMed
9) Kantarjian HM, et al : Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173, 2003.
PubMed
10) Kantarjian H, et al : Phase 2 clinical and pharmacologic study of clofarabine in patients with refrac-tory or relapsed acute leukemia. Blood 102:2379-2386, 2003.
PubMed
11) Faderl S, et al : A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638-1645, 2008.
PubMed
12) Kaasgaard T, Andresen TL : Liposomal cancer therapy : exploiting tumor characteristics. Expert Opin Drug Deliv 7:225-243, 2010.
PubMed
13) Gelmon KA, et al : Phase I study of liposomal vincristine. J Clin Oncol 17:697-705, 1999.
PubMed
14) Glantz MJ, et al : Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116, 1999.
PubMed
15) Gokbuget N, et al : Liposomal cytarabine is effective and tolerable in the treatment of central nerv-ous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 96:238-244, 2011.
 
16) Yahagi Y, Usui N : Notch and γ-secretase inhibitor. Jpn J Cancer Chemotherapy 36:744-748, 2009.
 
17) Wei P, et al : Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9:1618-1628, 2010.
 
18) Furman RR, Hoelzer D : Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Semin Oncol 34:S29-34, 2007.
PubMed
19) Ravandi F, Gandhi V : Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leu-kaemia and lymphoma. Expert Opin Investig Drugs 15:1601-1613, 2006.
 
20) Galmarini CM : Drug evaluation : forodesine-PNP inhibitor for the treatment of leukemia, lym-phoma and solid tumor. IDrugs 9:712-722, 2006.
 
21) Gandhi V, et al : A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106:4253-4260, 2005.
PubMed
22) Bantia S, et al : Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 3:879-887, 2003.
PubMed
23) Furman RR, et al : Forodesine IV (BXC-1777) is clinically active in relapsed/refractory T-cell leukemia. Results of a phase II A study. Blood 108:524a, 2006 (abstr 1851).
 
24) Bredius RG, et al : Pulmonary hypertension in two severe combined immunodeficiency disease patients posthaematopoietic stem cell transplantation. Br J Haematol 125:405-406, 2004.
PubMed
25) Raetz EA, et al : Chemoimmunotherapy reinduction with epratuzumab in children with acute lym-phoblastic leukemia in marrow relapse : a Children's Oncology Group Pilot Study. J Clin Oncol 26:3756-3762, 2008.
 
26) Fullmer A, et al : Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep 4:148-156, 2009.
PubMed
27) Rowe JM : Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. Best Pract Res Clin Haematol 21:485-502, 2008.
PubMed
28) Weiden PL, et al : Antileukemic effect of graft-versus-host disease in human recipients of alloge-neic-marrow grafts. N Engl J Med 300:1068-1073, 1979.
 
29) Goldstone AH, et al : In adults with standard-risk acute lymphoblastic leukemia, the greatest bene-fit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemother-apy in all patients : final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008.
 
30) Martino R, et al : Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 21:1023-1027, 1998.
 
31) Duval M, et al : Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730-3738, 2010.
 
32) Terwey TH, et al : Allogeneic SCT in refractory or relapsed adult ALL is effective without prior rein-duction chemotherapy. Bone Marrow Transplant 42:791-798, 2008.
PubMed
33) Kurtzberg J, et al : Phase I study of 506U78 administered on a consecutive 5-day schedule in chil-dren and adults with refractory hematologic malignancies. J Clin Oncol 23:3396-3403, 2005.
 
34) DeAngelo DJ, et al : Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma : Cancer and Leukemia Group Bstudy 19801. Blood 109:5136-5142, 2007.
 
35) Stock W : Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 51:188-198, 2010.
PubMed
36) Fielding AK, et al : Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplan-tation over chemotherapy in the pre-imatinib era : results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 113:4489-4496, 2009.
 
37) Fielding AK : How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 116:3409-3417, 2010.
 
P.468 掲載の参考文献
1) Jones LK, Saha V : Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 130:489-500, 2005.
PubMed
2) Takeuchi J, et al : Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 16:1259-1266, 2002.
PubMed
3) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460-466, 2006.
 
4) Rambaldi A, et al : Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1;19) chro-mosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leu-kemia. Leuk Lymphoma 21:457-466, 1996.
 
5) Czuczman MS, et al : Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia : cancer and leukemia Group B study 8364. Blood 93:3931-3939, 1999.
 
6) Larson RA, et al : A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia : cancer and leukemia group B study 8811. Blood 85:2025-2037, 1995.
 
7) Ottmann OG, et al : A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971, 2002.
 
8) Yanada M, et al : Recent advances in the treatment of Philadelphia chromosome-positive acute lym-phoblastic leukemia. Int J Hematol 89:3-13, 2009.
 
9) Thomas DA, et al : Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396-4407, 2004.
PubMed
10) Talpaz M, et al : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006.
PubMed
11) Ravandi F, et al : First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treat-ment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116:2070-2077, 2010.
 
12) Barrett AJ, et al : Bone marrow transplantation for Philadelphia chromosome-positive acute lympho-blastic leukemia. Blood 79:3067-3070, 1992.
 
13) Lee S, et al : Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leu-kaemia in remission treated with allogeneic bone marrow transplantation : the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 120:145-153, 2003.
 
14) Wassmann B, et al : Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell trans-plantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 16:2358-2365, 2002.
PubMed
15) Vignetti M, et al : Imatinib plus steroids induces complete remissions and prolonged survival in eld-erly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without addi-tional chemotherapy : results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676-3678, 2007.
 
P.475 掲載の参考文献
1) Muller-Hermalink HK, et al : Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p180-182, IARC Press, Lyon, 2008.
 
2) Chiorazzi N, Ferrarini M : Cellular origin (s) of chronic lymphocytic leukemia : cautionary notes and additional considerations and possibilities, Blood 117:1781-1791, 2011.
PubMed
3) Kikushige Y, et al : Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-259, 2011.
PubMed
4) Puente XS, et al : Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475 (7354):101-105, 2011.
PubMed
5) 鈴宮淳司 : 慢性リンパ性白血病. 造血器腫瘍取扱い規約, 第1版 (日本血液学会・日本リンパ網内系 学会編), p48-52, 金原出版, 2010.
 
6) Hallek M, et al ; International Workshop on Chronic Lymphocytic Leukemia : Guidelines for the diag-nosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008.
 
7) Rawstron AC, et al : Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359:575-583, 2008.
PubMed
8) Bennett JM, et al : Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42:567-584, 1989.
 
9) NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphoma, Ver.4, 2011 [http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf].
 
10) Eichhorst B, et al ; ESMO Guidelines Working Group : Chronic lymphocytic leukaemia : ESMO Clini-cal Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5):v162-164, 2010.
 
11) Gribben JG : How I treat CLL up front. Blood 115:187-197, 2010.
 
12) Smolej L : How I treat elderly or comorbid patients with chronic lymphocytic leukemia. Acta Medica (Hradec Kralove) 53:213-220, 2010.
PubMed
13) Gribben JG, O'Brien S : Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29:544-550, 2011.
 
14) Hallek M, Pflug N : State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 25:1-9, 2011.
PubMed
15) Michallet M, et al ; EBMT Chronic Leukemia Working Party : Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia : results of European intergroup randomized trial comparing autografting versus observation. Blood 117:1516-1521, 2011.
PubMed
P.480 掲載の参考文献
1) Roulland S, et al : Follicular lymphoma-like B cells in healthy individuals : a novel intermediate step in early lymphomagenesis. J Exp Med 203:2425-2431, 2006.
 
2) Hirt C, et al : Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. Br J Haematol 138:349-353, 2007.
PubMed
3) Carlotti E, et al : Transformation of follicular lymphoma to diffyse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lym-phoma clone. Blood 113:3553-3557, 2009.
 
4) McDonnell TJ, et al : bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989.
PubMed
5) Egle A, et al : VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103:2276-2283, 2004.
PubMed
6) Hoglund M, et al : Identification of cytogenetic subgroups and karyotypic pathways of clonal evolu-tion in follicular lymphomas. Genes Chromosomes Cancer 39:195-204, 2004.
 
7) Dave SS, et al : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004.
PubMed
8) Glas AM, et al : Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105:301-307, 2005.
PubMed
9) Elenitoba-Johnson KS, et al : Involvement of multiple signaling pathways in follicular lymphoma transformation : p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 100:7259-7264, 2003.
PubMed
10) Pangault C, et al : Follicular lymphoma cell niche : identification of a preeminent IL-4-dependent TFH-B cell axis. Leukemia 24:2080-2089, 2010.
PubMed
11) Glas AM, et al : Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390-398, 2007.
PubMed
12) Alvaro T, et al : Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24:5350-5357, 2006.
PubMed
13) Ruminy P, et al : Sμ mutation patterns suggest different progression pathways in follicular lymphoma : early direct or late from FL progenitor cells. Blood 112:1951-1959, 2008.
 
14) Eide MB, et al : Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116:1489-1497, 2010.
PubMed
15) Salles G, et al : Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) : a phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
 
P.486 掲載の参考文献
1) Isaacson PG, Wright DH : Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983.
 
2) Isaacson PG, et al : Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 10 Mature B-cell lymphoma. In : WHO Classification of Tumours of Haemato-poietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p214-219, IARC, Lyon, 2008.
 
3) Guidoboni M, et al : Infectious agents in mucosa-associated lymphoid tissue-type lymphomas : pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma 6:289-300, 2006.
PubMed
4) Ferry JA : Extranodal lymphoma. Arch Pathol Lab Med 132:565-578, 2008.
PubMed
5) Inagaki H : Mucosa-associated lymphoid tissue lymphoma : Molecular pathogenesis and clinicopa-thological significance. Pathol Int 57:474-484, 2007.
 
6) Ruskone-Fourmestraux A, et al : EGILS consensus report Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60:747-758, 2011.
PubMed
7) Tsang RW, et al : Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21:4157-4164, 2003.
PubMed
8) Martinelli G, et al : Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979-1983, 2005.
PubMed
9) Conconi A, et al : Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741-2745, 2003.
PubMed
10) Psyrri A, et al : Primary extranodal lymphomas of stomach : clinical presentation, diagnostic pitfalls and management. Ann Oncol 19:1992-1999, 2008.
 
11) Jager G, et al : Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lym-phoid tissue type with cladribine : aphase II study. J Clin Oncol 20:3872-3877, 2002.
 
12) Troch M, et al : A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 94:738-742, 2009.
PubMed
13) Esmaeli B, et al : Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20:709-714, 2009.
PubMed
14) Zucca E, Cavalli F : Extranodal lymphoma. Ann Oncol 11 (Suppl 3):219-222, 2000.
 
P.493 掲載の参考文献
1) Zhou Y, et al : Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113 (4):791-798, 2008.
PubMed
2) Parry-Jones N, et al : Cytogenetic abnormalities additional to t(11;14)correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis : a study of 60 cases by FISH. Br J Haematol 137 (2):117-124, 2007.
 
3) Campo E, et al : Mantle-cell lymphoma. Semin Hematol 36 (2):115-127, 1999.
PubMed
4) Anderson JR , et al : Epidemiology of the non-Hodgkin's lymphomas : distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9 (7):717-720, 1998.
PubMed
5) Gualco G, et al : BCL6, MUM1, and CD10 expression in mantle cell lymphoma. Appl Immunohisto-chem Mol Morphol 18 (2):103-108, 2010.
 
6) Norton AJ, et al : Mantle cell lymphoma : natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6 (3):249-256, 1995.
 
7) Yatabe Y, et al : Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma : a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95 (7):2253-2261, 2000.
 
8) Banks PM, et al : Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16 (7):637-640, 1992.
PubMed
9) Tolksdorf G : Morphological and immunological definition of a malignant lymphoma derived from ger-minal-centre cells with cleaved nuclei (centrocytes). Br J Cancer 41 (2):168-182, 1980.
 
10) Bosch F, et al : Mantle cell lymphoma : presenting features, response to therapy, and prognostic factors. Cancer 82 (3):567-575, 1998.
PubMed
11) Romaguera JE, et al : Frequency of gastrointestinal involvement and its clinical significance in man-tle cell lymphoma. Cancer 97 (3):586-591, 2003.
 
12) Hosein PJ, et al : Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 86 (10):841-845, 2011.
PubMed
13) Gill S, et al : [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Mye-loma 8 (3):159-165, 2008.
 
14) Herrmann A, et al : Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27 (4):511-518, 2009.
PubMed
15) Martin P, et al : Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma : overall survival exceeding 7 years with standard therapies. Ann Oncol 19 (7):1327-1330, 2008.
 
16) Ondrejka SL, et al : Indolent mantle cell leukemia : a clinicopathological variant characterized by iso-lated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96 (8):1121-1127, 2011.
 
17) Fernandez V, et al : Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70 (4):1408-1418, 2010.
PubMed
18) Gladden AB, et al : Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25 (7):998-1007, 2006.
PubMed
19) Lovec H, et al : Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13 (15):3487-3495, 1994.
PubMed
20) Fu K, et al : Cyclin D1-negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling. Blood 106 (13):4315-4321, 2005.
PubMed
21) Rosenwald A, et al : The proliferation gene expression signature is a quantitative integrator of onco-genic events that predicts survival in mantle cell lymphoma. Cancer Cell 3 (2):185-197, 2003.
 
22) Jares P, et al : Genetic and molecular pathogenesis of mantle cell lymphoma : perspectives for new targeted therapeutics. Nat Rev Cancer 7 (10):750-762, 2007.
PubMed
23) Pinyol M, et al : Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89 (1):272-280, 1997.
PubMed
24) Greiner TC, et al : p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87 (10):4302-4310, 1996.
PubMed
25) Hoster E, et al : A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111 (2):558-565, 2008.
PubMed
26) Hartmann E, et al : Five-gene model to predict survival in mantle-cell lymphoma using frozen or for-malin-fixed, paraffin-embedded tissue. J Clin Oncol 26 (30):4966-4972, 2008.
 
27) Determann O, et al : Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy : results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111 (4):2385-2387, 2008.
 
28) Raty R, et al : Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur J Cancer 39 (3):321-329, 2003.
PubMed
29) Mozos A, et al : SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94 (11):1555-1562, 2009.
PubMed
30) Ghielmini M, et al : Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma : a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23 (4):705-711, 2005.
PubMed
31) Foran JM, et al : European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18 (2):317-324, 2000.
 
32) Lenz G, et al : Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincris-tine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma : results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23 (9):1984-1992, 2005.
 
33) Griffiths R : Addition of rituximab to chemotherapy alone as first-line therapy improves over-all survival in elderly patients with mantle cell lymphoma. Blood 118 (18):4808-4816, 2011.
PubMed
34) Schulz H, et al : Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma : a systematic review and meta-analysis. J Natl Cancer Inst 99 (9):706-714, 2007.
PubMed
35) Delarue R, et al : RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) : final results of a phase II study from the GELA, Blood 112 (Abstract 581):218, 2008.
 
36) Epner EM, et al : A multicenter trial of hyper-CVAD+ rituximab in patients with newly diagnosed mantle cell lymphoma. Blood 110 (Abstract387):121, 2007.
 
37) Nickenig C, et al : Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity com-pared with com-bined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107 (5):1014-1022, 2006.
PubMed
38) de Guibert S, et al : Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 91 (3):425-426,2006.
PubMed
39) Romaguera JE, et al : High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23 (28):7013-7023, 2005.
PubMed
40) Howard OM, et al : Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lym-phoma : molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20 (5):1288-1294, 2002.
 
41) Romaguera JE, et al : Untreated aggressive mantle cell lymphoma : results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39 (1-2):77-85, 2000.
PubMed
42) Khouri IF, et al : Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell trans-plantation : an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16 (12):3803-3809, 1998.
 
43) Teodorovic I, et al : Efficacy of four different regimens in 64 mantle-cell lymphoma cases : clinicopa-thologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13 (11):2819-2826, 1995.
 
44) Meusers P, et al : Multicentre randomized therapeutic trial for advanced centrocytic lymphoma : anthracycline does not improve the prognosis. Hematol Oncol 7 (5):365-380, 1989.
 
45) Lacasce A, et al : R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma : a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. Blood 114 (Abstract403):167, 2009.
 
46) van't Veer MB, et al : High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 144 (4):524-530, 2009.
 
47) Dreyling M, et al : Early consolidation by myeloablative radiochemotherapy followed by autolo-gous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma : results of a prospective randomized trial of the European MCL Network. Blood 105 (7):2677-2684, 2005.
 
48) Schaffel R, et al : Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 21 (1):133-139, 2010.
PubMed
49) Damon LE, et al : Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma : CALGB 59909. J Clin Oncol 27 (36):6101-6108, 2009.
PubMed
50) Geisler CH, et al : Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue : a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112 (7):2687-2693, 2008.
 
51) Dreger P, et al : Rituximab-augmented myeloablation for first-line autologous stem cell transplanta-tion for mantle cell lymphoma : effects on molecular response and clinical outcome. Haematologica 92 (1):42-49, 2007.
 
52) Khouri IF, et al : Long-term follow-up of autologous stem cell transplantation in patients with dif-fuse mantle cell lymphoma in first disease remission : the prognostic value of beta2-microglobulin and the tumor score. Cancer 98 (12):2630-2635, 2003.
 
53) Geisler CH, et al : Update of the NORDIC MCL2 trial : 10-year survival 57% following intensive immunochemotherapy and ASCT, but late relapse do occur. Ann Oncol 22 (Abstract102), 2011.
 
54) Cook G, et al : Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL) : a study of the British society for blood and marrow transplantation. Biol Blood Marrow Transplant 16 (10):1419-1427, 2010.
PubMed
55) Kiss TL, et al : Stem cell transplantation for mantle cell lymphoma : if, when and how? Bone Mar-row Transplant 36 (8):655-661, 2005.
 
56) Maris MB, et al : Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (12):3535-3542, 2004.
PubMed
57) Khouri IF, et al : Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 (23):4407-4412, 2003.
PubMed
58) Martin P, et al : Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27 (8):1209-1213, 2009.
PubMed
59) Eve HE, et al : Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 27 (32):e189-190;author reply e91, 2009.
PubMed
60) Rummel M, et al : Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent and mantle cell lymphomas : final result of a randomized phase III study of StiL (Study Group Indolent Lymphomas, Germany). Blood 114:405, 2009.
 
61) Inwards DJ, et al : Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-853) or 2-CDA and rituximab (N0189) in the North Central Cah-cer Treatment Group. Cancer 113 (1):108-116, 2008.
 
62) Pott C, et al : R-CHOP vs R-FC followed by maintenance with rituximab or IFN : first results of MRD assessment within the randomized trial for elderly patients with MCL. Ann Oncol 22:233, 2011.
 
63) Robinson KS, et al : Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26 (27):4473-4479, 2008.
PubMed
64) Forstpointner R, et al : The addition of rituximab to a combination of fludarabine, cyclophospha-mide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as com-pared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (10):3064-3071, 2004.
 
65) Habermann TM, et al : Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145 (3):344-349, 2009.
PubMed
66) Goy A, et al : Bortezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20 (3):520-525, 2009.
 
67) Ruan J, et al : Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lym-phoma and mantle cell lymphoma. J Clin Oncol 29 (6):690-697, 2011.
 
P.502 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
 
2) Lenz G, et al : Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008.
 
3) Miyazaki K et al : CD5-positive diffuse large B-cell lymphoma : a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22 (7):1601-1607, 2011.
PubMed
4) Hans CP, et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004.
PubMed
5) Shimada K, et al : Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895-902, 2009.
 
P.507 掲載の参考文献
1) Fisher RI, et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.
PubMed
2) Coiffier B, et al : CHOP chemotherapy plus rituXimab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
PubMed
3) Feugier P, et al : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005.
 
4) Habermann TM, et al : Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006.
 
5) Pfreundschuh M, et al : CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised con-trolled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006.
 
6) Pfreundschuh M, et al : Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008.
PubMed
7) Ohmachi K, et al : Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lym-phoma : final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 22:1382-1391, 2011.
 
8) Pfreundschuh M, et al : Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
 
9) Pro B, et al : Durable remissions with brentuximab vedotin (SGN-35) : Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ASCO Annual Meeting : #8032, 2011.
 
10) Delarue R, et al : R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma : results of the interim analysis of the LNH03-6B GELA study. ASH Annual Meeting : abstract 406, 2009.
 
11) Shipp MA, et al : International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas : report of the Jury. J Clin Oncol 17:423-429, 1999.
 
12) Gianni AM, et al : High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1298, 1997.
PubMed
13) Milpied N, et al : Initial treatment of aggressive lymphoma with high-dose chemotherapy and autolo-gous stem-cell support. N Engl J Med 350:1287-1295, 2004.
 
14) Martelli M, et al : High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with par-tial response to front-line chemotherapy : a prospective randomized italian multicenter study. J Clin Oncol 14:534-542, 1996.
 
15) Gisselbrecht C, et al : Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002.
PubMed
16) Stiff PJ, et al : Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP+-R for eight cycles to CHOP+-R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). ASCO Annual Meeting : #8001, 2011.
 
17) Schmitz N, et al : Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma : Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). ASCO Annual Meeting : #8002, 2011.
 
18) Miller TP, et al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high -grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998.
PubMed
19) Bonnet C, et al : CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007.
 
20) Reyes F, et al : ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005.
PubMed
21) Persky DO, et al : Phase II study of rituximab plus three cycles of CHOP and involved-field radio-therapy for patients with limited-stage aggressive B-cell lymphoma : Southwest Oncology Group study 0014. J Clin Oncol 26:2258-2263, 2008.
 
P.512 掲載の参考文献
1) Feugier P, et al : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005.
 
2) Philip T, et al : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
PubMed
3) Kewalramani T, et al : Rituximab and ICE as second-line therapy before autologous stem cell trans-plantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004.
PubMed
4) Vellenga E, et al : Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL : a prospective randomized HOVON trial. Blood 111:537-543, 2008.
PubMed
5) Martin A, et al : R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma : the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 93:1829-1836, 2008.
PubMed
6) Hagberg H, Gisselbrecht C ; CORAL study group : Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse Iarge B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not : an update of the CORAL study. Ann Oncol 17:iv31-32, 2006.
PubMed
7) Gisselbrecht C, et al : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010.
 
P.517 掲載の参考文献
1) Picarsic J, et al : Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer 117:4540-4550, 2011.
 
2) Lenze D, et al : The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 25:1869-1876, 2011.
 
3) Rodig SJ, et al : Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 32:113-122, 2008.
PubMed
4) Naresh KN, et al : Diagnosis of Burkitt lymphoma using an algorithmic approach-applicable in both resource-poor and resource-rich countries. Br J Haematol 154:770-776, 2011.
PubMed
5) Wasterlid T, et al : Population based study of prognostic factors and treatment in adult Burkitt lym-phoma : a Swedish Lymphoma Registry study. Leuk Lymphoma 52:2090-2096, 2011.
 
6) Nelson M, et al : An increased frequency of 13q deletions detected by fluorescence in situ hybridiza-tion and its impact on survival in children and adolescents with Burkitt lymphoma : results from the Children's Oncology Group study CCG-5961. Br J Haematol 148:600-610, 2010.
 
7) Mussolin L, et al : Minimal disseminated disease in high-risk Burkitt's lymphoma identifies patients with different prognosis. J Clin Oncol 29:1779-1784, 2011.
PubMed
8) Magrath I, et al : Adult and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
PubMed
9) Mead GM, et al : An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma : results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002.
PubMed
10) Maruyama D, et al : Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with fea-tures intermediate between diffuse large B cell lymphoma and BL Int J Hematol 92:732-743, 2010.
PubMed
11) Lacasce A, et al : Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas : preserved efficacy with decreased toxicity. Leuk Lymphoma 45:761-767, 2004.
PubMed
12) Mead GM, et al : A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:2248-2260, 2008.
PubMed
13) Mohamedbhai SG, et al : Rituximab in combination with CODOX-M/IVAC : a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol 152:175-181, 2011.
PubMed
14) Thomas DA, et al : Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470, 1999.
 
15) Thomas DA, et al : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
P.524 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
 
2) Amin HM, Lai R : Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110:2259-2267, 2007.
PubMed
3) Savage KJ, et al : ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically dif-ferent from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified : report from the International Peripheral T-Cell Lymphoma Project, Blood 111:5496-5504, 2008.
 
4) Vose J, et al : International peripheral T-cell and natural killer/T-cell lymphoma study : pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
5) Weisenburger DD, et al : International Peripheral T-cell Lymphoma Project : Peripheral T-cell lymphoma, not otherwise specified : a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117 (12):3402-3408, 2011.
 
6) Gisselbrecht C, et al : Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas, Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82, 1998.
 
7) Hyo R, et al : Improved prognosis of NK-cell lymphoma/leukemia, but not for T-cell lymphomas : a nationwide survey of NK-and associated T-cell neoplasms by the NK-cell Tumor Study Group (NKTSG). Ann Oncol 22 (Suppl 4):iv164, 2011.
 
8) Seidemann K, et al : Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma : a report of the Berlin-Frankfurt-MUnster Group Trial NHL-BFM 90. Blood 97:3699-3706, 2001.
PubMed
9) Brugieres L, et al : Impact of the methotrexate administration dose on the need for intrathecal treat-ment in children and adolescents with anaplastic large-cell lymphoma : results of a randomized trial of the EICNHL Group. J Clin Oncol 27:897-903, 2009.
 
10) Takamatsu Y, et al : THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma : A multicenter phase II study. Eur J Haematol 84:391-393, 2010.
PubMed
11) Schmitz N, et al : Treatment and prognosis of mature T-cell and NK-cell lymphoma : an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lym-phoma Study Group. Blood 116:3418-3425, 2010.
 
12) Gutierrez A, et al : Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 42:773-781, 2008.
PubMed
13) Reimer P, et al : Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas : results of a prospective multicenter study. J Clin Oncol 27:106-113, 2009.
PubMed
14) Corradini P, et al : Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lym-phomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.
 
15) Foss FM, et al : Peripheral T-cell lymphoma. Blood 117:6756-6767, 2011.
PubMed
P.526 掲載の参考文献
2) Shimoyama M : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma : A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991.
 
3) Tsukasaki K, et al : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma : A proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2009.
PubMed
4) Takasaki Y, et al : Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115 (22):4337-4343, 2010.
PubMed
5) Tsukasaki K, et al : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group. J Clin Oncol 25:5458-5564, 2007.
 
6) Hishizawa M, et al : Transplantation of allogeneic hematopoietic stem cells for adult T-cell leu-kemia : a nationwide retrospective study. Blood 116 (8):1369-1376, 2010.
 
7) Bazarbachi A, et al : Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved sllrvival in the leukemic subtypes. J Clin Oncol 28 (27):4177-4183, 2010.
PubMed
8) Yamamoto K, et al : Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28 (9):1591-1598, 2010.
PubMed
P.529 掲載の参考文献
1) Dogan A, et al : Angioimmunoblastic T-cell lymphoma. In : WHO CIassification of Tumours of Hae-matopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p309-311, IARC Press, Lyon, 2008.
 
2) Tobinai K, et al : Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood 72:1000-1006, 1988.
PubMed
3) International T-Cell Lymphoma Project : International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study : pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
4) Dupuis J, et al : Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL) : a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490-494, 2006.
PubMed
5) de Leval L, et al : The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952-4963, 2007.
PubMed
6) Watanabe T, et al : Pretreatment total serum protein is a significant prognostic factor for the out-come of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 51:813-821, 2010.
 
7) Mourad N, et al : Clinica1, biologic, and pathologic features in 157 patients with angioimmunoblas-tic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111:4463-4470, 2008.
 
8) Gallamini A, et al : Peripheral T-cell lymphoma unspecified (PTCL-U) : a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
 
9) Kewalramani T, et al : Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haemato1134:202-207, 2006.
 
10) Reimer P, et al : Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lym-phomas : results of a prospective multicenter study. J Clin Oncol 27:106-113, 2009.
 
11) Corradini P, et al : Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lym-phomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.
 
12) Gallamini A, et al : Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma : results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007.
PubMed
13) Yamamoto K, et al : Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010.
PubMed
14) Ishida T, et al : CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10:5494-5500, 2004.
 
15) Bruns I, et al : Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 19:1993-1995, 2005.
 
P.536 掲載の参考文献
1) Uchiyama T, et al : Adult T-cell leukemia : clinical and hematologic features of 16 cases. Blood 50:481-492, 1977.
PubMed
P.542 掲載の参考文献
1) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.
PubMed
2) 濱田利久 : 本邦における皮膚悪性リンパ腫の現状. 日皮会誌 120:2657-2661, 2010.
 
3) Kim YH, et al : TNM classification system for primary cutaneous lymphomas other than mycosis fun-goides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:479-484, 2007.
 
4) Vonderheid EC, et al : Update on erythrodermic cutaneous T-cell lymphoma : Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95-106, 2002.
PubMed
5) Olsen E, et al : Revisions to the staging and classification of mycosis fungoides and Sezary syn-drome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC), Blood 110:1713-1722, 2007.
 
6) Whittaker SJ, et al : Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 149:1095-1107, 2003.
 
7) Bekkenk MW, et al : Primary and secondary cutaneous CD30 (+) lymphoproliferative disorders : a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000.
 
8) Woo DK, et al : Prognostic factors in primary cutaneous anaplastic large cell lymphoma : characterization of clinical subset with worse outcome. Arch Dermatol 145:667-674, 2009.
PubMed
9) Fujita A, et al : Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. J Dermatol 38:524-530, 2011.
PubMed
10) Willemze R, et al : Subcutaneous panniculitis-like T-cell lymphoma : definition, classification, a prognostic factors : an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111:838-845, 2008.
 
P.547 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), LARC, Lyon, 2008.
 
2) 山口素子 : NK/T 細胞リンパ腫の新しい治療. 臨血 51:1587-1594, 2010.
 
3) Suzuki R, et al : Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040, 2010.
PubMed
4) Lee J, et al : Extranodal natural killer T-cell lymphoma, nasal-type : a prognostic model from a ret-rospective multicenter study. J Clin Oncol 24:612-618, 2006.
 
5) Suzuki R, et al : Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 118:6018-6022, 2011.
PubMed
6) Kim GE, et al : Angiocentric lymphoma of the head and neck : patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000.
PubMed
7) Yamaguchi M, et al : Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594-5600, 2009.
 
8) Kim SJ, et al : Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma : Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027-6032, 2009.
 
9) 山口素子, 小口正彦 : RT+ DeVIC療法. 悪性リンパ腫治療マニュアル改訂第3版 (飛内賢正ほか 編), p259-264, 南江堂, 2009.
 
10) Kim HJ, et al : High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma : a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 37:819-824, 2006.
PubMed
11) Lee J, et al : Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma : a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 14:1356-1364, 2008.
PubMed
12) Yamaguchi M, et al : Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage or relapsed/refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008.
PubMed
13) Yamaguchi M, et al : Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type : the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410-4416, 2011.
 
14) Jaccard A, et al : Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117:1834-1839, 2011.
PubMed
15) Kwong YL, et al : Management of T-cell and natural-killer-cell neoplasms in Asia : consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1093-1101, 2009.
PubMed
P.552 掲載の参考文献
1) Ishida F, Kwong YL : Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 3:593-602, 2010.
PubMed
2) Ryder J, et al : Aggressive natural killer cell leukemia : report of a Chinese series and review of the literature. Int J Hematol 85:18-25, 2007.
PubMed
3) Suzuki R, et al : Aggressive natural killer-cell leukemia revisited : large granular lymphocyte leuke-mia of cytotoxic NK cells. Leukemia 18:763-770, 2004.
 
4) Ko YH, et al : Aggressive natural killer cell leukemia : is Epstein-Barr virus negativity an indicator of a favorable prognosis? Acta Haematol 120:199-206, 2009.
PubMed
5) Mizuno S, et al : Interferon-gamma prevents apoptosis in Epstein-Barr virus-infected natural killer cell leukemia in an autocrine fashion. Blood 93:3494-3504, 1999.
 
6) Makishima H, et al : Chemokine system and tissue infiltration in aggressive NK-cell leukemia. Leuk Res 31:1237-1245, 2007.
PubMed
7) Makishima H, et al : Significance of chemokine receptor expression in aggressive NK cell leukemia. Leukemia 19:1169-1174, 2005.
 
8) Karube K, et al : Identification of FOXO3 and PRDM1 as tumor suppressor gene candidates in NK cell neoplasms by genomic and fUnctional analyses. Blood 118:3195-3204, 2011.
PubMed
9) Yamanaka Y, et al : Aberrant overexpression of microRNAs activate AKT signaling via down-regula-tion of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 114:3265-3275, 2009.
 
10) Caligiuri MA : Human natural killer cells. Blood 112:461-469, 2008.
PubMed
11) Chan JKC, et al : Aggressive NK-cell leukaemia. In : WHO Classification of Tumours of Haemato-poietic and ymphoid Tissues (ed by Swerdlow SH, et al), p276-277, IARC, Lyon, 2008.
 
12) Ishida F, et al : Aggressive NK-cell leukemia (ANKL) : Experience in 34 patients and therapeutic potentials of L-asparaginase and allogeneic hematopoietic cell transplantation. Blood 116:3091a, 2010.
 
13) Suzuki R, et al : Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040, 2010.
PubMed
14) Yamaguchi M, et al : Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed, or refractory extranodal NK/T-cell lymphoma, nasal type : the NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol 29:4410-4416, 2011.
 
15) Ito T, et al : Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur J Haematol 81:107-111, 2008.
PubMed
P.560 掲載の参考文献
1) Lukes RJ, Butler JJ : The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063-1083, 1966.
PubMed
2) Harris NL, et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
 
3) Mason DY, et al : Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathologi-cal entity. Am J Surg Pathol 18:526-530, 1994.
 
4) Harris NL : Hodgkin's disease : classification and differential diagnosis. Mod Pathol 12:159-175, 1999.
PubMed
5) Marafioti T, et al : Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453-458, 1997.
PubMed
6) Carbone PP, et al : Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (11):1860-1861, 1971.
 
7) Rosenberg SA, et al : Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res 31 (11):1862-1863, 1971.
 
8) Lister TA, et al : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 7:1630-1636, 1986.
 
9) Kaplan HS, Rosenberg SA : The treatment of Hodgkin's disease. Med Clin North Am 50:1591-1610, 1966.
PubMed
P.566 掲載の参考文献
1) Nogova L, et al : Lymphocyte-predominant and classical Hodgkin's lymphoma : a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439, 2008.
 
2) Diehl V, et al : Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin s disease and lymphocyte-rich classical Hodgkin's disease : report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783, 1999.
PubMed
3) Biasoli I, et al : Nodular, lymphocyte-predominant Hodgkin lymphoma : a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631-639, 2010.
 
4) Al-Mansour M, et al : Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 2010.
PubMed
5) Lukes RJ, et al : Natural history of Hodgkin's disease as related to its pathologic picture. Cancer 19:317-344, 1966.
 
6) Miettinen M, et al : Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 51:2293-2300, 1983.
PubMed
7) Chen RC, et al : Early-stage, lymphocyte-predominant Hodgkin's lymphoma : patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28:136-141, 2010.
PubMed
8) Nogova L, et al : Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lym phocyte-pred ominant Hodgkin's lymphoma : a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687, 2005.
 
9) Wirth A, et al : Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma : a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221-1229, 2005.
PubMed
10) Wilder RB , et al : European Organization for Research and Treatment of Cancerand Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94:1731-1738, 2002.
 
11) Canellos GP, et al : Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
 
12) Duggan DB, et al : Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease : report of an intergroup trial. J Clin Oncol 21:607-614, 2003.
 
13) Canellos GP, et al : Primary systemic treat mento fadvanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin) : 10-year follow-up. Ann Oncol 14:268-272, 2003.
 
14) Bodis S, et al : Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 15:3060-3066, 1997.
PubMed
15) Canellos GP, Mauch P : What is the appropriate systemic chemotherapy for lymphocyte-predomi-nant Hodgkin's lymphoma? J Clin Oncol 28:e8, 2010.
 
16) Rehwald U, et al : Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101:420-424, 2003.
 
17) Schulz H, et al : Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma : long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109-111, 2008.
 
18) Unal A, et al : Familial nodular lymphocyte predominant Hodgkin lymphoma : Successful treatment with CHOP plus rituximab. Leuk Lymphoma 46:1613-1617, 2005.
PubMed
19) Cheson BD, et al : Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
PubMed
20) Terasawa T, et al : Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma : a systematic review. J Clin Oncol 27:1906-1914, 2009.
PubMed
P.575 掲載の参考文献
1) Lister TA, et al : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.
PubMed
2) Mauch PM : Controversies in the management of early stage Hodgkin's disease. Blood 83:318- 329, 1994.
 
3) Hasenclever D, Diehl V : A prognostic score for advanced Hodgkin's disease. Intemational Prognos-tic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
 
4) Cheson BD, et al : Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
PubMed
5) Gallamini A, et al : Early interim 2- [18F]fluoro-2-deoxy-D-glucose positron emission tomogra-phy is prognostically superior to international prognostic score in advanced-stage Hodgkin's lym-phoma : a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007.
 
6) Terasawa T, et al : Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffise large B-cell lymphoma : a systematic review. J Clin Oncol 27:1906-1914, 2009.
 
7) Sher DJ, et al : Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin's lym-phoma : the importance of involved-field radiotherapy. Ann Oncol 20:1848-1853, 2009.
 
8) Engert A, et al : Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma : results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003.
 
9) Bonadonna G, et al : ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease : long-term results. J Clin Oncol 22:2835-2841, 2004.
PubMed
10) Ferme C, et al : Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916-1927, 2007.
PubMed
11) Engert A, et al : Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010.
PubMed
12) Eich HT, et al : Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma : final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010.
 
13) Takenaka T, et al : Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincris-tine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease : a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol 30:146-152, 2000.
 
14) Canellos GP, et al : Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
 
15) Duggan DB, et al : Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease : report of an intergroup trial. J Clin Oncol 21:607-614, 2003.6
 
16) Gobbi PG, et al : ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma : final results of a multicen-ter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005.
 
17) Johnson PW, et al : Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma : results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23:9208-9218, 2005.
 
18) Horning SJ, et al : Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease : mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002.
 
19) Diehl V, et al : Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003.
PubMed
20) Federico M, et al : ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma : results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27:805-811, 2009.
 
21) Viviani S, et al : ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365:203-212, 2011.
PubMed
22) Engert A, et al : Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodg-kin's lymphoma : 10 years of follow-up of the GHSG HD9 study. J Clin Onco 27:4548-4554, 2009.
 
23) Schmitz N, et al : Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's dis-ease : a randomised trial. Lancet 359:2065-2071, 2002.
 
24) Younes A, et al : Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010.
PubMed
P.582 掲載の参考文献
1) Grass S, et al : Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance : a case-control study. Lancet Oncol 10:950-956, 2009.
PubMed
2) Grass S, et al : Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma. Cancer Sci 102:565-568, 2011.
PubMed
3) Palumbo A, Anderson K : Multiple myeloma. N Engl J Med 364:1046-1060, 2011.
PubMed
4) Kumar SK, et al : Management of newly diagnosed symptomatic multiple myeloma : updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095-1110, 2009.
PubMed
5) Zhan F, et al : The molecular classification of multiple myeloma. Blood 108:2020-2028, 2006.
PubMed
6) Pei H, et al : MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470:124-128, 2011.
PubMed
7) Martinez-Garcia E, et al : The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117:211-220, 2011.
 
8) Hurt EM, et al : Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199, 2004.
PubMed
9) Annunziata CM, et al : A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117:2396-2404, 2011.
PubMed
10) Shaffer AL, et al : IRF4 addiction in multiple myeloma. Nature 454:226-231, 2008.
PubMed
11) Lopez-Girona A, et al : Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154:325-336, 2011.
PubMed
12) Zheng Y, et al : Macrophages are an abundant component of myeloma microenvironment and pro-tect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114:3625-3628, 2009.
 
13) Abe M : Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 94:334-343, 2011.
PubMed
14) Raab MS, et al : Multiple myeloma. Lancet 374:324-339, 2009.
PubMed
P.587 掲載の参考文献
1) Durie BGM : Staging and kinetics of multiple myeloma. Semin Oncol 13:300-309, 1986.
 
2) The International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121:749-757, 2003.
 
3) Durie BGM, et al : Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55:364-372, 1980.
 
4) Duri BGM, salamon SE : A clinical staging system for multiple myeloma. cancer 36:842-854, 1975.
 
5) Jacobson JL, et al : A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441-450, 2003.
 
6) Greipp PR, et al : International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005.
PubMed
7) Fonseca R, et al : Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (del13) in multiple myeloma : an eastern cooperative oncology group study. Cancer Res 62:715-720, 2002.
 
8) Stewart AK, et al : A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21:529-534, 2007.
PubMed
9) Avet-Loiseau H, et al : Genetic abnormalities and survival in multiple myeloma : the experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495, 2007.
PubMed
10) Fonseca R, et al : Myeloma and the t(11;14) (q13;32) ; evidence for a biologically defined unique sub-set of patients. Blood 99:3735-3741, 2002.
 
11) Fonseca R, et al : Clinical and biologic implication of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003.
PubMed
12) Chang H, et al : P53 gene deletion detected by nuorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358-360, 2005.
PubMed
13) Fonseca R, et al : Genetics and cytogenetics of multiple myeloma : A workshop report. Cancer Res 64:1546-1558, 2004.
PubMed
14) Rajkumar SV : Multiple myeloma : 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:57-65, 2011.
PubMed
15) Palumbo A, Anderson K : Multiple myeloma. N Engl J Med 364:1046-1060, 2011.
PubMed
P.594 掲載の参考文献
1) Moreau P, et al : Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 117:3041-3044, 2011.
PubMed
2) Macro M, et al : Dexamethasone+ thalidomide (Dex/Thal) compared to VAD as a pretransplant treatment in newly diagnosed multiple myeloma (MM) : A randomized trial. Blood 108:22a, abstract 57, 2006.
 
3) Lokhorst HM, et al : A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115:1113-1120, 2010.
PubMed
4) Sonneveld P, et al : HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and mainte-nance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 116:23, abstract 40, 2010.
 
5) Morgan GJ, et al : The addition of thalidomide to the induction treatment of newly presenting mye-loma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood 114:149, abstract 352, 2009.
 
6) Rajkumar SV, et al : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma : an open-label ran-domized controlled trial. Lancet Oncol 11:29-37, 2010.
 
7) Cavo M, et al : Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma : a randomized phase 3 study. Lancet 376:2075-2085, 2010.
PubMed
8) Rosinol L, et al : Thalidomide/dexamethasone (TD) vs bortezomib (Velcade) (R)/thalidomide/dexame-thasone (VTD) vs VBMCP/VBAD/Velcade (R) as induction regimens prior to autologous stem cell transplantation (ASCT) in multiple myeloma (MM) : Results of a phase III PETHEMA/GEM trial. Blood 114:59, abstract 130, 2009.
 
9) Moreau P, et al : Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo mul-tiple myeloma (MM) : Results of IFM 2007-02 study. J Clin Oncol 28:15S, abstract 8014, 2010.
 
10) Reeder CB, et al : Cyclophosphamide, bortezomib and dexamethasone induction for newly diag-nosed multiple myeloma : high response rates in a phase II clinical trial. Leukemia 23:1337-1341, 2009.
 
11) Richardson PG, et al : Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686, 2010.
PubMed
12) Kumar S, et al : Novel three-and four-drug combination regimens of bortezomib, dexame-thasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma : Results from the multicenter, randomized, phase 2 EVOLUTION study. Blood 116:275, abstract 621, 2010.
 
13) Offidani M, et al : Outcome and toxicity in the modern era of new drugs for multiple myeloma : a reappraisal for comparison with future investigational trials. Clin Lymphoma Myeloma Leuk 10:353-360, 2010.
PubMed
14) Kumar SK, et al : Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma : Results from a phase 2 trial. Am J Hematol 86:640-645, 2011.
PubMed
15) Kumar SK, et al : Management of newly diagnosed symptomatic multiple myeloma : updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095-1110, 2009.
PubMed
16) Niesvizky R, et al : BiRD (Biaxin (R) [clarithromycin]/Revlimid (R) [lenalidomide]/dexamethasone) com-bination therapy results in high complete-and overall-response rates in treatment-naive sympto-matic multiple myeloma. Blood 111:1101-1109, 2008.
 
17) Roussel M, et al : Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma : a phase 2 study of the Inter-groupe Francophone du Myelome (IFM). Blood 115:32-37, 2010.
 
18) Palumbo A, et al : A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus melphalan (200mg/m2) and autologous transplantation (Mel200) in newly diagnosed mye-loma patients : An interim analysis. Blood 114:148, abstract 350, 2009.
 
19) Attal M, et al : Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006.
PubMed
20) Spencer A, et al : Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788-1793, 2009.
PubMed
21) Zangari M, et al : Eight-year median survival in multiple myeloma after total therapy 2 : roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 141:433-444, 2008.
PubMed
22) Facon T, et al : Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomized trial. Lancet 370:1209-1218, 2007.
PubMed
23) Palumbo A, et al : Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma : updated results of a randomized controlled trial. Blood 112:3107-3114, 2008.
PubMed
24) Hulin C, et al : Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J Clin Onco 27:3664-3670, 2009.
 
25) Wijermans P, et al : Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma : the HOVON 49 study. J Clin Oncol 28:3160-3166, 2010.
PubMed
26) Waage A, et al : Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405-1412, 2010.
 
27) Fayers PM, et al : Thalidomide for previously untreated elderly patients with multiple myeloma : meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239-1247, 2011.
PubMed
28) Mateos MV, et al : Bortezomib plus melphalan and prednisone compared with melphalan and predni-sone in previously untreated multiple myeloma : updated follow-up and impact of subsequent ther-apy in the phase III VISTA trial. J Clin Oncol 28:2259-2266, 2010.
 
29) Mateos MV, et al : Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalido-mide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma : a ran-domized trial. Lancet Oncol 11:934-941, 2010.
 
30) Boccadoro M, et al : Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients. J Clin Oncol 28:576s, abstract 8013, 2010.
 
31) Bringhen S, et al : Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:4745-4753, 2010.
PubMed
32) Morgan GJ, et al : Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX) : secondary outcomes from a random-ized controlled trial. Lancet Oncol 12:743-752, 2011.
 
33) Lacy MQ, et al : Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053, 2006.
 
34) Kyle RA, et al : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472, 2007.
 
P.601 掲載の参考文献
1) 飯田真介 : 再発・難治性骨髄腫に対する治療戦略と新規薬剤のさらなる開発. 臨床血液 51:1511-1522, 2010.
 
2) Morgan GJ, et al : Lenalidomide (Revlimid), in combination with cyclophosphamide and dexametha-sone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137:268-269, 2007.
 
3) Davies FE, et al : The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haemato-logica 92:149-1150, 2007.
 
4) Kropff M, et al : Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 138:330-337, 2007.
PubMed
5) Pineda-Roman M, et al : VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22:1419-1427, 2008.
PubMed
6) Palumbo A, et al : Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 109:2767-2772, 2007.
PubMed
7) Orlowski RZ, et al : Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : combination therapy improves time to progression. J Clin Oncol 25:3892-3901, 2007.
 
8) A-Loiseau H : Ultra high-risk myeloma. In : American Society of Hematology 2010 Education Pro-gram Book, p489-493, American Society of Hematology, Washington, DC, 2010.
 
9) Anderson KC, et al : Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM) : encouraging outcomes and tolerability in a phase II study. J Clin Oncol 27 (SupPl):442s, Abstract #8536, 2009.
 
10) Nair B, et al : Superior results of total therapy 3 in gene expression profiling-defined low-risk mul-tiple myeloma confirmed in subsequent trial 2006-2066 with bortezomib, lenalidomide and dex-amethasone maintenance. Blood 115:4168-4173, 2010.
 
11) Siegel D, et al : Results of PX-171-003-A1, an open-label, single-arm, phase 2 study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. ASH, Abstract#985, 2010.
 
12) Lacy MQ, et al : Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24:1934-1939, 2010.
PubMed
13) Lacy MQ, et al : Pomalidomide plus low-dose dexamethasone in myeloma refractory to both borte-zomib and lenalidomide : comparison of 2 dosing strategies in dual-refractory disease. Blood 118:2970-2975, 2011.
 
14) Knop S, et al : The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Hematologica 90:1287-1288, 2005.
 
15) Michael M, et al : Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 15:13-19, 2010.
 
P.624 掲載の参考文献
1) Attardo-Parrinello G, et al : Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med 147 (9):1629-1633, 1987.
PubMed
2) Ascari E, et al : Treatment of painfU1 bone lesions and hypercalcemia. Eur J Haematol (Suppl) 51:135-139, 1989.
PubMed
3) Belch AR, et al : Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9 (8):1397-1402, 1991.
PubMed
4) Lahtinen R, et al : Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340 (8827):1049-1052, 1992.
PubMed
5) Roux C, et al : Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15 (1):41-49, 1994.
 
6) McCloskey EV, et al : A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100 (2):317-325, 1998.
 
7) Menssen HD, et al : Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20 (9):2353-2359, 2002.
 
8) Brincker H, et al : Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma : a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 101 (2):280-286, 1998.
 
9) Berenson JR, et al : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 (8):488-493, 1996.
 
10) Rosen LS, et al : Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma : a phase III, double-blind, comparative trial. Cancer J 7 (5):377-387, 2001.
PubMed
11) Rosen LS, et al : Long-term efficacy and safety of zoledronic acid compared with pamidronate diso-dium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : a randomized, double-blind, multicenter, comparative trial. Cancer 98 (8):1735-1744, 2003.
PubMed
12) Berenson JR, et al : Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 (2):593-602, 1998.
 
13) UK myeloma forum. British Committee for Standards in Haematology : Diagnosis and management of multiple myeloma. Br J Haematol 115 (3):522-540, 2001.
PubMed
14) Durie BG, et al ; Scientific Advisors of the International Myeloma Foundation : Myeloma manage-ment guidelines : a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4 (6):379-398, 2003.
 
15) Barosi G, et al : Italian Society of Hematology ; Italian Society of Experimental Hematology ; Italian Group for Bone Marrow Transplantation : Management of multiple myeloma and related-disorders : guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 89 (6):717-741, 2004.
 
16) Smith A, et al ; UK Myeloma Forum ; Nordic Myeloma Study Group ; British Committee for Stan-dards in Haematology : Guidelines on the diagnosis and management of multiple myeloma. Br J Hae-matol 132 (4):410-451, 2006.
 
17) Kyle RA, et al : Arnerican Society of Clinical Oncology : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (17):2464-2472, 2007.
 
18) 日本骨髄腫研究会 (編) : 多発性骨髄腫の診療指針, 文光堂, 2004.
 
19) Shipman CM, et al : The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58 (23):5294-5297, 1998.
PubMed
20) Takahashi R, et al : A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 25 (1):77-83, 2001.
PubMed
21) Shipman CM, et al : Bisphosphonates induce apoptosis in human myeloma cell lines : a novel anti-tumour activity. Br J Haematol 98 (3):665-672, 1997.
PubMed
22) Ural AU, et al : The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 78 (5):443-449, 2003.
PubMed
23) Iguchi T, et al : Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apopto-sis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15 (7):719-727, 2003.
 
24) Kunzmann V, et al : Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96 (2):384-392, 2000.
PubMed
25) Derenne S, et al : Zoledronate is a potent inhibitor of myeloma cell groWth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14 (12):2048-2056, 1999.
PubMed
26) Gordon S, et al : Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 119 (2):475-483, 2002.
PubMed
27) Dhodapkar MV, et al Anti-myeloma activity of pamidronate in vivo. Br J Haematol 103 (2):530-532, 1998.
PubMed
28) Kondo H, Mori A : Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 43 (4):919-921, 2002.
PubMed
29) Hofbauer LC, Schoppet M : Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (4):490-495, 2004.
PubMed
30) Tassone P, et al : The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 21 (4):867-873, 2002.
PubMed
31) Yata K, et al : Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells. Int J Hematol 75 (5):534-539, 2002.
PubMed
32) Ciepluch H, et al : Combination of pamidronate and thalidomide in the therapy of treatment-resis-tant multiple myeloma. Med Sci Monit 8 (4):PI31-36, 2002.
 
P.634 掲載の参考文献
33) Terpos E, et al : Pamidronate increases markers of bone formation in patients with multiple mye-loma in plateau phase under interferon-alpha treatment. Calcif Tissue Int 68 (5):285-290, 2001.
 
34) Morris TC, et al ; Northern Ireland Regional Haematology Group : Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol 18 (1):79-84, 2001.
PubMed
35) Imseis RE, et al : Effect of calcitriol and pamidronate in multiple myeloma. Am J Med Sci 318 (1):61-66, 1999.
PubMed
36) Salomo M, et al : How myeloma cells escape bisphosphonate-mediated killing : development of spe-cific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 122 (2):202-210, 2003.
 
37) Musto P, et al : Pamidronate reduces skeleta1 events but does not improve progression-free survival in early-stage untreated myeloma : results of a randomized trial. Leuk Lymphoma 44 (9):1545-1548, 2003.
PubMed
38) Bagan JV, et al : Avascular jaw osteonecrosis in association with cancer chemotherapy : series of 10 cases. J Oral Pathol Med 34 (2):120-123, 2005.
 
39) Bamias A, et al : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol 23 (34):8580-8587, 2005.
PubMed
40) Zarychanski R, et al : Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81 (1):73-75, 2006.
PubMed
41) Badros A, et al : Osteonecrosis of the jaw in multiple myeloma patients : clinical features and risk factors. J Clin Oncol 24 (6):945-952, 2006.
PubMed
42) Montazeri AH, et al : Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79 (1):69-71, 2007.
 
43) Woo SB, et al : Narrative [corrected] review : bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (10):753-761, 2006.
PubMed
44) Hoff AO, et al : Osteonecrosis of the jaw in patients receiving intraveous bisphosphonate therapy. ASCO meeting, abstr no. 8528, 2006.
 
45) Thakker SG, et al : Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 23:51-56, 2006.
 
46) Migliorati CA, et al : Bisphosphonate-associated osteonecrosis : a long-term complication of bisphos-phonate treatment. Lancet Oncol 7:508-514, 2006.
 
47) Kanat O, et al : Bisphosphonate-associated osteonecrosis of the jaws : case reports and analysis of 184 cases. ASCO meeting, abstr no. 18595, 2006.
 
48) Kelleher FC, et al : Is bisphosphonate-induced osteonecrosis of the jaw (BRONJ) an ischemic mani-festation of pseudo-osteopetrosis? : biochemical, densitometric, and imaging evidence. ASCO meeting, abstr no. 18621, 2006.
 
49) Weitzman R, et al : Critical review : updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62:148-52, 2007.
PubMed
50) Van Poznak C, Estilo C : Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 20 (9):1053-1062, 2006.
PubMed
51) Rodan GA, Fleisch HA : Bisphosphonates : mechanism of action. J Clin Oncol 97:2692-2696, 1996.
 
52) Wood J, et al : Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Phar-macol Exp Ther 302:1055-1061, 2002.
 
53) Santini D, et al : Pamidronate induces modification of circulating angiogenic factors in cancer patients. Clin Cancer Res 8:1080-1084, 2002.
PubMed
54) Kapitola J, et al : Effect of growth hormones and pamidronate on bone blood flow, bone mineral and IGF-1 levels in the rat. Physiol Res 49 (Suppl 1):S101-106, 2000.
 
55) Kapitola J, Zak J : Effect of pamidronate on bone blood flow in oophorectomised rates. Physiol Res 47:237-240, 1998.
 
56) Fournier P, et al : Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascu-lar regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544, 2002.
 
57) Rogers MJ, et al : Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978, 2000.
PubMed
58) Benford HL, et al : Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteo-clasts in vitro. Bone 28:465-473, 2001.
 
59) Iizuka T, et al : Alveolar bone remodelling after tooth extraction in normal and osteopetrotic (ia) rats. J Oral Pathol Med 21:150-155, 1992.
PubMed
60) Pozzi S, et al : Bisphosphonate-associated osteonecrosis of the jaw : a review of 35 cases and an evaluation of its frequency in multiple myeloma. Leuk Lymphoma 48:56-64, 2007.
 
61) Ruggiero SL, et al : Bisphosphonate-related osteonecrosis of the jaw : background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (4):433-441, 2006.
PubMed
62) Markowitz GS, et al : Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64 (1):281-289, 2003.
PubMed
63) Desikan R, et al : Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119 (2):496-499, 2002.
PubMed
64) Markowitz GS, : Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39 (5):1118-1122, 2002.
PubMed
65) Markowitz GS, et al : Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 (6):1164-1172, 2001.
PubMed
66) Elisaf M, et al : Multiple electrolytes abnormalities after pamidronate administration. Nephron 79 (3):337-339, 1998.
PubMed
67) Weber CK, et al : Reversible metastatic pulmonary calcification in a patient with multiple myeloma. Ann Hematol 72 (5):329-332, 1996.
 
68) Yaccoby S, et al : Antibody-based inhibition of DKK-1 suppress tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (5):2106-2111, 2007.
 
69) Ohshima K, et al : Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67 (1):1-5, 2001.
 
70) Musto P, et al : Clinical results of recombinant erythropoietin in transfusion-dependent patients with refratory multiple myeloma : role of cytokines and monitoring of erythropoietin. Eur J Haematol 58 (5):314-319, 1997.
 
71) Okuno P, et al : Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 170 (3), 1128-1134, 1990.
 
72) 三輪哲義 : 幹細胞純化 -白血病・骨髄腫診断アトラス, p470-471, メディカルレビュー社, 2008.
 
73) 三輪哲義 : 幹細胞純化 -白血病・骨髄腫診断アトラス, p472, メディカルレビュー社, 2008.
 
74) Tsunoda S, et al : [Coma, hyperviscosity syndrome, hyperammonemia and myelofibrosis in a patient with IgG, lambda type multiple myeloma]. Rinsho Ketsueki 30 (3):361-365, 1989.
 
75) Matsuzaki H, et al : Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Haematol 61 (3):131-137, 1995.
 
76) Lilleby K, et al : A prospective, randomised study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple mye-loma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (11):1031-1035, 2006.
 
77) Terpos E, et al : Increased bone mineral density in a subset of patients with relapsed multiple mye-loma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 21 (7):1561-1562, 2010.
 
78) Bhutani M, et al : Osteomalacia due to adult Fanconi syndrome in multiple myeloma. Leuk Lymphoma 52 (3):536-538, 2011.
PubMed
79) Faggioli L, et al : Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-gamma. Eur J Immunol 27 (11):3022-3030, 1997.
PubMed
80) Puthier D, et al : Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 112 (2):358-363, 2001.
PubMed
81) Isshiki I, et al : Hypercalcemia after High-Dose Chemoradiotherapy for Refractory Multiple Mye-loma ; Subject Heading. Hematology 5 (4):287-292, 2000.
 
82) Hagiwara S, et al : Multidisciplinary nutritional support for autologous hematopoietic stem cell trans-plantation : A cost-benefit analysis. Nutrition 27 (11-12):1112-1117, 2011.
 
83) Morgan GJ, et al : Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM) : Results of the Medical Research Council (MRC) Myeloma IX study. J Clin Oncol 28 (15s):abstr 8021, 2010.
 
84) Morgan GJ, et al : First-line treatment with zoledronic acid as compared with clodronic acid in mul-tiple myeloma (MRC Myeloma IX) : a randomised controlled trial. Lancet 376 (9757):1989-1999, 2010.
 
85) Morgan GJ, et al : Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX) : secondary outcomes from a random-ised controlled trial. Lancet Oncol 12 (8):743-752, 2011.
 
86) Henry DH, et al : Randomized, double-blind study of denosumab versus zoledronic acid in the treat-ment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29 (9):1125-1132, 2011.
PubMed
P.638 掲載の参考文献
1) The International Myeloma Working Group : Criteria for the classification of monoclonal gammo-pathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121:749-757, 2003.
 
2) Costello R, et al : Primary plasma cell leukaemia : a report of 18 cases. Leuk Res 25:103-107, 2001.
PubMed
3) Garcia-Sanz R, et al : Primary plasma cell leukemia : Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032-1037, 1999.
PubMed
4) Vela-Ojeda J, et al : Intermediate doses of melphalan and dexamethasone are better than vincris-tine, adriamycin and dexamethasone and polychemotherapy for the treatment of primary plasma cell leukaemia. Ann Hematol 81:362-367, 2002.
 
5) Jimenez-Zepeda VH, Dominguez VJ : Plasma cell leukemia : a rare condition. Ann Hematol 85:263-267, 2006.
PubMed
6) Gertz MA : Managing plasma cell leukemia. Leuk Lymphoma 48:5-6, 2007.
PubMed
7) Cha CH, et al : Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 118 (3):178-182, 2007.
PubMed
8) Tiedemann RE, et al : Genetic aberrations and survival in plasma cell leukemia. Leukemia 22 (5):1044-1052, 2008.
PubMed
9) Colovic M, et al : Thirty patients with primary plasma cell leukemia : a single center experience. Med Oncol 25 (2):154-160, 2008.
PubMed
10) Chang H, et al : Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 33 (2):259-262, 2009.
PubMed
11) Christou L, et al : Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur J Haematol 67 (1):51-53, 2001.
PubMed
12) Bagalkot V, et al : An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45 (48):8149-8152, 2006.
PubMed
13) Hovenga S, et al : Consolidation therapy with autologous stem cell transplantation in plasma cell leu-kemia after VAD, high-dose cyclophosphamide and EDAP courses : a report of three cases and a review of the literature. Bone Marrow Transplant 20 (10):901-904, 1997.
 
14) Majolino I, et al : Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 22 (5):449-455, 1998.
PubMed
15) Sica S, et al : Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant : molecular follow-up of minimal residual disease. Bone Marrow Transplant 22 (8):823-825, 1998.
PubMed
16) Panizo C, et al : Long-term survival in primary plasma cell leukemia after therapy with VAD, autolo-gous blood stem cell transplantation and interferon-alpha. Acta Haematol 101 (4):193-196, 1999.
 
17) Kishi Y, et al : Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant 26 (5):573-576, 2000.
PubMed
18) Cernelc P, Mlakar U : Maintenance treatment of primary plasma cell leukemia with interferon alpha. Transplant Proc 34 (7):2929-2930, 2002.
PubMed
19) Mak YK, et al : Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia. Clin Lab Haematol 25 (1):55-58, 2003.
 
20) Saccaro S, et al : Primary plasma cell leukemia : report of 17 new cases treated with autologous or allogeneic stem cell transplantation and review of the literature. Am J Hematol 78:288-294, 2005.
PubMed
21) Johnson MR, et al : Primary plasma cell leukemia : morphologic, immunophenotypic, and cytoge-netic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol 10 (5):263-268, 2006.
 
22) Kroeger WH, et al : Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell trans-plantation. Onkologie 30 (4):193-195, 2007.
 
23) Masuda M, et al : Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia. Jpn J Clin Oncol 37 (9):701-703, 2007.
PubMed
24) Nonami A, et al : Successful treatment of primary plasma cell leukaemia by allogeneic stem cell trans-plantation from haploidentical sibling. Jpn J Clin Oncol 37 (12):969-972, 2007.
 
25) Turhal N, et al : Multiple myeloma : a patient with unusual features including intracranial and menin-geal involvement, testicular involvement, organomegaly, and plasma cell leukemia. Am J Hematol 57 (1):51-56, 1998.
 
26) Wellwood J, et al : Relapsed plasma cell leukaemia presenting with aggressive extramedullary plas-macytomas in the meninges and testis-a missed opportunity for induction CNS prophylaxis. Leuk Lymphoma 43 (4):893-896, 2002.
PubMed
27) Fowler R, Imrie K : Thalidomide-associated hepatitis : a case report. Am J Hematol 66 (4):300-302, 2001.
PubMed
28) Johnston RE, Abdalla SH : Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 43 (2):351-354, 2002.
PubMed
29) Tsiara S, et al : Thalidomide administration for the treatment of resistant plasma cell leukemia. Acta Haematol 109 (3):153-155, 2003.
PubMed
30) Alexandrescu DT, et al : Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide : a case report and review of the literature. Clin Exp Dermatol 30 (4):391-394, 2005.
 
31) Petrucci MT, et al : Thalidomide does not modify the prognosis of plasma cell leukemia patients : experience of a single center. Leuk Lymphoma 48 (1):180-182, 2007.
 
32) Brock P, et al : Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol 86 (1):66-68, 2007.
 
33) Esparis-Ogando A, et al : Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 114 (4):665-667, 2005.
PubMed
34) Finnegan DP, et al : Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 47 (8):1670-1673, 2006.
PubMed
35) Grassinger J, et al : Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 85 (2):132-133, 2006.
PubMed
36) Ataergin S, et al : VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 81 (12):987-988, 2006.
PubMed
37) Capalbo S, et al : Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta Oncol 46 (2):262-264, 2007.
PubMed
38) Musto P, et al ; GIMEMA Cooperative Group : Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 109 (11):2285-2290, 2007.
PubMed
39) Kim SJ, et al : Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol 37 (5):382-384, 2007.
PubMed
40) Katodritou E, et al : Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone : do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 32 (7):1153-1156, 2008.
 
41) Al-Nawakil C, et al : Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 49 (10):2012-2014, 2008.
PubMed
42) Jaskiewicz AD, et al : Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 25 (12):1820-1825, 2005.
PubMed
43) Benson DM, Smith MK : Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 48 (7):1423-1425, 2007.
PubMed
44) Musto P, et al : Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 32 (10):1637-1638, 2008.
PubMed
45) Gemmel C, et al : Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 81 (2):119-123, 2002.
 
46) Oka S, et al : Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leuk Res 30 (12):1581-1583, 2006.
PubMed
47) Telek B, et al : [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation]. Orv Hetil 149 (41):1957-1959, 2008.
PubMed
48) Chan SM, et al : Complete remission of primary plasma cell leukemia with bortezomib, doxorubi-cin, and dexamethasone : acase report. Cases J 2 (1):121, 2009.
 
49) Mele G, et al : Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther 32 (5):915-919, 2010.
PubMed
50) Mahindra A, et al : Hematopoietic cell transplantation for primary plasma cell leukemia : results from the Center for International Blood and Marrow Transplant Research. Leukemia, 2011. [Epub ahead of print]
 
51) D'Arena G, et al : Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia : a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol, 2011. [Epub ahead of print]
 
52) Lebovic D, et al : Clinical outcomes of patients with plasma cell leukemia in the era of novel thera-pies and hematopoietic stem cell transplantation strategies : a single-institution experience. Clin Lymphoma Myeloma Leuk 11 (6):507-511, 2011.
 
53) Kraj M, et al : Flow cytometric immunophenotypic characteristics of plasma cell leukemia. Folia Histochem Cytobiol 49 (1):168-182, 2011.
PubMed
54) Pagano L, et al : Primary plasma cell leukemia : a retrospective multicenter study of 73 patients. Ann Oncol 22 (7):1628-1635, 2011.
PubMed
55) Funes C, et al : Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant. J Clin Apher 25 (4):223-225, 2010.
 
56) Libby E, et al : Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. J Hematol 85 (9):733-734, 2010.
 
57) Kraj M, et al : Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 35 (2):169-176, 2011.
PubMed
58) Drake MB, et al : Primary plasma cell leukemia and autologous stem cell transplantation. Haemato-logica 95 (5):804-809, 2010.
 
59) Guglielmelli T, et al : Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol 2009:867380, 2009.
PubMed
60) Ramsingh G, et al : Primary plasma cell leukemia : a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 115 (24):5734-5739, 2009.
PubMed
61) Abe M, et al : Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplan-tation combined with low-dose thalidomide maintenance therapy. Intern Med 48 (20):1833-1835, 2009.
 
62) Olivieri A, et al : Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia : a case report. Leuk Res 33 (11):e191-193, 2009.
PubMed
63) Dispenzieri A, et al : International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 (2):215-224, 2009.
 
64) Roussel M, et al : Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma : a phase 2 study of the Inter-groupe Francophone du Myelome (IFM). Blood 115 (1):32-37, 2010.
 
65) Thompson PA, et al : Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 46 (5):764-765, 2011.
PubMed
66) Lonial S, et al : A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma : a dose- and schedule-finding study. Clin Cancer Res 16 (20):5079-5086, 2010.
PubMed
67) Dimopoulos MA, et al : Primary plasma cell leukaemia. Br J Haematol 88 (4):754-759, 1994.
PubMed
68) Chiecchio L, et al : Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 48 (7):624-636, 2009.
PubMed
69) Kruger WH, et al : Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 30 (4):193-195, 2007.
PubMed
P.649 掲載の参考文献
8) Pollard JA, et al : Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115:2372-2379, 2010.
 
9) Imaizumi M, et al : Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia : the Japa-nese childhood acute myeloid leukaemia cooperative study. Br J Haematol 152:89-98, 2011.
 
10) Diverio D, et al : Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:84-89, 1998.
 
11) Creutzig U, et al : AML patients with Down syndrome have a high cure rate with AML-BFM ther-apy with reduced dose intensity. Leukemia 19 (8):1355-1360, 2005.
 
12) Kudo K, et al : Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regi-men in children with Down syndrome and acute myeloid leukemia : the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 25:5442-5447, 2007.
 
13) Kanezaki R, et al : Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder : mutation classes correlate with progression to myeloid leukemia. Blood 116:4631-4638, 2010.
PubMed
14) 嶋田博之ほか : 慢性骨髄性白血病. 小児白血病・リンパ腫の診療ガイドライン2007年版 (日本小児血液学会編), p40-43, 金原出版, 2007.
 
15) Shima H, et al : Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 159:676-681, 2011.
PubMed
P.656 掲載の参考文献
1) Waldenstrom J : Macroglobulinaemia. Acta Haematol 20:33-39, 1958.
PubMed
2) Owen RG, et al : Clinicopathological definition of Waldenstrom's macroglobulinemia : consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobu-linemia. Semin Oncol 30 (2):110-115, 2003.
 
3) Gertz MA et al : Treatment recommendations in Waldenstrom's macroglobulinemia : consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobu-inemia. Semin Oncol 30 (2):121-126, 2003.
 
4) Treon SP, et al : Update on treatment recommendations from the third international workshop on Waldenstrom macroglobulinemia. Blood 107:3442-3446, 2006.
PubMed
5) Dimopoulos MA, et al : Update on treatment recommendations from the Fourth International Work-shop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27 (1):120-126, 2009.
 
6) Gertz MA, et al : Waldenstrom's macroglobulinemia. Oncologist 5:63-67, 2000.
PubMed
7) Dimopoul os MA, et al : Diagnos is and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23 (7):1564-1577, 2005.
 
8) Fonseca R, Hayman S : Waldenstrom macroglobulinemia. Br J Haematol 138:700-720, 2007.
PubMed
9) Vitolo U, et al : Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 67:172-185, 2008.
PubMed
10) Treon SP : How I treat Waldenstrom macroglobulinemia. Blood 114:2375-2385, 2009.
 
11) Kyle RA, Rajkumar SV : Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23 (1):3-9, 2009.
PubMed
12) Gertz, MA : Waldenstrom macroglobulinemia : 2011 update on diagnosis, risk stratification, and management. Am J Hematol 66:412-416, 2011.
 
13) Pangalis GA, et al : B-chronic lymphocytic leukemia, small lym-phocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia : A clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 36:104-114, 1999.
 
14) Ho AW, et al : CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 112 (12):4683-4689, 2008.
PubMed
15) Morice WG, et al : Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol 22 (6):807-816, 2009.
PubMed
16) Schop RF, et al : Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100 (8):2996-3001, 2002.
PubMed
17) Schop RF, et al : Deletion of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 132:55-60, 2002.
PubMed
18) Chang H, et al : Analysis of IgH translocations, chromosome 13q14 and 17p13.1 (p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia : A single center study of 22 cases. Leukemia 18:1160-1162, 2004.
PubMed
19) Terre C, et al : Trisomy 4, a new chromosomal abnormality in Waldenstrom macroglobulinemia : a study of 39 cases. Leukemia 20:1634-1636, 2006.
PubMed
20) Liu YC, et al : Deletion (20q) as the sole abnormality in Waldenstrom macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet 169:69-72, 2006.
PubMed
21) Schop RF, et al : 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 169 (2):150-153, 2006.
PubMed
22) Ocio EM, et al : 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 136:80-86, 2007.
PubMed
23) Chang H, et al : Prognosti crelevance of 6q deletion in Waldenstrom's macroglobulinemia : A multi-center study. Clin Lymphoma Myeloma 9:36-38, 2009.
 
24) Chng WJ, et al : Gene xpression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 108:2755-2763, 2006.
 
25) Gutierrez NC, et al : Gene expression profiling of B lymphocytes and plasma cells from Walden-strom macroglobulinemia : comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21:541-549, 2007.
 
26) Hatjiharissi E, et al : Comprehensive molecular characterization of malignant and microenvironmen-tal cells in Waldenstrom macroglobulinemia by gene expression profiling. Blood 110 (Suppl):abstr 3174, 2007.
 
27) MacKay F, et al : BAFF and APRIL : a tutorial on B-cell survival. Annu Rev Immunol 21:231-264, 2003.
 
28) Elsawa SF, et al : B-lymphocyte stimulator (BLys) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107:2882-2888, 2006.
PubMed
29) Turner CA, et al : Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77:297-306, 1994.
PubMed
30) Leleu X, et al : Biological sequelae TRAF2 down regulation in Waldenstrom macroglobulinemia (WM). Blood 110 (Suppl):abstr 3526, 2007.
 
31) Braggio E, et al : Identification of copy number abnormalities and inactivating mutations in two nega-tive regulators of nuclear factor-kappa B signalling pathways in Waldenstrom macroglobulinemia. Cancer Res 69:3579-3588, 2009.
 
32) Adamia S, et al : Identification of genetic variations (GVs) causing splicing of TNF family members and adaptor proteins that modulate NFκB pathways in Waldenstrom macroglobulinemia (WM). Blood 110 (Suppl):abstr 2516, 2007.
 
33) Braggio E, et al : Inactivation of tumor necrosis factor 3 gene (TRAF3) is frequently identified in Waldenstrom macroglobulinemia patients. Blood 110 (Suppl):abstr 2476, 2007.
 
34) Blum W, Porcu P : Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 33:350-354, 2007.
PubMed
35) Adamia S, et al : Abnormal expression of hyaluronan synthase in patients with Waldenstrom macro-globulinemia. Semin Oncol 30:165-168, 2003.
 
36) Xu L, et al : Abnormal expression of the plasma cell differentiation factor X-box protein 1 (Xbp-1) in Waldenstrom macroglobulinemia. Blood 106 (Suppl):abstr 1003, 2005.
 
37) Wu Y, et al : Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinitiy rcceptor for TNF family members APRIL and BLys. J Biol Chem 275:35478-35485, 2000.
 
38) Ngo HT, et al : Analysis of chemokines and adhesion markers in Waldenstrom macroglobulinemia. Blood 109 (Suppl):abstr 4653, 2006.
 
39) Hatzimichael EC, et al : Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom macroglobulinemia. Eur J Haematol 66:1-6, 2001.
PubMed
40) Tournilhac O, et al : Mast cells in Waldenstrom macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17:1275-1282, 2006.
PubMed
41) Ngo HT, et al : The interaction of CXCR4/SDF-1 and VLA-4 regulates adhesion and transendothelial migration in Waldenstrom macroglobulinemia. Blood 110 (Suppl):abstr 2617, 2007.
 
42) Hatjiharissi E, et al : Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Res 67:3777-3784, 2007.
PubMed
43) Leleu X, et al : The Akt pathways regulates survival and homing in Waldenstrom macroglobulinemia. Blood 110:4417-4426, 2007.
PubMed
44) Nobile-Orazio E, et al : Peripheral neuropathy in macroglobulinemia : Incidence and antigen-speci-ficity of M proteins. Neurology 37:1506-1514, 1987.
 
45) Gertz MA, Kyle RA : Hyperviscosity syndrome. J Intensive Care Med 10:128-141, 1995.
PubMed
46) Bjorkholm M, et al : Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia : A two-institution study. Semin Oncol 30:226-230, 2003.
PubMed
47) Stone MJ , et al : Autoantibody actvity in Waldenstrom's macroglobulinemia. Clin Lymphoma 5:225-229, 2005.
 
48) Baehring JM, et al : Neurologial manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol 4:547-556, 2008.
 
49) Stone MJ : Waldenstrom's macroglobulinemia : hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 9:97-99, 2009.
PubMed
50) Berentsen S : Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 9:110-112, 2009.
PubMed
51) Ramchandren S, Lewis RA : Monoclonal gammopathy and neuropathy. Curr Opin Neurol 22:480-485, 2009.
PubMed
52) 三輪哲義 : 幹細胞純化-白血病・骨髄腫診療アトラス, メディカルレビュー社, 2008.
 
53) Morel P, et al : Patients with the description of a new scoring system and its validation on 253 other patients. Blood 96 (3):852-858, 2000.
PubMed
54) Dhodapkar MV, et al : Prognostic factor sand response to fludarabine the rapy in Waldenstrom's mac-roglobulinemia : An update of a US intergroup trial (SWOG S9003). Semin Oncol 30:220-225, 2003.
 
55) Kyle RA, et al : Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobuline-mia : consens us panel recomm e nda tions from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 (2):116-120, 2003.
 
56) Dimopoulos M, et al : The intemational staging system for multiple myeloma is applicable in sympto-matic Waldenstrom's macroglobulinemia. Leuk Lymphoma 45 (9):1809-1813, 2004.
 
57) Ghobrial IM, et al : Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 133 (2):158-164, 2006.
PubMed
58) Dimopoulos MA, et al : The International Prognostic Scoring System for Waldenstrom's macroglobu-linemia is applicable in patients treated with rituximab-based regimens. Haematologica 93:1420-1422, 2008.
 
59) Morel P, et al : International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113 (18):4163-4170, 2009.
PubMed
60) Kastritis E, et al : Prognostication in young and old patients with Waldenstrom's macroglobulinemia : importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 9 (1):50-52, 2009.
 
61) Kastritis E, et al ; Greek Myeloma Study Group : Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 34:1340-1343, 2010.
 
62) Kyle RA, et al : Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102 (10):3759-3764, 2003.
PubMed
63) Gobbi PG, et al : Prognostic validation of the international classification of immunoglobulin M gam-mopathies : a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 11 (5):1786-1790, 2005.
 
64) Kyle RA, et al : Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gam-mopathy of undetermined significance. Clin Lymphoma 5 (4):257-260, 2005.
 
65) Baldini L, et al : Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symp-tomatic lymphoid disorders : proposal for a common prognostic scoring system. J Clin Oncol 23 (21):4662-4668, 2005.
 
66) Blade J, et al : Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22:1651-1657, 2008.
PubMed
67) Kyle RA, et al : IgM monoclonal gammopathy of undetermined significance and smoldering Walden-strom's macroglobulinemia. Clin Lymphoma Myeloma 9:17-18, 2009.
 
68) McMaster ML, Landgren O : Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry B Clin Cytom 78 (Suppl 1):S91-S97, 2010.
 
69) Berenson JR, et al : Monoclonal gammopathy of undetermined significance : A consensus statement. Br J Haematol 150:28-38, 2010.
PubMed
70) Leleu X, et al : Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 49 (6):1104-1107, 2008.
PubMed
71) Schuster SR, et al : IgM multiple myeloma : Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 85:853-855, 2010.
PubMed
72) Petrucci MT, et al : Waldenstrom's macroglobulinaemia : results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 226 (6):443-447, 1989.
PubMed
73) Case DC Jr, et al : Waldenstrom's macroglobulinemia : long-term results with the M-2 protocol. Cancer Invest 9 (1):1-7, 1991.
 
74) Kyle RA, et al : Waldenstrom's macroglobulinaemia : a prospective study comparing daily with inter-mittent oral chlorambucil. Br J Haematol 108 (4):737-742, 2000.
 
75) Annibali O, et al : Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone : results and cost analysis. Cancer 103 (3):582-587, 2005.
PubMed
76) Dimopoulos MA, et al : Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadeno-sine. Ann Intern Med 118:195-198, 1993.
 
77) Dimopoulos MA, et al : 2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobu-linemia previously treated with fludarabine. Ann Oncol 5 (3):288-289, 1994.
 
78) Hellmann A, et al : Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refrac-tory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol 63 (1):35-41, 1999.
PubMed
79) Foran JM, et al : Multicenter phase II study of fludarabine phosphate for patients with newly diag-nosed lymphoplasmacytoidlymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17 (2):546-553, 1999.
 
80) Thalhammer-Scherrer R, et al : Fludarabine therapy in Waldenstrom's macroglobulinemia. Ann Hematol 79 (10):556-559, 2000.
PubMed
81) Dhodapkar MV, et al : Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia : results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98 (1):41-48, 2001.
 
82) Leblond V, et al : Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98 (9):2640-2644, 2001.
 
83) Tamburini J, et al : Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia : results in 49 patients. Leukemia 19 (10):1831-1834, 2005.
 
84) Tedeschi A, et al : Fludarabine-based combination therapies for Waldenstrom's macroglobuline-mia. Clin Lymphoma Myeloma 9:67-70, 2009.
 
85) Peinert S, et al : Fludarabine based combinations are highly effective as first-line or salvage treat-ment in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 51:2188-2197, 2010.
PubMed
86) Carney DA, et al : Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 24:2056-2062, 2010.
PubMed
87) Leleu X, et al : Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 27 (2):250-255, 2009.
PubMed
88) Laurencet FM, et al : Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 79 (7-8):1215-1219, 1999.
 
89) Weide R, et al : Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenstrom's macroglobulinaemia. Leuk Lymphoma 36 (1-2):203-206, 1999.
 
90) Weide R, et al : The polyneuropathy associated with Waldenstrom's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Hae-matol 109 (4):838-841, 2000.
 
91) Treon SP, et al : CD20-directed antibody-mediated immunotherapy induces responses and facili-tates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24 (3):272-279, 2001.
 
92) Dimopoulos MA, et al : Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20 (9):2327-2333, 2002.
PubMed
93) Gertz MA, et al : Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM) : an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45 (10):2047-2055, 2004.
 
94) Treon SP, et al : Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16 (1):132-138, 2005.
PubMed
95) Gertz MA, et al : Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macro-globulinaemia : A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 147:677-680, 2009.
 
96) Ghobrial IM, et al : Initial increase in the cryoglobulin level after rituximab therapy for type II cryo-globulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 77:329-330, 2004.
 
97) Ghobrial IM, et al : Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia : an Eastern Cooperative Oncology Group Study. Cancer 101 (11):2593-2598, 2004.
 
98) Ghobrial IM, et al ; Eastern Cooperative Oncology Group : Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia : An Eastern Coopera-tive Oncology Group Study. Cancer 101:2593-2598, 2004.
 
99) Treon SP, et al : Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 113 (16):3673-3678, 2009.
PubMed
100) Dimopoulos MA, et al : Primary treatment of Waldenstrom macroglobulinemia with dexametha-sone, rituximab, and cyclophosphamide. J Clin Oncol 25 (22):3344-3349, 2007.
 
101) Tam CS, et al : Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106:2412-2420, 2006.
 
102) Buske C, et al ; German Low-Grade Lymphoma Study Group : The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma : Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:153-161, 2009.
 
103) Ioakimidis L, et al : Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 9:62-66, 2009.
 
104) Treon SP, et al : Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112:4452-4457, 2008.
PubMed
105) Treon SP, et al : Lenalidomide and rituximab in Waldenstrom macroglobulinemia. Clin Cancer Res 15:355-360, 2009.
PubMed
106) Chen C, et al : Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lym-phoma Myeloma 9:74-76, 2009.
 
107) Ghobrial IM, et al : Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28 (8):1422-1428, 2010.
PubMed
108) Treon SP, et al : Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab : WMCTG clinical trial 05-180. J Clin Oncol 27:3830-3835, 2009.
PubMed
109) Desikan R, et al : High-dose therapy with autologous haemopoietic stem cell support for Walden-strom's macroglobulinaemia. Br J Haematol 105 (4):993-996, 1999.
 
110) Gilleece MH, et al : The outcome of haemopoietic stem cell transplantation in the treatment of lym-phoplasmacytic lymphoma in the UK : a British Society Bone Marrow Transplantation study. Hema-tology 13 (2):119-127, 2008.
 
111) Caravita T, et al : High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia. Bone Marrow Transplant 43 (7):587-588, 2009.
PubMed
112) Kyriakou C, et al : High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia : the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 (13):2227-2232, 2010.
 
113) Anagnostopoulos A, et al : Autologous or allogeneic stem cell transplantation in patients with Walden-strom's macroglobulinemia. Biol Blood Marrow Transplant 12 (8):845-854, 2006.
 
114) Rummel MJ, et al : Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treat-ment in patients with indolent lymphomas and Waldenstrom's macroglobulinemia [abstract]. The Sixth International Workshop on Waldenstrom's Macroglobulinemia, Oct 6.10, Venice, Italy, 2010.
 
115) Rummel MJ, et al : Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23 (15):3383-3389, 2005.
 
116) Ghobrial IM, et al : Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 28:1408-1414, 2010.
 
117) Ghobrial IM, et al : Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 16:1033-1041, 2010.
PubMed
118) Garcia-Sanz R, Ocio EM : Novel treatment regimens for Waldenstrom's macroglobulinemia. Expert Rev Hematol 3:339-350, 2010.
PubMed
119) Ansell SM, et al : Diagnosis and management of Waldenstrom macroglobulinemia : Mayo stratifica-tion of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 85:824-833, 2010.
 

VI 小児造血器腫瘍の臨床

P.668 掲載の参考文献
1) Pui CH, et al : Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008.
PubMed
2) Iwamoto S, et al : Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 94:185-192, 2011.
 
3) Ohta H, et al : Flow cytometric analysis of de novo acute myeloid leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 93:135-137, 2011.
 
4) Mullighan CG, et al : BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114, 2008.
PubMed
5) Mullighan CG, et al : Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009.
PubMed
6) Mullighan CG, et al : Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246, 2009.
 
7) Cario G, et al : Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393-5397, 2010.
 
8) Becker H, et al : Favorable prognostic impact of NPM1 mutations in older patients with cytogeneti-cally normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures : a Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010.
 
9) Schnittger S, et al : Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005.
PubMed
10) Suzuki T, et al : Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854-2861, 2005.
PubMed
11) Taskesen E, et al : Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients : further evi-dence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469-2475, 2011.
 
12) Dufour A, et al : Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 28:570-577, 2010.
PubMed
13) Stirewalt DL, Radich JP : The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3:650-665, 2003.
PubMed
14) Shimada A, et al : Tandem duplications of MLL and FLT3 are correlated with poor prognosis in pedi-atric acute myeloid leukemia : A study of the Japanese childhood AML Cooperative Study Group. Pediatr Blood Cancer 50:264-269, 2008.
 
15) Baccarani M, et al : Evolving concepts in the management of chronic myeloid leukemia : recommen-dations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006.
 
P.675 掲載の参考文献
1) Pui CH, et al : Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004.
PubMed
2) Rubnitz JE, et al : Acute mixed lineage leukemia in children the experience of St Jude Children's Research Hospital. Blood 113:5083-5089, 2009.
 
3) Mullighan CG, et al : Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009.
PubMed
4) Evans WE, Relling MV : Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.
PubMed
5) Reiter A, et al : Chemotherapy in 998 unselected childhood acute lymphoblstic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994.
 
6) Manabe A, et al : Significance of the complete clearance of peripheral blasts after 7 days of predniso-lone treatment in children with acute lymphoblastic leukemia : The Tokyo Children's Cancer Study Group Study L99-15. Haematologica 93:1155-1160, 2008.
 
7) Igarashi S, et al : No advantage of dexamethasone over prednisolone for the outcome of standard-and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23:6489-6498, 2005.
 
8) Hasegawa D, et al : The utility of performing the initial lumbar puncture on day 8 in remission induc-tion therapy for childhood acute lymphoblastic leukemia : TCCSG L99-15 study. Pediatr Blood Can-cer 58:23-30, 2012.
 
9) Toyoda Y, et al : Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18:1508-1516, 2000.
PubMed
10) Conter V, et al : Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia : a multicentre randomised trial? Lancet 369:123-131, 2007.
PubMed
11) Pui CH, et al : Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009.
PubMed
12) Conter V, et al : Molecular response to treatment redefines all prognostic factors in children and ado-lescents with B-cell precursor acute lymphoblastic leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study, Blood 115:3206-3214, 2010.
 
13) Tsuchida M, et al : Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 24:383-396, 2010.
 
14) Tsurusawa M, et al : Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 24 (2):335-344, 2010.
 
P.679 掲載の参考文献
1) Rai KR, et al : Treatment of acute myelocytic leukemia : a study by cancer and leukemia group B. Blood 58:1203-1212, 1981.
 
2) Tsukimoto I, et al : Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia : the AML99 trial from the Japanese Childhood AML Coopera-tive Study Group. J Clin Oncol 27:4007-4013, 2009.
 
3) Dohner H, et al : Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010.
 
4) Rubnitz JE, et al : Minimal residual disease-directed therapy for childhood acute myeloid leukaemia : results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010.
PubMed
5) Mizushima Y, et al : Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype : a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol 91:831-837, 2010.
 
6) Shimada A, et al : No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype : a study of the Japanese Childhood AML Cooperative Study Group. Leukemia 21:1307, 2007.
 
7) Shimada A, et al : KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21) : a study of the Japanese Childhood AML Cooperative Study Group. Blood 107:1806-1809, 2006.
 
P.684 掲載の参考文献
1) Hasle H, et al : A pediatric approach to the WHO classification of myelodysplastic and myeloprolifer-ative diseases. Leukemia 17:277-282, 2003.
 
2) Baumann I, et al : Juvenile myelomonocytic leukaemia. In : WHO Classification of Tumours of Hae-matopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p82-84, IARC, Lyon, 2008.
 
3) Niemeyer CM, Kratz CP : Paediatric myelodysplastic syndromes and juvenile myelomonocytic leu-kaemia : molecular classification and treatment options. Br J Haematol 140:610-624, 2008.
 
P.685 掲載の参考文献
4) Hasle H, Niemeyer CM : Advances in the prognostication and management of advanced MDS in children. Br J Haematol 154:185-195, 2011.
PubMed
5) 平林真介, 真部淳 : 骨髄異形成症候群の中央診断 : 445例の追跡調査. 日小児血液会誌 23:53-57, 2009.
Medical*Online
6) Hasle H, et al : The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 18:2008-2014, 2004.
PubMed
7) Baumann I, et al : Childhood myelodysplastic syndrome. In : WHO Classification of Tumours of Hae-matopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p104-107, IARC, Lyon, 2008.
 
8) Kardos G, et al : Refractory anemia in childhood : a retrospective analysis of 67 patients with particu-lar reference to monosomy 7. Blood 102:1997-2003, 2003.
 
9) Hasegawa D, et al : Treatment of children with refractory anemia : the Japanese Childhood MDS Study Group Trial (MDS99). Pediatr Blood Cancer 53:1011-1015, 2009.
 
10) Stary J, et al : Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant 35:S13-16, 2005.
PubMed
11) Locatelli F : *The role of allogeneic haematopoietic stem cell transplantation in children with myelo-dysplastic syndromes. Haematologica 94:s10, 2009.
 
12) Strahm B, et al : Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 40:329-333, 2007.
PubMed
13) Sloand EM, Rezvani K : The role of the immune system in myelodysplasia : implications for therapy. Semin Hematol 45:39-48, 2008.
PubMed
14) Yoshimi A, et al : Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica 92:397-400, 2007.
PubMed
15) Strahm B, et al : Hematopoietic stem cell transplantation for advanced MDS in children : results of the EWOG-MDS98 study. Leukemia 25:455-462, 2011.
PubMed
16) Gohring G, et al : Complex karyotype newly defined : the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 116:3766-3769, 2010.
PubMed
17) Hasegawa D, et al : Methylation status of the p15 and p16 genes in paediatric myelodysplastic syn-drome and juvenile myelomonocytic leukaemia. Br J Haematol 128:805-812, 2005.
 
18) Niemeyer CM, et al : Chronic myelomonocytic leukemia in childhood : a retrospective analysis of 110 cases. Blood 89:3534-3543, 1997.
PubMed
19) de Vries AC, et al : Molecular basis of juvenile myelomonocytic leukemia. Haematologica 95:179-182, 2010.
PubMed
20) Matsuda K, et al : Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109:5477-5480, 2007.
PubMed
21) Flotho C, et al : Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood 111:966-967, 2008.
PubMed
22) Matsuda K, et al : Long-erm survival after nonintensive chemotherapy in some juvenile myelomono-cytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations. Blood 115:5429-5431, 2010.
 
23) Yoshida N, et al : Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr Res 65:334-340, 2009.
PubMed
24) Manabe A, et al : Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 16:645-649, 2002.
 
25) Locatelli F, et al : Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelo-monocytic leukemia (JMML) : results of the EWOG-MDS/EBMT trial. Blood 105:410-419, 2005.
 
26) Bergstraesser E, et al : Non-hematopoietic stem cell transplantation treatment of juvenile myelo-monocytic leukemia : a retrospective analysis and definition of response criteria. Pediatr Blood Can-cer 49:629-633, 2007.
 
27) Matsuda K, et al : Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile mye-lomonocytic leukemia : the growth of a 6-MP-refractory clone that already exists at onset. Leuke-mia 20:485-490, 2006.
 
28) Yoshimi A, et al : Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomohocytic leukaemia. Br J Haematol 129:542-549, 2005.
PubMed
29) Yoshimi A, et al : Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 19:971-977, 2005.
 
30) Ybshimi A, et al : Second allogeneic hematopoietic stem cell transplantation (HSCT) results in out-come similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 21:556-560, 2007.
 
31) Yabe M, et al : A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant 12:862-867, 2008.
PubMed
32) Kotecha N, et al : Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14:335-343, 2008.
PubMed
33) Gaipa G, et al : Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement. Leukemia 23:791-793, 2009.
PubMed
34) Furlan I, et al : Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 113:2867-2868, 2009.
 
35) Olk-Batz C, et al : Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 117:4871-4880, 2011.
PubMed
P.690 掲載の参考文献
1) Zipursky A : Transient leukaemia -a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 120:930-938, 2003.
PubMed
2) Wechsler J, et al : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32:148-152, 2002.
PubMed
3) Xu G, et al : Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102:2960-2968, 2003.
PubMed
4) Klusmann JH, et al : Treatment and prognostic impact of transient leukemia in neonates with Doen syndrome. Blood 111:2991-2998, 2008.
 
5) Muramatsu H, et al : Low-dose cytosine arabinoside therapy for neonates with Down syndrome (DS) and transient leukemia (TL). Blood (ASH annual meeting abstracts) 116:469-470, 2010.
 
6) Shimizu R, et al : GATA1-related leukaemias. Nat Rev Cancer 8:279-287, 2008.
PubMed
7) Alford KA, et al : Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disor-der and myeloid leukemia. Blood 118:2222-2238, 2011.
 
8) Chou S, Lodish HF : Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. Proc Natl Acad Sci USA 107:7799-7804, 2010.
PubMed
9) Toki T, et al : The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia. Leukemia 23:95-103, 2009.
PubMed
10) Klusmann JH, et al : Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 24:1659-1672, 2010.
PubMed
11) Massey GV, et al : A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS) : Children's Oncology Group (COG) study POG-9481. Blood 107:4606-4613, 2006.
 
12) Kanezaki R, et al : Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder : mutation classes correlate with progression to myeloid leukemia. Blood 116:4631-4638, 2010.
PubMed
13) Sandoval C, et al : Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically nor-mal trisomy 21 mosaic infant : case report and review of the literature. Pediatr Blood Cancer 44:85-91, 2005.
 
14) Muramatsu H, et al : Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol 142:610-615, 2008.
PubMed
15) 村松秀城, 菊地陽 : 一過性骨髄異常増殖症 (TAM)の治療戦略. 日小児血液会誌 25:179-184, 2011.
Medical*Online
P.695 掲載の参考文献
1) Quintanilla-Martinez L, et al : EBV+ T-cell lymphoma of childhood. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p278-280, WHO Press, Lyon, 2008.
 
2) Imashuku S : Clinical features and treatment strategies of Epstein-Barr virus-associated hemophago-cytic lymphohistiocytosis. Crit Rev Oncol Hematol 44:259-272, 2002.
 
3) Okano M, et al : Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80:64-69, 2005.
PubMed
4) Kimura H : Pathogenesis of chronic active Epstein-Barr virus infection : is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16:251-261, 2006.
 
5) Anagnostopoulos I, et al : Morphology, immunophenotype, and distribution of latently and/or pro-ductively Epstein-Barr virus-infected cells in acute infectious mononucleosis : implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744-750, 1995.
 
6) Sugaya N, et al : Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in chronic active EBV infection. J Infect Dis 190:985-988, 2004.
PubMed
7) Kimura H, et al : Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98:280-286, 2001.
PubMed
8) Kimura H, et al : Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187:527-533, 2003.
PubMed
9) Kimura H, et al : Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis 200:1078-1087, 2009.
PubMed
10) Henter JI, et al : HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lympho-histiocytosis. Pediatr Blood Cancer 48:124-131, 2007.
 
11) Gotoh K, et al : Clinical and virologic characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 46:1525-1534, 2008.
PubMed
12) Kawa K, et al : Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 46:77-83, 2010.
PubMed
13) Wang Q, et al : High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphopro-liferative disorders in childhood. Blood 116:5941-5947, 2010.
 
14) Iwatsuki K, et al : The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 140:715-721, 1999.
PubMed
15) Cohen JI, et al : Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompro-mised hosts : a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 20:1472-1482, 2009.
 

VII 特論

P.703 掲載の参考文献
1) Leone G, et al : Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 184:39-45, 2010.
PubMed
2) Godley LA, Larson RA : Therapy-related myeloid leukemia. Semin Oncol 35:418-429, 2008.
PubMed
3) Vardiman JW, et al : The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia : rationale and important changes. Blood 114:937-951, 2009.
PubMed
4) Sill H, et al : Therapy-related myeloid neoplasms : pathobiology and clinical characteristics. Br J Pharmacol 162:792-805, 2011.
PubMed
5) Kayser S, et al : The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137-2145, 2011.
PubMed
6) Voso MT, et al : Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 184:46-49, 2010.
PubMed
7) Trumpp A, et al : Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10:201-209, 2010.
PubMed
8) Pedersen-Bjergaard J, et al : Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20:1943-1949, 2006.
PubMed
9) Levine RL, Gilliland DG : Myeloproliferative disorders. Blood 112:2190-2198, 2008.
PubMed
10) Swolin B, et al : Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera : single center experience and review of literature. Ann Hematol 87:467-474, 2008.
PubMed
11) Ding Y, et al : AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 114:5201-5205, 2009.
PubMed
12) Imagawa J, et al : Clinical and genetic features of therapy-related myeloid neoplasms after chemo-therapy for acute promyelocytic leukemia. Blood 116:6018-6022, 2010.
 
P.708 掲載の参考文献
1) Pfleger L, Tappeiner J : [On the recognition of systematized endotheliomatosis of the cutaneous blood vessels reticuloendotheliosis?]. Hautarzt 10:359-363, 1959.
PubMed
2) Mori S, et al : Cellular characteristics of neoplastic angioendotheliosis. An immunohistological marker study of 6 cases. Virchows Arch A Pathol Anat Histopathol 407:167-175, 1985.
PubMed
3) Nakamura S, et al : Intravascular large B-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
 
4) Shimada K, et al : Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895-902, 2009.
 
5) Shimada K, et al : Intravascular large B-cell lymphoma ; recent advances and future perspectives. Rinsho Ketsueki 51:447-453, 2010.
 
6) Murase T, et al : Intravascular large B-cell lymphoma (IVLBCL) : a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478-485, 2007.
 
7) Matsue K, et al : Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 90:417-421, 2011.
 
8) Molina A : A decade of rituximab : improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59:237-250, 2008.
 
9) Ferreri AJ, et al : Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol 15:1215-1221, 2004.
PubMed
10) Shimada K, et al : Retrospective analysis of intravascular large B-cell lymphoma treated with ritu-ximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008.
 
11) Ferreri AJ, et al : Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 26:5134-5136 ; author reply 5136-5137, 2008.
 
12) Boehme V, et al : CNS events in elderly patients with aggressive lymphoma treated with modern che-motherapy (CHOP-14) with or without rituximab : an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896-3902, 2009.
 
13) Chihara D, et al : Incidence and risk factors for central nervous system relapse in patients with dif-fuse large B-cell lymphoma : analyses with competing risk regression model. Leuk Lymphoma 52:2270-2275, 2011.
 
14) Shimada K, et al : Central nervous system involvement in intravascular large B-cell lymphoma : A retrospective analysis of 109 patients. Cancer Sci 101:1480-1486, 2010.
 
15) Nakazato T, et al : Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen. Rinsho Ketsueki 51:148-152, 2010.
 
P.713 掲載の参考文献
1) Koblin BA, et al : Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 144:916-923, 1996.
PubMed
2) Gabutti G, et al : AIDS related neoplasms in Genoa, Italy. Eur J Epidemiol 11:609-614, 1995.
PubMed
3) Polesel J, et al : Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 22:301-306, 2008.
 
4) Engels EA, et al : Trends in cancer risk among people with AIDS in the United States, 1980-2002. AIDS 20:1645-1654, 2006.
PubMed
5) Swerdlow SH, et al (ed) : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
6) Straus DJ : Human immunodeficiency virus-associated lymphomas. Med Clin North Am 81:495-510, 1997.
PubMed
7) Sarker D, et al : Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 17:861-865, 2003.
PubMed
8) Kaplan LD, et al : Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1641-1648, 1997.
 
9) Heise W, et al : Malignant gastrointestinal lymphomas in patients with AIDS. Digestion 58:218-224, 1997.
PubMed
10) Beck PL, et al : HIV-associated non-Hodgkin's lymphoma of the gastrointestinal tract. Am J Gas-troenterol 91:2377-2381, 1996.
 
11) Imrie KR, et al : HIV-associated lymphoma of the gastrointestinal tract : the University of Toronto AIDS-Lymphoma Study Group experience. Leuk Lymphoma 16:343-349, 1995.
 
12) Kaplan LD, et al : Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma : AIDS-malignancies consortium trial 010, Blood 24:1538-1543, 2005.
 
13) Wang ES, et al : Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose metho-trexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunode-ficiency virus-associated Burkitt lymphoma. Cancer 98:1196-1205, 2003.
 
14) Sparano JA, et al : Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115:3008-3016, 2010.
PubMed
15) Castillo JJ, et al : Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist 15:293-299, 2010.
PubMed
16) Teruya-Feldstein J, et al : CD20-negative large-cell lymphoma with plasmablastic features : a clinically heterogenous spectrum in both HIV-positive and-negative patients. Ann Oncol 15:1673-1679, 2004.
PubMed
17) Flinn IW, Ambinder RF : AIDS primary central nervous system lymphoma. Curr Opin Oncol 8:373-376, 1996.
PubMed
18) Fine HA, Mayer RJ : Primary central nervous system lymphoma. Ann Intern Med 119:1093-1104, 1993.
PubMed
19) Maher EA, Fine HA : Primary CNS lymphoma. Semin Oncol 26:346-356, 1999.
PubMed
20) Jacomet C, et al : Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 11:1725-1730, 1997.
PubMed
21) Shah GD, et al : Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730-4735, 2007.
PubMed
P.729 掲載の参考文献
1) Li JL, et al : The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol 118:85-99, 1989.
PubMed
2) DiJoseph J, et al : CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-Hodgkin's lymphoma. Eur J Cancer 38:S150, 2002.
 
3) DiJoseph J, et al : CMC-544, an anti-CD22 antibody-targeted calicheamicin therapeutic for the treatment of B lymphoid malignancies. Blood 100:160a, 2002.
 
4) Advani A, et al : Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozo-gamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I study. J Clin Oncol 28:2085-2093, 2010.
 
5) Ogura M, et al : Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 101:1840-1845, 2010.
PubMed
6) Wierda W, et al : Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749-1755, 2010.
PubMed
7) Terui Y, et al : Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). J Clin Oncol 28 (Suppl):e18525 (abstr), 2010.
 
8) Tobinai K, et al : Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab. J Clin Oncol 28 (15) (Suppl):e18552 (abstr), 2010.
 
9) Tobinai K, et al : Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci 102 (2):432-438, 2011.
PubMed
10) Yoshie O, et al : Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99 (5):1505-1511, 2002.
PubMed
11) Ishida T, et al : Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma : its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9 (10 Pt 1):3625-3634, 2003.
 
12) Ishida T, et al : CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10 (16):5494-5500, 2004.
 
13) Yamamoto K, et al : Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010.
PubMed
14) Younes A, et al : Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363 (19):1812-1821, 2010.
 
15) Prince HM, et al : Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11):1870-1877, 2010.
PubMed
16) O'Connor OA, et al : Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 (4):676-684, 2005.
PubMed
17) Read MA, et al : The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2 (5):493-506, 1995.
PubMed
18) Fisher RI, et al : Multicenter phase II study of bortezomib in patients with relapsed or refractory man-tle cell lymphoma. J Clin Oncol 24:4867-4874, 2006.
 
19) Hay N, Sonenberg N : Upstream and downstream of mTOR. Genes Dev 18:1926-1945, 2004.
PubMed
20) Bjornsti MA, Houghton PJ : The TOR pathway : A target for cancer therapy. Nat Rev Cancer 4:335-348, 2004.
PubMed
21) Tobinai K, et al : Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 92 (4):563-570, 2010.
PubMed
22) Giblett ER, et al : Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067-1069, 1972.
PubMed
23) Gandhi V, et al : A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106:4253-4260, 2005.
PubMed
24) Robertson MJ, et al : Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 (13):1741-1746, 2007.
PubMed
25) Richardson PG, et al : Immunomodulatory drug CC-5013 overcomes drug resistance and is well tol-erated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002.
 
26) Marks P, et al : Histone deacetylases and cancer : Causes and therapies. Nat Rev Cancer 1:194-202, 2001.
PubMed
27) Finnin MS, et al : Structures of a histone deacetylase homologue bound to the TSA and SAHA inhib-itors. Nature 401:188-193, 1999.
 
28) O'Connor OA, et al : Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malig-nancies. J Clin Oncol 24 (1):166-173, Epub 2005 Dec 5, 2006.
 
29) Piekarz RL, et al : Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32):5410-5417, 2009.
PubMed
30) Piekarz RL, et al : Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117 (22):5827-5834, 2011.
PubMed
31) Ogura M, et al : Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101:2054-2058, 2010.
 
32) Ohmachi K, et al : Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101:2059-2064, 2010.
 
33) Rummel MJ, et al : Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005.
 
34) O'Connor OA, et al : Pralatrexate in patients with relapsed or refractory peripheral T-cell lym-phoma : results from the pivotal PROPEL study. J Clin Oncol 29 (9):1182-1189, 2011.
 
P.734 掲載の参考文献
1) Campana D, Coustan-Smith E : Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 38:139-152, 1999.
PubMed
2) Coustan-Smith E, et al : A simplified flow cytometric assay identifies children with acute lymphoblas-tic leukemia who have a superior clinical outcome. Blood 108:97-102, 2006.
 
3) Borowitz MJ, et al ; Children's Oncology Group : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors : a Children's Oncology Group study. Blood 111:5477-5485, 2008.
 
4) van Dongen JJ, et al : Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352:1731-1738, 1998.
PubMed
5) Willemse MJ, et al : Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor-B-ALL. Blood 99:4386-4393, 2002.
PubMed
6) Conter V, et al : Molecular response to treatment redefines all prognostic factors in children and ado-lescents with B-cell precursor acute lymphoblastic leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010.
 
7) Okamoto T, et al : Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia-A retrospective study by the children's cancer and leu-kemia study group in Japan. Leuk Lymphoma 43:1001-1006, 2002.
 
8) Yamaji K, et al : Minimal residual disease-based augmented therapy in childhood acute lymphoblas-tic leukemia : a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 15:1287-1295, 2010.
 
9) Ekert C, et al : Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia. Lancet 358:1239-1241, 2001.
 
10) Bader P, et al : Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16:1668-1672, 2002.
PubMed
11) Sramkova L, et al : Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48:93-100, 2007.
PubMed
12) Pongers-Willemse MJ, et al : Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrange-ments and TAL1 deletion as PCR targets : report of the BIOMED-1 CONCERTED ACTION : investi-gation of minimal residual disease in acute leukemia. Leukemia 13:110-118, 1999.
 
13) van Dongen JJ, et al : Design and standardization of PCR primers and protocols for detection of immunoglobulin and T-cell receptor gene recombinants in suspect lymphoproliferations : report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003.
 
14) Flohr T, et al : Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicen-ter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771-782, 2008.
 
15) Waanders E, et al : Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 25:254-258, 2011.
PubMed
P.741 掲載の参考文献
1) Ohta M : Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly. Geriatr Gerontol Int 9:115-123, 2009.
PubMed
2) 大田雅嗣 : 加齢に伴う高齢者造血器腫瘍の特徴. 臨床血液 49:382-389, 2008.
 
3) Erba HP : Prognostic factors in eldary patients with AML and the implications for treatment. Hema-tology Am Soc Hematol Educ Program 420-428, 2007.
 
4) Dombret H, et al : Acute myeloid leukemia in the elderly. Semin Oncol 35:430-438, 2008.
PubMed
5) Sekeres MA, Stone RM : The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 14:24-30, 2002.
PubMed
6) Rollig C, et al : A novel prognostic model in elderly patients with acute myeloid leukemia : results of 909 patients entered into the prospective AML96 trial. Blood 116:971-978, 2010.
PubMed
7) Pollyea DA, et al : Acute myeloid leukaemia in the elderly : a review. Br J Haematol 152:524-542, 2011.
PubMed
8) Estey EH : General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 43:89-95, 2006.
PubMed
9) Mori M, et al : Treatment of acute myeloid leukemia patients aged more than 75 years : results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma 47:2062-2069, 2006.
 
10) Grimwade D, et al : The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) : analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001.
PubMed
11) Kantarjian H, et al : Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome : predictive prognostic models for outcome. Cancer 106:1090-1098, 2006.
 
12) Robles C, et al : Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia : an Eastern Cooperative Oncology Group Trial (E5483). Leuke-mia 14:1349-1353, 2000.
 
13) Faderl S, et al : A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638-1645, 2008.
PubMed
14) Amadori S, et al : Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia : final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ema-tologiche dell'Adulto Leukemia Groups. Leukemia 19:1768-1773, 2005.
 
15) Petersdorf S, et al : Preliminary results of Southwest Oncology Group Study S0106 : an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-con-solidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute mye-loid leukemia. Blood 114:790, 2009.
 
16) Lowenberg B, et al : Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more : results of a multicenter phase 3 study. Blood 115:2586-2591, 2010.
PubMed
17) Latagliata R, et al : The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. Ann Oncol 8:1273-1275, 1997.
PubMed
18) Asou N, et al : Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia : the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 48 (Suppl 1):S65-71, 2001.
 
19) Ohnishi K, et al : Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute pro-myelocytic leukemia : need for careful electrocardiogram monitoring. Leukemia 16:617-622, 2002.
 
20) Ohnishi K : PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelo-cytic leukemia. Int J Clin Oncol 12:313-317, 2007.
 
21) Legrand O, et al : Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol 97:596-602, 1997.
PubMed
22) Kantarjian HM, et al : Acute lymphocytic leukaemia in the elderly : characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 88:94-100, 1994.
PubMed
23) O'Brien S, et al : Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 113:2097-2101, 2008.
PubMed
24) Wassmann B, et al : A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol 82:716-720, 2003.
PubMed
25) Gokbuget N, Hoelzer D : Treatment with monoclonal antibodies in acute lymphoblastic leukemia : current knowledge and future prospects. Ann Hematol 83:201-205, 2004.
PubMed
26) Gleissner B, et al : Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia : a prospective study of the Gemlan Multicenter Trial Group and con-firmed polymerase chain reaction analysis. Blood 99:1536-1543, 2002.
 
27) Yanada M, et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460-466, 2006.
 
28) Lilly MB, et al : Dasatinib 140 mg once daily versus 70mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib : Results from a phase 3 study. Am J Hematol 85:164-170, 2010.
 
29) Kantarjian H, et al : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006.
 
30) Foa R, et al : Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-posi-tive acute lymphoblastic leukemia. Blood 118:6521-6528, 2011.
 
31) Giles FJ, et al : MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leuke-mia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500-502, 2007.
PubMed
32) Estey E, et al : Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109:1395-1400, 2007.
PubMed
33) Wallen H, et al : Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23:3439-3446, 2005.
 
34) Falda M, et al : Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hemato-logical malignancies : results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicen-ter prospective clinical trial. Am J Hematol 82:863-866, 2007.
 
35) Bertz H, et al : Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21:1480-1484, 2003.
PubMed
36) Hegenbart U, et al : Treatment for acute myelogenous leukemia by low-dose, total-body, irradia-tion-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24:444-453, 2006.
 
37) Rubinstein P, et al : Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565-1577, 1998.
PubMed
38) Laughlin MJ, et al : Outcomes after transplantation of cord blood or bone marrow from unrelatcd donors in adults with leukemia. N Engl J Med 351:2265-2275, 2004.
 
39) Rocha V, et al : Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351:2276-2285, 2004.
 
40) Takahashi S, et al : Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104:3813-3820, 2004.
PubMed
41) Miyakoshi S, et al : Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 10:3586-3592, 2004.
PubMed
P.750 掲載の参考文献
1) 河敬世 : 血球貧食症候群 : オーバービュー. 血液・腫瘍科 54 (3):237-244, 2006.
 
2) Henter JI, et al : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 (2):124-131, 2007.
PubMed
3) Takada H, et al : Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma 42 (1-2):21-28, 2001.
 
4) Raja SM, et al : Cytotoxic granule-mediated apoptosis : unraveling the complex mechanism. Curr Opin Immunol 15 (5):528-532, 2003.
PubMed
5) Menasche G, et al : Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev 203:165-179, 2005.
PubMed
6) Stepp SE, et al : Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286 (5446):1957-1959, 1999.
PubMed
7) Feldmann J, et al : Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461-473, 2003.
 
8) zur Stadt U, et al : Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromo-some 6q24 and identification of mutation in syntaxin 11. Hum Mol Genet 14 (6):827-834, 2005.
 
9) Barbosa MD, et al : Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 382 (6588):262-265, 1996.
PubMed
10) Parolini S, et al : X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 192 (3):337-346, 2000.
 
11) Ishii E, et al : Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86 (1):58-65, 2007.
PubMed
12) Dilber E, et al : Hemophagocytic syndrome as an initial presentation of miliary tuberculosis without pulmonary findings. Scand J Infect Dis 34 (9):689-692, 2002.
PubMed
13) Kasahara Y, et al : Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemo-phagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 44 (3):283-294, 2002.
 
14) Takahashi N, et al : Lymphoma associated hemophagocytic syndrome in Japan. Rinsho Ketsueki 40 (7):542-549, 1999.
PubMed
15) Murase T, et al : Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intra-vascular lymphomatosis : a report of five cases and review of the literature. Br J Haematol 99 (3):656-664, 1997.
 
16) Murase T, et al : Intravascular large B-cell lymphoma (IVLBCL) : a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109 (2):478-485, 2007.
 
17) Takahashi N, et al : A clinicopathological study of 20 patients with T/natural killer (NK)-cell lym-phoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 74 (3):303-308, 2001.
 
18) Chuang HC, et al : Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma : nuclear factor-kappa B path-way as a potential therapeutic target. Cancer Sci 98 (9):1281-1287, 2007.
 
19) Nakamura S, et al : The WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Steven H, et al), p252-253, International Agency for Research on Cancer, Lyon, 2008.
 
20) 熊倉俊一ほか : 膠原病に伴う血球貧食症候群. 血液・腫瘍科 57 (6):139-156, 2008.
 
21) Spitzer TR : Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 27 (9):893-898, 2001.
PubMed
22) Miyakoshi S, et al : Successful engraftment after reduced-intensity umbilical cord blood transplanta-tion for adult patients with advanced hematological disease. Clin Cancer Res 10 (11):3586-3592, 2004.
 
23) Sullivan KM, et al : Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67 (4):1172-1175, 1986.
 
24) Takagi S, et al : High incidence of haemophagocytic syndrome following umbilical cord blood trans-plantation for adults. Br J Haematol 147:543-553, 2009.
 
25) Schneider EM, et al : Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100 (8):2891-2898, 2002.
PubMed
26) Ost A, et al : Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopa-thology 32 (4):310-316, 1998.
 
27) Arico M, et al : Haemophagocytic lymphohistiocytosis : proposal of a diagnostic algorithm based on perforin expression. Br J Haematol 119 (1):180-188, 2002.
PubMed
28) Marcenaro S, et al : Analysis of natural killer-cell function in familial hemophagocytic lymphohistio-cytosis (FHL) : defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108 (7):2316-2323, 2006.
 
29) Teramura T, et al : Qantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 43 (1):173-179, 2002.
 
30) Tsuda H, et al : Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 65 (3):215-226, 1997.
PubMed
31) 高橋直人 : 血球貧食症候群. 血液・腫瘍科 49 (4):497, 2004.
 
32) Trottestam H, et al : Chemoimmunotherapy for hemophagocytic lymphohistiocytosis : long term results of the HLH-94 treatment protocol. Blood 118 (17):4577-4584, 2011.
PubMed
33) Ohga S, et al : Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocyto-sis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer 54 (2):299-306, 2010.
 
34) Cooper N, et al : Stem cell transplantation with reduced-intensity conditioning for haemophagocytic lymphohistiocytosis. Blood 107 (3):1233-1236, 2006.
PubMed
35) Kinchen JM, et al : Phagocytic signaling : you can touch but you can't eat. Curr Biol 18 (12):1-5, 2008.
 
P.760 掲載の参考文献
1) Chen TC, et al : Fluoroquinolones are associated with delayed treatment and resistance in tuberculo-sis : a systematic review and meta-analysis. Int J Infect Dis 15 (3):e211-216, 2011.
 
2) Magiorakos AP, et al : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacte-ria : an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2011. [Epub ahead of print]
 
3) 厚生労働省 院内感染対策サーベイランス事業 JANIS [http://www.nih-janis.jp/index.asp].
 
4) 遠藤理香ほか : 多剤耐性緑膿菌による慢性気管支炎の増悪に静注用コリスチン製剤が有効であった嚢胞性線維症の1例. 感染症誌 79:945-949, 2005.
 
5) Tateda K, et al : 'Break-point Checkerboard Plate' for screening of appropriate antibiotic combina-tions against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis 38 (4):268-272, 2006.
 
6) 前崎繁文ほか ; 関東甲信越薬剤耐性緑膿菌研究会 : 臨床分離薬剤耐性緑膿菌における各種抗菌薬の併用効果の検討. Jpn J Antibiot 59:11-20, 2006.
 
7) Docquier JD, et al : IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomo-nas putida clinical isolate. Antimicrob Agents Chemother 47:1522-1528, 2003.
 
8) Araoka H, et al : Monobactam and aminoglycoside combination therapy against metallo-beta-lacta-mase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point check-erboard plate'. Scand J Infect Dis 42:231-233, 2010.
 
9) Nordmann P, et al : The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9 (4):228-236, 2009.
PubMed
10) Yong D, et al : Characterization of a new metallo-beta-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53 (12):5046-5054, 2009.
 
11) Kumarasamy KK, et al : Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK : a molecular, biological, and epidemiological study. Lancet Infect Dis 10 (9):597-602, 2010.
 
12) Walsh TR, et al : Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health : an environmental point prevalence study. Lancet Infect Dis 11 (5):355-362, 2011.
 
13) Muto CA, et al : SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 24:362-386, 2003.
PubMed
14) 吉田勇ほか : 各種抗菌薬に対する臨床分離株の感受性サーベイランス. 日化療会誌 51:179-208, 2003.
 
15) Rybak M, et al : Therapeutic monitoring of vancomycin in adult patients : a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98, 2009.
 
16) Best EL, et al : The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 50 (11):1450-1457, 2010.
PubMed
P.765 掲載の参考文献
1) Brown HN, Kelly MJ : Stages of bone marrow transplantation : a psychiatric perspective. Psychosom Med 38:439-446, 1976.
PubMed
2) Baker F, et al : Psychological distress among adult patients being evaluated for bone marrow transplantation. Psychosomatics 38:10-19, 1997.
PubMed
3) Jenkins PL, et al : A retrospective study of psychosocial morbidity in bone marrow transplantation recipients. Psychosomatics 32:65-71, 1991.
PubMed
4) Lee SJ, et al : Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant 35:77-83, 2005.
PubMed
5) 赤穂理絵 : 造血幹細胞移植1年後の心理状態とQOL. 分子精神医学 5:505-507, 2005.
Medical*Online
6) 吉内一浩 : 無菌病棟によるリエゾン. 血液・腫瘍科 45:495-499, 2002.
 
7) 赤穂理絵 : 造血幹細胞移植における精神心理的問題. 内科 104:303-306, 2009.
 
8) 八島朋子 : 移植患者のリハビリテーションと社会復帰. がん看護 9:415-417, 2004.
 
9) Kopp M, et al : Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treat-ment : a comparison with healthy control. Eur Haematol 74:304-308, 2005.
 
10) 平井啓 : 再発不安に対する問題解決療法. 腫瘍内科 5:181-186, 2010.
 
11) Akechi T, et al : Problem-solving therapy for psychological distress in Japanese cancer patients : pre-liminary clinical experience from psychiatric consultations. Jpn J Clin Oncol 38:867-870, 2008.
 
12) Ferguson RJ, et al : Cognitive-behavioral management of chemotherapy-related cognitive change. Psycooncology 16:772-777, 2007.
PubMed
13) 近藤咲子 : チーム医療における看護師の役割. 血液・腫瘍科 55:613-616, 2007.
 
14) National Coalition for Cancer Survivorship. [http://www.canceradvocacy.org/]
 
15) 清水研 : がん患者のサバイバーシップ : サバイバーとサバイバーシップ. 腫瘍内科 5:95-99, 2010.
 
P.766 掲載の参考文献
3) 神田善伸, 渡邊知映 : 化学療法を受ける大切なあなたへ, そしてあなたの大切な人へ : 冊子.
 
4) 渡邊知映 : セクシュアリティに関するカウンセリング. みんなに役立つ造血幹細胞移植の基礎と臨床, p315-319, 医薬ジャーナル社, 2008.
 
5) Socie G, et al : Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101:3373-3385, 2003.
PubMed
6) Salooja N, et al : Pregnancy outcomes after peripheral blood or bone marrow transplantation : a retro-spective survey. Lancet 358:271-276, 2001.
PubMed
7) 中塚幹也 : 血液疾患治療時の不妊とその対策. 血液フロンティア 15:77, 2005.
 
8) Lee SJ, et al : American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006.
 
9) Levine J, et al : Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 28:4831-4841, 2010.
 
10) Rovo A, et al : Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 108:1100-1105, 2006.
PubMed
11) van der Kaaij MA, et al : Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 28:168-179, 2010.
PubMed
12) Harel S, et al : Management of fertility in patients treated for Hodgkin lymphoma. Haematologica 96:1692-1699, 2011.
PubMed
13) Ramasamy K, et al : Successful pregnancies involving men with chronic myeloid leukemia on imati-nib therapy. Br J Haematol 137:374-383, 2007.
 
14) Tham YL, et al : The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30:126-132, 2007.
PubMed
15) Ault P, et al : Pregnancy among Patients with chronic myeloid leukemia with imatinib. J Clin Oncol 24:1204-1208, 2006.
PubMed
16) Kuwabara A, et al : Poor outocome after reinduction of imatinib in patients with chronic myeloid leu-kemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116:1014-1016, 2010.
 
17) 日本造血細胞移植学会平成22年度全国調査報告書, 2011年3月.
 
18) Kuwayama M, et al : Highly efficient vitrification method for cryopreservation of human oocytes. Reproductive BioMedicine Online 11:300-308, 2005.
PubMed
19) 寺元章吉, 加藤修 : 白血病患者さんの卵子保存. 「改訂版」白血病と言われたら (全国骨髄バンク推進連絡協議会編), p155-167, 2008.
 
20) Nakagawa K, et al : Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation : a report of two successful cases. Bone Marrow Transplant 37:583-587, 2006.
PubMed
21) Dolmans MM, et al : Reimplantation of cryopreserved ovarian tissue from patients with acute lympho-blastic leukemia is potentially unsafe. Blood 116:2908-2914, 2010.
 
P.776 掲載の参考文献
1) 中塚幹也 : 不妊. 血液・腫瘍科 55:585-589, 2007.
 
2) 品川克至ほか : 不妊について. 「改訂版」白血病と言われたら (全国骨髄バンク推進連絡協議会編), p147-155, 2008.
 

書評

最近チェックした商品履歴

Loading...